<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Biosci</journal-id><journal-id journal-id-type="iso-abbrev">Cell Biosci</journal-id><journal-title-group><journal-title>Cell &#x00026; Bioscience</journal-title></journal-title-group><issn pub-type="epub">2045-3701</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410852</article-id><article-id pub-id-type="pmc">PMC12102857</article-id>
<article-id pub-id-type="publisher-id">1406</article-id><article-id pub-id-type="doi">10.1186/s13578-025-01406-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhaoxi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Alice Pik-Shan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Vincent Wai-Sun</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7525-5812</contrib-id><name><surname>Hui</surname><given-names>Hannah Xiaoyan</given-names></name><address><email>hannahhui@cuhk.edu.hk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t33hh48</institution-id><institution-id institution-id-type="GRID">grid.10784.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0482</institution-id><institution>School of Biomedical Sciences, </institution><institution>The Chinese University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037p24858</institution-id><institution-id institution-id-type="GRID">grid.412615.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1803 6239</institution-id><institution>Department of Breast and Thyroid Surgery, </institution><institution>The First Affiliated Hospital of Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t33hh48</institution-id><institution-id institution-id-type="GRID">grid.10784.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0482</institution-id><institution>Department of Medicine and Therapeutics, </institution><institution>The Chinese University of Hong Kong, </institution></institution-wrap>Hong Kong, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t33hh48</institution-id><institution-id institution-id-type="GRID">grid.10784.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0482</institution-id><institution>Hong Kong Institute of Diabetes and Obesity, Prince of Wales Hospital, </institution><institution>The Chinese University of Hong Kong, </institution></institution-wrap>Shatin, Hong Kong, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t33hh48</institution-id><institution-id institution-id-type="GRID">grid.10784.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0482</institution-id><institution>Li Ka Shing Institute of Health Sciences, Prince of Wales Hospital, </institution><institution>The Chinese University of Hong Kong, </institution></institution-wrap>Shatin, Hong Kong, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t33hh48</institution-id><institution-id institution-id-type="GRID">grid.10784.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0482</institution-id><institution>Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, Shenzhen Research Institute, </institution><institution>The Chinese University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>64</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern linked to the increasing prevalence of metabolic syndrome, including obesity and type 2 diabetes (T2D). MASLD remains a significant clinical challenge due to the absence of effective therapeutic interventions. Intermittent fasting (IF) has emerged as a promising non-pharmacological strategy for managing MASLD. Although the exact mechanisms underpinning the possible beneficial effects of IF on MASLD are not yet fully elucidated, the gut microbiota and its metabolic byproducts are increasingly recognized as potential mediators of these effects. The gut-liver axis may act as an important conduit through which IF exerts its beneficial influence on hepatic function. This review comprehensively examines the impact of various IF protocols on gut microbiota composition, investigating the resultant alterations in microbial diversity and metabolomic profiles, and their potential implications for liver health and the improvement of MASLD.</p></abstract><funding-group><award-group><funding-source><institution>Lo Kwee-Seong Biomedical Research Start-up Fund</institution></funding-source><award-id>7106480</award-id><award-id>7106481</award-id><principal-award-recipient><name><surname>Hui</surname><given-names>Hannah Xiaoyan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Society of Chinese Bioscientists in America (SCBA) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par21">Metabolic dysfunction-associated fatty liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a significant public health issue that impacts around 30% of adults worldwide and is strongly linked to the increasing prevalence of metabolic syndrome including type 2 diabetes (T2D) and obesity [<xref ref-type="bibr" rid="CR1">1</xref>]. MASLD is characterized by excessive lipid accumulation in hepatocytes, leading to metabolic stress and liver injury [<xref ref-type="bibr" rid="CR2">2</xref>], and is frequently co-existing with overweight/obesity, insulin resistance, T2D, and metabolic dysregulation [<xref ref-type="bibr" rid="CR3">3</xref>]. While most MASLD patients have isolated steatosis (metabolic dysfunction-associated steatotic liver [MASL]), its histopathological features have a gradual progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and to advanced liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC), eventually leading to liver- or cardiovascular-related mortality [<xref ref-type="bibr" rid="CR4">4</xref>]. Over the past two decades, MASLD has emerged as the most common chronic liver disease, with a global prevalence of 30.1% [<xref ref-type="bibr" rid="CR5">5</xref>]. This rate continues to rise in tandem with the increasing prevalence of metabolic syndrome, T2D, cardiovascular disease, and other chronic metabolic conditions. By 2030, it is estimated that the number of MASLD cases could reach approximately 314.58 million, highlighting the significant impact MASLD is expected to have in the coming decades [<xref ref-type="bibr" rid="CR6">6</xref>]. The exact pathogenesis of MASLD remains unclear, but it is believed to involve multiple parallel factors, including insulin resistance, hormones secreted by adipose tissue, nutritional factors, gut microbiota, as well as genetic and epigenetic influences [<xref ref-type="bibr" rid="CR7">7</xref>]. These multiple converging pathogenic pathways pose challenges for drug development, and to date, resmetirom is the only pharmacological agent being approved by the United States Food and Drug Administration (FDA) since 14 March 2024, for the treatment of adults with MASH. Lifestyle interventions, aiming for weight loss with reduction of total caloric intake and alteration of the composition of macronutrients in the diet, remain to be the primary therapy for people with MASLD [<xref ref-type="bibr" rid="CR8">8</xref>]. Emerging evidence highlights that the timing of food intake significantly influences the risk of MASLD, with factors such as skipping breakfast, irregular eating patterns, and nighttime eating playing key roles [<xref ref-type="bibr" rid="CR9">9</xref>]. Conversely, changing dietary habits, including time-restricted feeding (TRF), can enhance overall quality of life and metabolic function, thereby reducing the risk of developing metabolic syndrome such as obesity [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, intermittent fasting (IF), which alternates between fasting and feeding states, may provide significant weight loss and benefits for liver and overall metabolic health in MASLD patients.</p><p id="Par22">IF has various forms, such as alternate-day fasting (ADF), periodic fasting (PF), TRF, and fasting-mimicking diet (FMD), with the advantage of reducing caloric intake [<xref ref-type="bibr" rid="CR11">11</xref>]. IF is simple, cost-effective, and has high participant adherence compared to other dietary interventions, making it a favored dietary approach for patients with metabolic syndrome [<xref ref-type="bibr" rid="CR12">12</xref>]. A growing body of clinical evidence indicates that IF regimens, including the 5:2 fasting protocol and TRF, significantly reduce body weight, enhance glycemic control, and inhibit the progression of liver steatosis and fibrosis in MASLD patients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. However, the specific influence of IF on MASLD warrants further exploration, as the gut-liver interaction is a crucial component. The gut-liver axis is the bidirectional communication between gut microbiota and the liver, where microbial metabolites influence liver function and metabolism, while the liver affects gut permeability, thus playing a critical role in metabolic regulation and liver disease progression [<xref ref-type="bibr" rid="CR16">16</xref>]. As a crucial component of the gut-liver axis, the composition of the gut microbiota can be influenced by a variety of factors, including antibiotic usage, lifestyle choices, dietary habits, and host genetics. Both animal studies and human clinical trials have demonstrated that IF significantly modulates the gut microbiota, enhancing its overall health and fostering the enrichment of beneficial microbes linked to reduced inflammation and improved metabolic function (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Thus, the beneficial microbiota and their metabolites resulting from IF may promote metabolic processes and support liver health through interactions within the gut-liver axis.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Impact of IF on Metabolic and Liver Status in MASLD Patients on RCT Studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of IF</th><th align="left">Study duration</th><th align="left">Sample size</th><th align="left">Body weight</th><th align="left">Lipid profile</th><th align="left">Glucose and insulin metabolism</th><th align="left">Liver steatosis</th><th align="left">Liver fibrosis</th><th align="left">Other outcomes</th><th align="left">Author, Year</th></tr></thead><tbody><tr><td align="left">ADF vs. Ctrl</td><td align="left">8&#x000a0;weeks</td><td align="left">43 (33:10)</td><td align="left">&#x02193;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02193;</td><td align="left">&#x02193;</td><td align="left">&#x02193;ALT</td><td align="left">Johari et al. 2019 [<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td align="left">TRF vs. SC</td><td align="left">12&#x000a0;weeks</td><td align="left">32 (17:15)</td><td align="left">&#x02193;</td><td align="left"/><td align="left">&#x02193;HOMA-IR</td><td align="left">&#x02193;</td><td align="left">&#x02193;</td><td align="left">&#x02193;leptin</td><td align="left">Hodge et al. 2014 [<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left">5:2 IF vs. LCHF vs. SC</td><td align="left">12&#x000a0;weeks</td><td align="left">74 (25:25:24)</td><td align="left">&#x02193;</td><td align="left">&#x02193;LDL-C</td><td align="left"><p>&#x02193;HbA1c</p><p>&#x02193;HOMA-IR</p></td><td align="left">&#x02193;</td><td align="left">&#x02193;</td><td align="left"/><td align="left">Holmer et al. 2021 [<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td align="left">5:2 IF vs. SC</td><td align="left">12&#x000a0;weeks</td><td align="left">44 (21:23)</td><td align="left">&#x02193;</td><td align="left">&#x02193;Triglycerides</td><td align="left">&#x02013;</td><td align="left">&#x02193;</td><td align="left">&#x02193;</td><td align="left"><p>&#x02193;ALT</p><p>&#x02193;CRP</p></td><td align="left">Varkaneh et al. 2022 [<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left">5:2 IF vs. Liraglutide</td><td align="left">24&#x000a0;weeks</td><td align="left">61 (31:30)</td><td align="left">&#x02193;</td><td align="left"><p>&#x02193;Triglycerides</p><p>&#x02193;LDL-C</p><p>&#x02191;HDL-C</p></td><td align="left"><p>&#x02193;FBG</p><p>&#x02193;HOMA-IR</p></td><td align="left">&#x02193;</td><td align="left"/><td align="left">&#x02193;ALT</td><td align="left">Xiao et al. 2022 [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr></tbody></table><table-wrap-foot><p>no change, <italic>ALT</italic> alanine aminotransferase, <italic>Ctrl</italic> control, <italic>CRP</italic> C-reactive protein, <italic>FBG</italic> fasting blood glucose, <italic>HbA1c</italic> hemoglobin A1c, <italic>HDL-C</italic> high-density lipoprotein cholesterol, <italic>HOMA-IR</italic> homeostatic model assessment for insulin resistance, <italic>IF</italic> interment fasting, <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>ADF</italic> alternate day fasting, <italic>LCHF</italic> low carbon high fat diet, <italic>RCT</italic> randomized controlled trial, <italic>SC</italic> standard care</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Preclinical studies investigating the effects of IF on the gut microbiome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Intervention</th><th align="left">Animal Model</th><th align="left">Biospecimen</th><th align="left">Microbiological Analysis Method</th><th align="left">Primary Results on microbiota</th><th align="left">Author, Year</th></tr></thead><tbody><tr><td align="left">TRF with 7&#x000a0;h feeding per day for 28&#x000a0;weeks</td><td align="left">Young (5&#x000a0;months) and aged (21&#x000a0;months) male Fisher 344&#x02009;&#x000d7;&#x02009;Brown Norway hybrid F1 rats</td><td align="left">Feces</td><td align="left"><italic>16&#x000a0;s rRNA</italic></td><td align="left"><p>Alpha diversity &#x02191;</p><p>&#x02191;: <italic>Verrucomicrobia, RuminococcaceaeUCG-005, Ruminococcus_gauvreauil_group, Ruminococcus1, Akkermansia, Ileibacterium</italic></p><p>&#x02193;: <italic>Actinobacteria, Patscibacteria, Romboutsia</italic><italic>, </italic><italic>Alloprevotella</italic><italic>, </italic><italic>Leuconostoc</italic><italic>, </italic><italic>LachnospiraceaeUCG-005</italic><italic>, </italic><italic>Lactobacillus</italic><italic>, </italic><italic>Turicibacter</italic></p></td><td align="left">Hernandez et al. 2022 [<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">ADF for 7&#x000a0;months</td><td align="left">Male B6.BKS(D)-Lepr<sup>db</sup> /J homozygous Lepr <sup>db/db</sup> mice</td><td align="left">Feces</td><td align="left">16&#x000a0;s rRNA</td><td align="left"><p>&#x02191;: <italic>Firmicutes, Lactobacillus, Oscillospira, Ruminococcus</italic></p><p>&#x02193;: <italic>Bacteroidetes, Verrucomicrobia, Akkermansia, Bacteroides, Bifidobacterium</italic></p></td><td align="left">Beli et al. 2018 [<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left">ADF for 4&#x000a0;weeks</td><td align="left">7-week-old female C57BL/6&#x000a0;J mice</td><td align="left">Feces</td><td align="left">16&#x000a0;s rRNA</td><td align="left"><p>Gut bacteria richness &#x02191;</p><p>&#x02191;: <italic>Lactobacillaceae, Bacteroidaceae, Prevotellaceae</italic></p></td><td align="left">Cignarella et al. 2018 [<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left">Fast for 24&#x000a0;h</td><td align="left">6-week-old male C57BL/6 mice</td><td align="left">Feces</td><td align="left">16&#x000a0;s rRNA</td><td align="left"><p>&#x02191;: <italic>Akkermansia, Parabacteroides, Muribaculum, Eubacterium_coprostanoligenes, Muribaculaceae</italic></p><p>&#x02193;: <italic>Lactobacillus, Bifidobacterium</italic></p></td><td align="left">Zhang et al. 2023 [<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left">IF consisting of 50% calorie intake for 4&#x000a0;days, followed by 4&#x000a0;days of fasting, and then another 4&#x000a0;days of 50% CR</td><td align="left">C57BL/6&#x000a0;J mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02193; <italic>Parabacteroides distasonis</italic></td><td align="left">Li M et al. 2022 [<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">TRF with 8-h eating and 16-h fasting for 32&#x000a0;days</td><td align="left">7-week-old Male C57BL/6&#x000a0;J mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Firmicutes, Lactobacillales, Ligilactobacillus, Bacilli, Lachnospiraceae, Rikenellaceae, Alostipes</italic></p><p>&#x02193;: <italic>Prevotellaceae</italic></p></td><td align="left">Liu X et al. 2024 [<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left">PF: 3-week feeding with AL and then 1-week feeding with 40% amount of AL</td><td align="left">Ten-week-old female MMTV-TGF-a C57BL/6 mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>In the IF group of adult mice:</p><p>&#x02191;: <italic>Lachnoanaerobaculum, Peptococcus</italic></p></td><td align="left">Keles NA et al. 2024 [<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left">ADF for 10&#x000a0;weeks</td><td align="left">Male C57BL/6 mice are fed a HFHC diet for 16&#x000a0;weeks to establish a MASH model</td><td align="left">Cecum</td><td align="left">16S rDNA gene sequencing</td><td align="left"><p>&#x003b1;-diversity &#x02191;</p><p>&#x02191;: <italic>Lachnospiraceae, Peptococcaceae, Peptococcus, Butyricicoccus, Blautia</italic></p><p>&#x02193;: <italic>Cyanobacteria, Lactobacillus</italic></p></td><td align="left">Lin X et al. 2023 [<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">PF: a cycle of 11&#x000a0;days, with fasting on day 1, 3 and 5, and normal diet for the rest of the time for one month</td><td align="left">12-week-old male C57BL/6 mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>Gut microbiota richness &#x02191;</p><p>&#x02193; <italic>Parabacteroides distasonis</italic></p></td><td align="left">Xie S et al. 2022 [<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left">Low-protein low-carbohydrate FMD every other week for 8&#x000a0;weeks</td><td align="left">Six-week-old male C57BL/ksJ-db (db/db) mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Parabacteroides, Blautia</italic></p><p>&#x02193;: <italic>Prevotellaceae, Alistipes, Ruminococcaceae</italic></p></td><td align="left">Wei S et al. 2018 [<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left">ADF for 3&#x000a0;weeks</td><td align="left">male C57BL/6 mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x003b1;-diversity &#x02191;</p><p>&#x02191;: <italic>Bacteroidetes, g_Alistipes</italic></p><p>&#x02193;: <italic>Firmicutes, f_Bacillaceae, g_Bacteroides, g_Streptococcus, g_Corynebacterium</italic></p></td><td align="left">Liu T et al. 2024 [<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left">RAIF with a 16-h daily fasting for 30&#x000a0;days</td><td align="left">6&#x000a0;week male BALB/c mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Lachnospireceae, Ruminococcaceae</italic></td><td align="left">Su J et al. 2022 [<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left">TRF with a 8-h daily feeding</td><td align="left">DPP-IV-Fischer 344 male rats</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Lactobacillus spp., Akkermansia muciniphila</italic></td><td align="left">Palomba A et al. 2021 [<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">5:2 fasting for 12&#x000a0;weeks</td><td align="left">Adult Sprague&#x02013;Dawley rats</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Acetatifactor, Peptococcus</italic></p><p>&#x02193;: <italic>Prevotellaceae, Parabacteroides</italic></p></td><td align="left">Luo Y et al. 2024 [<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">ADF for 10&#x02013;12&#x000a0;weeks</td><td align="left">3-month-old 5XFAD mice</td><td align="left">Feces</td><td align="left">16S rRNA gene sequencing</td><td align="left"><p>&#x02191;: <italic>Firmicutes, Lactobacillaceae, Lactobacillus reuteri</italic></p><p>&#x02193;: <italic>Bacteroidetes</italic></p></td><td align="left">Pan RY et al. 2022 [<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left">TRF with 18-h fasting daily, ADF and CR</td><td align="left">Male C57BL/6 mice were fed a HFD for 6&#x000a0;week</td><td align="left">Stool, ileal, and cecal contents</td><td align="left">16S rRNA</td><td align="left"><p>&#x003b1;-diversity &#x02191;</p><p>IF did not change the fungal populations, with the most abundant genera being <italic>Candida, Penicillium, and Hanseniaspora. Actinobacteria</italic></p><p>&#x02191;: <italic>Bifidobacterium, Lactococcus, Clostridiales, Mucispirillum, Desulfovibrio, Coprococcus in ADF; Ruminococcus, Christensenellaceae, Lactococcus</italic> in TRF</p><p>&#x02193;: <italic>Bilophila, Enterococcus</italic> in ADF; <italic>Bilophila</italic> in TRF</p></td><td align="left">van der Merwe M et al. 2020 [<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left">TRF for 2&#x000a0;months</td><td align="left">9-week-old, wild-type Kunming mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Firmicutes, Clostridia, Ruminococcaceae, Roseburia</italic></td><td align="left">Hu D et al. 2019 [<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">12, 16 or 20&#x000a0;h fasting per day for 1&#x000a0;month</td><td align="left">C57BL/6&#x000a0;J male mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">16&#x000a0;h fasting: &#x02191;<italic>Akkermansia</italic> and &#x02193;<italic>Alistipes</italic></td><td align="left">Li L et al. 2020 [<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">TRF with 16&#x000a0;h daily fasting</td><td align="left">8-week-old, wild-type male C57BL/6 mice</td><td align="left">Ileum content and mucosa</td><td align="left">16S amplicon sequencing</td><td align="left">TRF restored diurnal dynamics of the ileal microbiome and transcriptome in HFD mice</td><td align="left">Dantas Machado AC et al. 2022 [<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td align="left">24-h fasting</td><td align="left">C57BL/6 mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Akkermansia, Bacteroidia, Deferribateres, Bacilli, Erysipelotrichia, Gamma-proteobacteria, Verrucomicrobiae</italic></p><p>&#x02193;: <italic>Clostridia</italic></p></td><td align="left">Graef FA et al. 2021 [<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">TRF with 15&#x000a0;h fasting daily for four weeks</td><td align="left">Male Wistar rats</td><td align="left">Feces</td><td align="left">Bacteria culture</td><td align="left">&#x02191;: <italic>Bifidobacterium, Enterococcus</italic></td><td align="left">Soares NL et al. 2021 [<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td align="left">Every other day feeding</td><td align="left">Male Sprague Dawley rats</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Lactobacillus</italic></td><td align="left">Prisco SZ et al. 2021 [<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left">Every other day feeding</td><td align="left">HFD obesity (6-week-old) C57BL/6&#x000a0;J mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Lactobacillus, Verrucomicrobiaceae, Akkermansia muciniphila</italic></td><td align="left">Yang H et al. 2023 [<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left">TRF with 18&#x000a0;h daily fasting 5&#x000a0;weeks</td><td align="left">12-month-old male Wistar rat</td><td align="left">cecum content</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Firmicutes, Bacteroidetes, Proteobacteria</italic></p><p>&#x02193;: <italic>Actinobacteria</italic></p></td><td align="left">Teker HT et al. 2023 [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left">Fasting for 24&#x000a0;h</td><td align="left">6 to 8-week-old male C57BL/6 mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Ruminococcaceae-UCG-014, Akkermansia, Parabacteroides</italic></p><p>&#x02193;: <italic>Helicobacter</italic></p></td><td align="left">Huang W et al. 2022 [<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td align="left">ADF for 2&#x000a0;weeks or 20&#x000a0;weeks</td><td align="left">C57BL/6 male</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>Short-term IF (2&#x000a0;weeks): &#x02191;<italic>Bacteroides, Muibaculum and Akkermansia</italic>; &#x02193; <italic>Ruminiclostridium</italic></p><p>Long-term IF (20&#x000a0;weeks): &#x02191; <italic>Lactobacillus</italic>; &#x02193; <italic>Akkermansia</italic></p></td><td align="left">Wu J et al. 2022 [<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td align="left">TRF with 16&#x000a0;h daily fasting</td><td align="left">Six-week-old male C57BL/6 mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Lactobacillus, Mucispirillum, Acetatifactor, Lachnoclostridium</italic></td><td align="left">Xia J et al. 2023 [<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left">24&#x000a0;h fasting followed by 24&#x000a0;h feeding</td><td align="left">female Balb/c mice (6&#x02013;8&#x000a0;weeks old)</td><td align="left">Cecum feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Alistipes, Rikenellaceae</italic></td><td align="left">Ma RX et al. 2023 [<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td align="left">5:2 IF regimen</td><td align="left">7-week-old C57BL/6 male mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Lactobacillus murinus OTU2</italic></td><td align="left">Zhang Z et al. 2021 [<xref ref-type="bibr" rid="CR72">72</xref>]</td></tr><tr><td align="left">TRF with 16&#x000a0;h daily fasting for 8&#x000a0;weeks</td><td align="left">Eight-week-old male Kunming mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Bacteroidetes, Lachnospiraceae, Ruminococcaceae</italic></p><p>&#x02193;: <italic>Firmicutes</italic></p></td><td align="left">Ye Y et al. 2020 [<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left">TRF with 16&#x000a0;h daily fasting</td><td align="left">Eight-week-old male C57BL/6&#x000a0;J mice</td><td align="left"><p>Cecum</p><p>Feces</p></td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Oscillibacter, Ruminococcaceae</italic></p><p>&#x02193;: <italic>Lactobacillus, Lactococcus</italic></p></td><td align="left">Zarrinpar A et al. 2014 [<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr><tr><td align="left"><p>ADF for 28&#x000a0;days</p><p>FMD for 3 cycles</p></td><td align="left">C57BL/6 wild-type male mice</td><td align="left">Feces</td><td align="left">qRT-PCR</td><td align="left"><p>ADF: &#x02191; <italic>Akkermansia, Lactobacillus</italic>; &#x02193; <italic>Deferribacteres</italic></p><p>FMD: &#x02191; <italic>Akkermansia</italic>; &#x02193; <italic>Deferribacteres</italic></p></td><td align="left">Gregor A et al. 2022 [<xref ref-type="bibr" rid="CR73">73</xref>]</td></tr><tr><td align="left">ADF for 18&#x000a0;weeks</td><td align="left">Male C57BL/6&#x000a0;J mice (5-week-old)</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Bacteroidetes</italic></p><p>&#x02193;: <italic>Firmicutes, Firmicutes/Bacteroidetes ratio</italic></p></td><td align="left">Wang S et al. 2023 [<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">ADF for 8&#x000a0;weeks</td><td align="left">Male C57BL/6&#x000a0;J mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x003b1;-diversity &#x02191;</p><p>&#x02191;: <italic>Verrucomicrobia, Akkermansia muciniphila</italic></p><p>&#x02193;: <italic>Firmicutes</italic></p></td><td align="left">Lei S et al. 2024 [<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td align="left">5:2 IF regimen for 1&#x000a0;month</td><td align="left">Drosophila melanogaster</td><td align="left">Flies</td><td align="left">16S qPCR quantification</td><td align="left">&#x02193;: <italic>Lactobacillus plantarum</italic></td><td align="left">Catterson JH et al. 2018 [<xref ref-type="bibr" rid="CR39">39</xref>]</td></tr><tr><td align="left">ADF for 4&#x000a0;weeks</td><td align="left">Healthy male Sprague&#x02013;Dawley rats (2&#x000a0;months old)</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Lactobacillus, Bacteroides, Alloprevotella, Prevotella 1, Rikenel-laceae RC9, Odoribacter, Catenibacterium spp.</italic></p><p>&#x02193;: <italic>Prevotellaceae UCG-003, Lachnospiraceae NK4A136, Lachnospiraceae UCG-008, Prevotella 9, [Eubacterium] coprostanoligenes, Ruminococcaceae UCG-008, Ruminococcaceae UCG-003</italic></p></td><td align="left">Wang J et al. 2023 [<xref ref-type="bibr" rid="CR76">76</xref>]</td></tr><tr><td align="left">ADF for 30&#x000a0;days</td><td align="left">Male C57BL/6&#x000a0;J mice (6-week-old)</td><td align="left">Entire intestinal contents</td><td align="left">16S rDNA Gene</td><td align="left"><p>&#x02191;: <italic>Firmicutes/Bacteroidetes ratio, Lactobacillus, Ruminococcus, Akkermansia</italic></p><p>&#x02193;: <italic>Helicobacter, Prevotella, Parasutterella</italic></p></td><td align="left">Liu J et al. 2021 [<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td align="left">ADFfor 28&#x000a0;days</td><td align="left">Diabetic male BKS.Cg-Dock7<sup>m</sup>&#x02009;+&#x02009;/&#x02009;+&#x02009;Lepr<sup>db</sup> /J Homozygous Lepr<sup>db/db</sup> mice</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Lactobacillus, butyrate-producing Odoribacter</italic></p><p>&#x02193;: <italic>Enterococcus, Streptococcus, and unknown Enterococcaceae</italic></p></td><td align="left">Liu Z et al. 2020 [<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left">ADFfor 30&#x000a0;days or 6&#x000a0;days</td><td align="left">Six-week-old male C57BL/6N mice</td><td align="left">Cecal contents</td><td align="left">16S rRNA</td><td align="left">&#x02191;: <italic>Firmicutes Bacteroidetes ratio, Lactobacillus reuteri</italic></td><td align="left">Li G et al. 2017 [<xref ref-type="bibr" rid="CR79">79</xref>]</td></tr><tr><td align="left">4-day cycles of FMD</td><td align="left">DSS-induced C57BL/6 mice (8-weeks-old, female)</td><td align="left">Feces</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Lactobacillaceae, Bifidobacteriaceae, Erysipelotrichaceae, Allobaculum</italic></p><p>&#x02193;: S24-7</p></td><td align="left">Rangan P et al. 2019 [<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td align="left">ADF for 10&#x000a0;weeks</td><td align="left">Male SHRSP Wistar-Kyoto rats</td><td align="left">Cecal content</td><td align="left">16S rRNA</td><td align="left"><p>&#x02191;: <italic>Bacteroides, Lactobacillus, Lachnospiraceae, Oscilltbacter</italic></p><p>&#x02193;: <italic>Proteobacteria, Parasutterella</italic></p></td><td align="left">Shi H et al. 2021 [<xref ref-type="bibr" rid="CR81">81</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>ADF</italic> Alternate day fasting, <italic>AL</italic> ad libitum, <italic>CR</italic> caloric restriction, <italic>DSS</italic> chronic dextran sodium, <italic>FMD</italic> fasting mimicking diet, <italic>IF</italic> intermittent fasting, <italic>HFD</italic> high-fat diet, <italic>HFHC</italic> high-fat and high-cholesterol, <italic>PF</italic> periodic fasting, <italic>RAIF</italic> ramadan-associated IF, <italic>SHRSP</italic> spontaneously hypertensive stroke-prone, <italic>TRF</italic> Time-restricted feeding</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Clinical studies investigating the effects of IF on the gut microbiome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Fasting mode</th><th align="left">Study design</th><th align="left">Study population</th><th align="left">Country</th><th align="left">Primary results on microbiota</th><th align="left">Author, Year</th></tr></thead><tbody><tr><td align="left">5:2 IF for 24&#x000a0;weeks</td><td align="left">HELENA Trial: RCT</td><td align="left"><p>IF group: 49 overweight or obese adults</p><p>Control group: 52 overweight or obese adults</p></td><td align="left">Germany</td><td align="left">&#x02191;: <italic>Lactobacillales, Bacilli</italic></td><td align="left">Sowah SA et al. 2022 [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left"><p>IF1-P: one fasting day (total of 36&#x000a0;h) and six feeding days per week</p><p>IF2-P: two fasting days (60&#x000a0;h total) and five feeding days per week</p></td><td align="left">Secondary analysis of a larger, registered trial</td><td align="left"><p>Overweight/obesity adults</p><p>IF1-P: n&#x02009;=&#x02009;10</p><p>IF2-P: n&#x02009;=&#x02009;10</p></td><td align="left">USA</td><td align="left"><p>IF1-P: &#x02191; <italic>Ruminococcaceae Incertae Sedis, Eubacterium fissicatena;</italic> $<italic>Sellimonas</italic></p><p>IF2-P: &#x02191;<italic>Ruminococcaceae Incertae Sedis</italic>, $<italic>Eubacterium ventriosum</italic></p></td><td align="left"><p>Mohr AE et al</p><p>2022 [<xref ref-type="bibr" rid="CR82">82</xref>]</p></td></tr><tr><td align="left">TRF: feeding&#x02009;&#x0003c;&#x02009;12&#x000a0;h one day for 12&#x000a0;weeks</td><td align="left">Non RCT</td><td align="left"><p>TRF group: 25 obese adults</p><p>Non-TRF group: 24 obese adults</p></td><td align="left">Italy</td><td align="left">&#x02191;: <italic>Lachnospiraceae, Parasutterella, Romboutsia</italic></td><td align="left">Ferrocino I et al. 2022 [<xref ref-type="bibr" rid="CR83">83</xref>]</td></tr><tr><td align="left">TRF: fasting 8&#x000a0;h one day for 25&#x000a0;days</td><td align="left">Non RCT</td><td align="left"><p>TRF group: 56 healthy males</p><p>Non-TRF group: 24 healthy males</p></td><td align="left">China</td><td align="left"><p>Gut microbial richness &#x02191;</p><p>&#x02191;: <italic>Prevotellaceae, Bacteroideaceae</italic></p></td><td align="left">Zeb F et al. 2020 [<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left">FMD for 12&#x000a0;months</td><td align="left">Auxiliary studies of RCT</td><td align="left"><p>FMD: 34 overweight or obese adults</p><p>Daily caloric restriction (DCR): 25 overweight or obese adults</p></td><td align="left">USA</td><td align="left">&#x02191;: <italic>Akkermansia</italic></td><td align="left">Stanislawski MA et al. 2021 [<xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td align="left">TRF: fasting at least 16&#x000a0;h one day for 27&#x000a0;days</td><td align="left">Observational study</td><td align="left">14 healthy women and 31 men</td><td align="left">Pakistan</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Lactobacillus, Bifidobacterium, Lactococcus</italic></p><p>&#x02193;: <italic>Pseudomonas triavilis, Brevibacillus limnophilus, Bacillus spp, Dorea spp</italic></p></td><td align="left">Khan MN et all. 2022 [<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left">Two calorie-restricted vegan days (max 1200&#x000a0;kcal/ day), followed by 5-days with a daily nutritional energy intake of 300&#x02013;350&#x000a0;kcal/day, then refeeding for 3&#x000a0;months</td><td align="left">Part of a RCT</td><td align="left">Male and female patients with metabolic symdrome</td><td align="left">Germany</td><td align="left">&#x02193;: <italic>Faecalibacterium prausnitzii, Eubacterium rectale, Coprococcus comes, Escherichia coli</italic></td><td align="left">Maifeld A et al. 2021 [<xref ref-type="bibr" rid="CR85">85</xref>]</td></tr><tr><td align="left">One-week low-calorie, plant-based fasting program, followed by a probiotic intervention for 6&#x000a0;weeks</td><td align="left">Observational study</td><td align="left">13 overweight aduls</td><td align="left">Austria</td><td align="left">&#x02191;: <italic>Lactobacilli, Enterobacteria, Bifidobacteria, Akkermansia</italic></td><td align="left">Remely M et al. 2015 [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left">RF at least 28&#x000a0;days</td><td align="left">Observational study</td><td align="left">30 healthy adults</td><td align="left">Iran</td><td align="left">&#x02191;: <italic>Bacteroides, Firmicutes</italic></td><td align="left">Mohammadzadeh A et al. 2021 [<xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td align="left">Buchinger fasting for 10&#x000a0;days</td><td align="left">Observational study</td><td align="left">16 healthy males</td><td align="left">Germany</td><td align="left"><p>&#x02191;: <italic>Bacteroidetes, Proteobacteria</italic></p><p>&#x02193;: <italic>Firmicutes, Lachnospiraceae, Ruminococcaceae</italic></p></td><td align="left">Mesnage R et al. 2019 [<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left">Buchinger fasting for 5&#x000a0;days</td><td align="left">Non RCT</td><td align="left"><p>Fasting group: 20 adults</p><p>Non-fasting group: 31 adults</p></td><td align="left">Austria</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Cyanobacteria, Verrcoumicrobia, Proteobacteria, Christensenella, Bifidobacteriaceae</italic></p><p>&#x02193;: <italic>Euryarchaeota, Firmicutes, Actinobacteria, Firmicutes/Bacteroidetes</italic> ratio</p></td><td align="left">Lilja S et al. 2021 [<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td align="left">RF (17&#x000a0;h of fasting per day during a 29-day period)</td><td align="left">Observational study</td><td align="left">9 healthy adults (7 females and 2 males)</td><td align="left">Turkey</td><td align="left">&#x02191;: <italic>Akkermansia muciniphila, Bacteroides fragilis</italic></td><td align="left">&#x000d6;zkul C et al. 2019 [<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td align="left">eTRF (early TRF, eating during a period of no more than 8&#x000a0;h between 06:00 and 15:00, and fasting for the rest of the day); mTRF (mid-day TRF, eating during a period of no more than 8&#x000a0;h between 11:00 and 20:00, and fasting for the rest of the day); control group (eating ad libitum) for 5&#x000a0;weeks</td><td align="left">RCT</td><td align="left"><p>Healthy adults without obesity:</p><p>eTRF: n&#x02009;=&#x02009;30</p><p>mTRF: n&#x02009;=&#x02009;30</p><p>control groups: n&#x02009;=&#x02009;30</p></td><td align="left">China</td><td align="left"><p>eTRF: &#x003b1;-diversity &#x02191;</p><p>mTRF: &#x02191;<italic>Leuconostocaceae</italic>; &#x02193;<italic>Escherichia/Shigella, Weissella</italic></p></td><td align="left">Xie Z et al. 2022 [<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left">RF: fasting 16&#x000a0;h one day for 30&#x000a0;days</td><td align="left"><p>Prospective clinical study</p><p>Non-RCT</p></td><td align="left"><p>Young healthy male adult cohort: n&#x02009;=&#x02009;30</p><p>Middle-aged healthy cohort:</p><p>Fasting group: n&#x02009;=&#x02009;27; control group: n&#x02009;=&#x02009;10</p></td><td align="left">China</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Lachnospiraceae, Ruminococcaceae</italic></p></td><td align="left">Su J et al. 2021 [<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr><tr><td align="left">TRF: fasting 16&#x000a0;h per day for 25&#x000a0;days</td><td align="left">Non-RCT</td><td align="left"><p>30 healthy men (18&#x02013;30 y of age):</p><p>TRF group: n&#x02009;=&#x02009;15; non-TRF group: n&#x02009;=&#x02009;15</p></td><td align="left">China</td><td align="left">&#x02191;: <italic>Bacteroidetes, Prevotlla_9, Faecalibacterium, Dialister</italic></td><td align="left">Zeb F et al. 2020 [<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td align="left">RF for 1&#x000a0;months</td><td align="left">Observational study</td><td align="left"><p>Chinese group: 16 healthy adults</p><p>Pakistani group: 18 healthy adults</p></td><td align="left">China/ Pakistan</td><td align="left"><p>Chinese group: &#x02191;<italic>Dorea, Klebsiella, Faecalibacterium</italic></p><p>Pakistani group: &#x02191;<italic>Sutterella, Parabacteroides, Alistipes</italic></p><p>&#x02193;: <italic>Coprococcus, Clostridium_XlV, Lachnospiracea</italic></p></td><td align="left">Ali I et al. 2021 [<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td align="left">ADF for 15&#x000a0;days</td><td align="left">RCT</td><td align="left"><p>Multiple sclerosis patients undergoing relapse</p><p>IF group: n&#x02009;=&#x02009;8</p><p>Control group: n&#x02009;=&#x02009;8</p></td><td align="left">USA</td><td align="left">&#x02191;: <italic>Faecalibacterium, Lachnospiracea incertae sedis, Blautia</italic></td><td align="left">Cignarella F et al. 2018 [<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left">5:2 IF for 8&#x000a0;weeks</td><td align="left">RCT</td><td align="left"><p>IF group: 21 obese adults</p><p>Control group: 18 obese adults</p></td><td align="left">China</td><td align="left">&#x02191;: <italic>Proteobacteria, Rumonococcaceae, Roseburia, Clostridium, Spirochaetes</italic></td><td align="left">Guo Y et al. 2021 [<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left">RF for 4&#x000a0;weeks</td><td align="left">Observational study</td><td align="left"><p>Healthy or overweight adults</p><p>15 Pakistanis and 5 Nigerians</p></td><td align="left">Korea</td><td align="left"><p>&#x02191;: <italic>Bacteroides, Lactobacillus, Sutterlla, Ruminococcaceae UCG-005, Agathobacter, Fusicatenibacter, Lachnoclostridium</italic></p><p>&#x02193;: <italic>Coprococcus, Lachnospiraceae NK4A136</italic></p></td><td align="left">Jo Y et al. 2023 [<xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td align="left">RF: fast for an average of 14&#x02013;15&#x000a0;h daily during the 29-day Ramadan month</td><td align="left">Observational study</td><td align="left">10 overweight or obese male</td><td align="left">Turkey</td><td align="left"><p>&#x003b1; diversity &#x02191;</p><p>&#x02191;: <italic>Bacteroidetes, Proteobacteria, Bacteroidia, Alphaproteobacteria, Erysipelotrichi, Bacteroidales, Erysipelotrichales, Actinomycetales, Erysipelotrichaceae, Prevotella</italic></p><p>&#x02193;: <italic>Firmicutes/ Bacteroidetes</italic> ratio, <italic>Firmicutes, Clostridia, Clostridiales, Ruminococcaceae</italic></p></td><td align="left">Selen H et al. 2024 [<xref ref-type="bibr" rid="CR95">95</xref>]</td></tr><tr><td align="left">TRF with 16&#x000a0;h of fasting for 1&#x000a0;months and then received rifaximin and continued with TRF for another month</td><td align="left">RCT</td><td align="left"><p>Obese aadults:</p><p>IF group: n&#x02009;=&#x02009;11</p><p>CR group: n&#x02009;=&#x02009;11</p><p>KD group: n&#x02009;=&#x02009;11</p><p>AL group: n&#x02009;=&#x02009;11</p></td><td align="left">Mexico</td><td align="left">IF: &#x02191;&#x003b1; diversity, &#x02191;<italic>Akkermansia muciniphila</italic>, &#x02193;LPS-producing bacteria (gram-negative species such as <italic>Bacteroides caccae</italic> and <italic>Bacteroides eggertii</italic>)</td><td align="left">Guevara-Cruz M et al. 2024 [<xref ref-type="bibr" rid="CR96">96</xref>]</td></tr><tr><td align="left">RF with 17&#x000a0;h fasting per day for 29 consecutive days</td><td align="left">Observational study</td><td align="left">12 healthy adults (7 women and 5 men)</td><td align="left">Turkey</td><td align="left"><p>&#x02191;: <italic>Proteobacteria, Escherichia, Shigella</italic></p><p>&#x02193;: <italic>Firmicutes, Blautia, Coprococcus, Dorea, Faecalicatena, Fusicatenibacter, Lachnoclostridium, Mediterraneibacter</italic></p></td><td align="left">Saglam D et al. 2023 [<xref ref-type="bibr" rid="CR97">97</xref>]</td></tr><tr><td align="left">5:2 IF for three weeks</td><td align="left">Observational study</td><td align="left">72 healthy adults ranging from regular to obese</td><td align="left">China</td><td align="left">&#x02191;: <italic>Parabacteroides distasonis, Bacteroides thetaiotaomicron</italic></td><td align="left">Hu X et al. 2023 [<xref ref-type="bibr" rid="CR98">98</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>ADF</italic> Alternate day fasting, <italic>AL</italic> ad libitum, <italic>CR</italic> caloric restriction, <italic>FMD</italic> fasting mimicking diet, <italic>IF</italic> intermittent fasting, <italic>KD</italic> ketogenic diet, <italic>LPS</italic> lipopolysaccharide, <italic>PF</italic> periodic fasting, <italic>RCT</italic> randomized controlled trial, <italic>RF</italic> ramadan fasting, <italic>TRF</italic> Time-restricted feeding</p></table-wrap-foot></table-wrap></p><p id="Par23">This review aims to examine the structural and functional alterations in the intestinal microbiota after IF treatment, evaluate the evidence related to the risk of MASLD, and elucidate the potential mechanisms by which IF modulates metabolic status and hepatic health via gut microbiota interactions.</p><p id="Par24"><bold>IF</bold>: IF is defined as an eating pattern that alternates between periods of fasting and eating, categorized into various types such as TRF, ADF, FMD and 5:2 diet&#x000a0;(Fig. <xref rid="Fig1" ref-type="fig">1</xref>). While it has been associated with numerous health benefits including improved metabolic health, liver health, weight loss, enhanced cognitive function, and reduced risk of chronic diseases, potential risks may include nutrient deficiencies, disordered eating behaviors, and negative impacts on mood and energy levels [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Types of IF. Four different types of IF were presented, including ADF, TRF, PF, and FMD</p></caption><graphic xlink:href="13578_2025_1406_Fig1_HTML" id="MO1"/></fig></p><p id="Par25"><bold>TRF</bold>: TRF, which limits daily food consumption to a window of 4 to 10&#x000a0;h, is considered a feasible fasting regimen for most individuals [<xref ref-type="bibr" rid="CR17">17</xref>]. Ramadan fasting is a religious ritual for Muslims and is also considered a form of TRF. Over 1.5 billion Muslims fast or abstain from drinking from dawn (Sahur) to sunset (Iftar) during Ramadan, which lasts for 28 to 30 days [<xref ref-type="bibr" rid="CR18">18</xref>], and therefore implementing IF and caloric restriction. Animal studies have demonstrated that TRF confers numerous benefits, including weight loss, obesity prevention, improved insulin sensitivity, reduced liver fat content, and prevention of hepatic steatosis and hyperlipidemia [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. TRF has also been shown to reduce weight, increase insulin sensitivity, and lower blood pressure, providing benefits for patients with MASLD and non-alcoholic steatohepatitis [<xref ref-type="bibr" rid="CR9">9</xref>]. Notably, previous human TRF studies have reported no serious adverse effects [<xref ref-type="bibr" rid="CR22">22</xref>]. Research indicates that the efficacy of TRF is influenced by the timing of food intake, with early TRF (eTRF) yielding greater health benefits than mid-day TRF (mTRF) [<xref ref-type="bibr" rid="CR23">23</xref>]. eTRF involves an 8&#x000a0;h eating window from 06:00 to 15:00, while mTRF restricts intake from 11:00 to 20:00. eTRF is associated with enhanced insulin sensitivity, lower fasting plasma glucose, reduced body mass and adiposity, diminished inflammation, improved liver health, and a more diverse gut microbiota compared to controls [<xref ref-type="bibr" rid="CR23">23</xref>]. In contrast, mTRF does not demonstrate these benefits to the same extent.</p><p id="Par26"><bold>ADF</bold>: ADF, also called every-other-day fasting (EODF), is defined as a strict 36&#x000a0;h period of caloric restriction (&#x0201c;fast day&#x0201d;), followed by a 12&#x000a0;h window of ad libitum food consumption (&#x0201c;feast day&#x0201d;) [<xref ref-type="bibr" rid="CR24">24</xref>]. Several studies indicate that short-term ADF (less than 24&#x000a0;weeks) promotes weight loss and alters the risk of chronic diseases including MASLD [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. However, the long-term side effects of ADF (24&#x000a0;weeks or more), including hypoglycemia, gastrointestinal damage, and impaired bone metabolism, remain controversial in humans [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par27"><bold>PF</bold>: The 5:2 IF regimen is regarded as one of the least restrictive and the most popular forms of periodic fasting, involving two non-consecutive days of moderate to complete caloric restriction per week, while permitting ad libitum food consumption on the remaining five days [<xref ref-type="bibr" rid="CR27">27</xref>]. Clinical trials indicated that 5:2 IF significantly reduced body fat, improved insulin resistance, and enhanced glycemic control, including glycated hemoglobin levels, in individuals with obesity and T2D [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Gallage et al. found that the 5:2 regimen could prevent and improve MASH and fibrosis, while also restricting the progression of HCC in various diet-induced MASH and MASH-HCC models. PPAR&#x003b1; and PCK1 are identified as hepatic mediators of the beneficial effects of fasting in MASH [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par28"><bold>FMD</bold>: FMD is a low-calorie, plant-based diet that strictly limits animal protein intake and is cyclically implemented for several consecutive days each month. This periodic energy restriction mimics the metabolic patterns of prolonged fasting, yet it is easier to adhere to and considered safer than complete caloric restriction [<xref ref-type="bibr" rid="CR31">31</xref>]. Human FMD consists of a 5-day regimen: on day 1, it provides 1,090&#x000a0;kcal (10% protein, 56% fat, and 34% carbohydrates), while days 2 to 5 offer a consistent formulation of 725&#x000a0;kcal (9% protein, 44% fat, and 47% carbohydrates) [<xref ref-type="bibr" rid="CR31">31</xref>]. A 4-day FMD reduced the size of multiple organs and systems in C57BL/6 mice, and upon re-feeding, there was an increase in the number of progenitor and stem cells, along with enhanced regenerative capacity. In middle-aged mice, bi-monthly FMD cycles extend lifespan, reduce visceral fat, lower cancer incidence and skin lesions, rejuvenate immune system function, and slow bone mineral density loss. In aged mice, FMD cycles promote hippocampal neurogenesis, decrease IGF-1 levels and PKA activity, increase NeuroD1 expression, and enhance cognitive function. Furthermore, a pilot clinical trial showed that three FMD cycles reduced risk factors and biomarkers for aging, diabetes, cardiovascular disease, and cancer, without significant adverse effects, supporting the use of FMD to extend healthspan [<xref ref-type="bibr" rid="CR31">31</xref>].</p><sec id="Sec2"><title>The protective effect of IF on MASLD</title><p id="Par29">IF appears to be a promising non-pharmacological intervention for the treatment of MASLD. While direct evidence supporting IF&#x02019;s ability to delay MAFLD-to-MASH progression remains limited, animal studies demonstrate its ability to suppress critical pathological pathways&#x02014;particularly inflammation, oxidative stress, and steatosis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. These findings provide indirect mechanistic support for its potential to slow disease conversion. IF may reduce total cholesterol (TC) and triglycerides (TG) in the liver and improve the serum lipid profile by lowering TC, TG, and LDL-C serum levels [<xref ref-type="bibr" rid="CR21">21</xref>]. Mice fed a high-fat high-cholesterol (HFHC) diet exhibited significantly elevated serum ALT and AST levels, alongside increased relative mRNA expression of inflammatory chemokine (MCP-1) and cytokine (TNF-&#x003b1;) in liver tissue. In contrast, IF significantly decreased serum ALT and AST levels, as well as the expression of hepatic inflammatory cytokine (TNF-&#x003b1;) [<xref ref-type="bibr" rid="CR21">21</xref>], exerting the hepatoprotective effects and anti-inflammatory actions of IF. In a MASH mouse model, a ten-week IF intervention significantly reduced body weight, energy intake, and epididymal fat percentage, while alleviating hepatic steatosis, ballooning degeneration, lobular inflammation, NAFLD activity score, and insulin resistance [<xref ref-type="bibr" rid="CR21">21</xref>]. Similarly, Li et al. found that fasting significantly improved obesity, insulin resistance, and hepatic steatosis [<xref ref-type="bibr" rid="CR32">32</xref>]. A mimicked fasting diet could reduce MASLD and even slow the progression of glucose intolerance and liver injury to more severe stages [<xref ref-type="bibr" rid="CR33">33</xref>]. Moreover, TRF intervention significantly alleviated obesity and MASH by restoring the rhythmicity of bacterial gena (such as <italic>Lactobacillus, Mucispirillum, Acetatifactor, and Lachnoclostridium)</italic> and intestinal amino acids [<xref ref-type="bibr" rid="CR19">19</xref>]<italic>.</italic></p><p id="Par30">In human randomized controlled trials (RCTs), it has been confirmed that IF, particularly the 5:2 regimen, can improve liver cirrhosis and fibrosis in patients with MASLD (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). A clinical trial found that, among individuals diagnosed with MASLD, an 8-week ADF regimen significantly reduced hepatic steatosis, improved liver shear wave elastography, and lowered ALT levels compared to unrestricted eating [<xref ref-type="bibr" rid="CR15">15</xref>]. Similarly, TRF has shown positive effects on liver transient elastography, visceral fat, and insulin resistance in MASLD patients [<xref ref-type="bibr" rid="CR34">34</xref>]. In contrast to ADF and TRF, a greater number of high-quality RCTs indicate that the 5:2 diet significantly improves clinical symptoms in MASLD. Holmer et al. conducted an open-label RCT comparing the 5:2 diet with standard care (SC) in 74 MASLD patients, demonstrating that the 5:2 diet was superior in reducing steatosis, LDL levels, and body weight [<xref ref-type="bibr" rid="CR35">35</xref>]. Additionally, a 12-week 5:2 intervention yielded significant improvements in liver stiffness (-1.8&#x000a0;kPa), ALT (-17.6 U/L), HOMA-IR, HbA1c, and LDL compared to baseline [<xref ref-type="bibr" rid="CR14">14</xref>]. Another study involving clinically diagnosed MASLD patients showed that a 24-week 5:2 diet intervention resulted in marked improvements in body weight, lipid profiles, blood glucose levels, liver function parameters, and hepatic fat content assessed by controlled attenuation parameter (CAP) [<xref ref-type="bibr" rid="CR13">13</xref>]. Based on current clinical evidence, the 5:2 diet may serve as the most promising therapeutic strategy for MASLD management.
</p></sec><sec id="Sec3"><title>The effect of IF on gut microbiome</title><p id="Par31">Dietary changes have rapid and lasting effects on the gut microbiota [<xref ref-type="bibr" rid="CR36">36</xref>]. The structure and function of the gut microbiota exhibit circadian rhythm patterns, and disruptions in the host's circadian rhythm&#x02014;such as irregular eating patterns&#x02014;can impact bacterial populations, leading to dysbiosis [<xref ref-type="bibr" rid="CR37">37</xref>]. Consequently, maintaining a stable gut microbiota is crucial, as IF promotes regularized eating and fasting patterns, thereby facilitating the restoration of a healthy circadian rhythm within the gut microbiome. In mouse models lacking circadian rhythms, IF has been shown to induce periodic activity within the gut microbiota [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Catterson et al. found that the short-term IF &#x0201c;2:5 diet&#x0201d; during early adulthood significantly extended lifespan in Drosophila by alleviating late-life gut pathology and enhancing gut barrier function, suggesting that even brief periods of fasting can confer lifelong health benefits [<xref ref-type="bibr" rid="CR39">39</xref>]. IF exerts a beneficial impact on the microbiome by enhancing microbial diversity and rhythmic activity, as well as modulating the abundance of specific bacterial taxa [<xref ref-type="bibr" rid="CR40">40</xref>]. These effects are particularly advantageous in attenuating the adverse consequences of high-fat diets on the microbiome and reducing the prevalence of obesity-associated microbial communities [<xref ref-type="bibr" rid="CR38">38</xref>]. Specifically, in experimental models subjected to high-fat dietary interventions, IF led to an increase in protective bacteria from the <italic>Ruminococcaceae</italic> family, while concurrently decreasing the abundance of pro-obesity taxa such as <italic>Lactobacillus</italic> [<xref ref-type="bibr" rid="CR38">38</xref>]. However, Age, sex, and health status may influence the effects of IF on the gut microbiome. Discrepancies in the impact of IF on the gut microbiome may also arise between animal experiments and human clinical studies. Using large datasets to compare the gut microbiota of mice and humans, it was found that the two share similarities at the phylum level, but there were significant differences at the species level [<xref ref-type="bibr" rid="CR41">41</xref>]. The gut microbiota of mice changed within a week due to dietary alterations, while changes in human gut microbiota occurred at a much slower rate [<xref ref-type="bibr" rid="CR42">42</xref>]. Although there are differences between the gut microbiota of humans and mice, both mouse models and human studies have shown that IF can alter the gut microbiota, subsequently influencing metabolic processes and liver health [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. Still, the restructuring effects of IF on the gut microbiota may vary due to differences in animal strains, rearing conditions, baseline microbiome characteristics, and feeding durations, so we have summarized the effects of different IF protocols on the gut microbiome in animal experiments (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) and human clinical studies (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec4"><title>The role of intestinal microflora in IF-induced improvement in MASLD</title><p id="Par32">The gut microbiota plays a crucial role in energy metabolism and lipid homeostasis, as germ-free (GF) or microbiota-depleted mice show reduced sensitivity to diet-induced obesity and metabolic syndrome [<xref ref-type="bibr" rid="CR99">99</xref>]. Gut microbiota potentially mediate the hepatoprotective and anti-inflammatory effects of IF according to substantial evidence from preclinical animal models (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>IF improves the gut environment, which in turn directly or indirectly protects against dysmetabolism and MASLD in diet-induced obesity/MASH mice. Mice subjected to a diet-induced obesity/MASH protocol were provided ad libitum access to a high-fat diet. These animals exhibited significant alterations in the gut microbiome, microbial metabolites, and intestinal barrier integrity, rendering them highly susceptible to dysmetabolism and MASH progression. IF restored cyclical fluctuations in gut microbiota composition, luminal metabolite profiles, gut signaling, and hepatic gene expression. Furthermore, fasting enhanced the abundance of beneficial gut bacteria and their metabolic byproducts while reinforcing intestinal barrier function. Collectively, these modifications conferred protection against dysmetabolism and MASH development</p></caption><graphic xlink:href="13578_2025_1406_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Gut-liver axis</title><p id="Par33">Gut-liver axis denotes the reciprocal communication between the gut and liver, and it has been emphasized in recent clinical approaches. the intestine is tightly knit to the liver though hepatic portal vein [<xref ref-type="bibr" rid="CR100">100</xref>], which circulates blood from intestine to liver. Under intricate regulation of gut barrier, essential substances in the enteric system pass through the intestinal lumen selectively, and finally empty into the bloodstream. However, inflammatory mediators, toxins, pathogens can enter the circulation if the gut barrier is compromised, whereby it loses the differential permeability and disturbs gut-liver homeostasis. Among these disturbances, the gut microbiota plays a predominant role [<xref ref-type="bibr" rid="CR101">101</xref>]; its imbalance results in dysbiosis that drives liver disorders, and its metabolites and byproducts deteriorate hepatic processes.</p><p id="Par34">Previous research showed that disorders of the gut, known as gut dysbiosis, can have a statistically significant relationship to certain pathophysiological alterations in the liver. Although the two organs are not physically in contact, their close proximity and several anatomical connections facilitate organ-to-organ crosstalk [<xref ref-type="bibr" rid="CR102">102</xref>]. Disruption of gut microbiome homeostasis can lead to dysbiosis, characterized by a reduction in beneficial taxa, such as <italic>Prevotella</italic>, and an increase in pathogenic taxa, such as <italic>Klebsiella pneumoniae</italic> [<xref ref-type="bibr" rid="CR103">103</xref>]. This imbalance can directly and indirectly impact the progression of MASLD [<xref ref-type="bibr" rid="CR103">103</xref>]. Antibiotic-induced microbiota-depleted (AIMD) mice exhibited significant increases in glucose, triglycerides (TG), free fatty acids (FFA), and corticosterone, along with a decrease in insulin. These changes correlated with elevated liver transcripts of PEPCK and G6Pase, while the expression of Hes1, a negative regulator of hepatic TG production, was reduced [<xref ref-type="bibr" rid="CR104">104</xref>]. Mechanistical studies have revealed that not only gut microbiota, but also cytokines, hormones and metabolites from the gut heavily influence common liver diseases. For instance, intestinal barrier impairment is regarded as a booster for developing MASLD [<xref ref-type="bibr" rid="CR9">9</xref>], while aberrant gut microbial behavior is considered a hallmark for such condition. Also, the deficiency of microbiota leads to excessive corticosterone production in ileal intestinal epithelial cells (IECs), which in turn affects circadian rhythm components and systemic metabolism. GF mice exhibit increased TG and hypoinsulinemia [<xref ref-type="bibr" rid="CR105">105</xref>]. Gut microbiota dysbiosis serves as both a pathogenic factor in MASLD onset and a regulator of its associated pathological processes. Transplanting gut bacteria from MASLD patients into mice can promote the development of liver inflammation and fibrosis associated with MASH by activating the accumulation of intrahepatic B cells through innate and adaptive immune mechanisms [<xref ref-type="bibr" rid="CR106">106</xref>]. When the dynamic balance of gut microbiota is disrupted, the integrity of the intestinal barrier is compromised, resulting in bacterial overgrowth and translocation, which causes an influx of bacterial metabolites into the bloodstream that triggers inflammatory cascades and exacerbates metabolic dysregulation, thereby promoting the development of MASLD [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec6"><title>Barrier systems against translocation of microorganisms</title><p id="Par35">The gut barrier system is a complex network of physical, biochemical, and immune components that protect the intestinal lining from harmful substances and pathogens [<xref ref-type="bibr" rid="CR16">16</xref>]. It includes a physical barrier of tightly joined epithelial cells, a mucosal layer, immune responses, and interactions with the gut microbiome, all crucial for maintaining gut health and homeostasis [<xref ref-type="bibr" rid="CR16">16</xref>]. The integrity of the gut barrier is essential for maintaining gut permeability and preventing endotoxemia, and it is also linked to metabolic diseases and the subsequent development of MASLD [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Brun et al. reported that obese ob/ob and db/db mice exhibited increased intestinal permeability, decreased expression of tight junction proteins occludin and ZO-1 in the intestinal mucosa, elevated circulating levels of pro-inflammatory cytokines, and the presence of portal endotoxemia [<xref ref-type="bibr" rid="CR109">109</xref>]. Increased intestinal permeability and reduced tight junctions induced by high-fat feeding strongly led to elevated levels of endotoxemia, which contributed to impaired glucose intolerance, body weight gain, fat mass accumulation, elevated inflammation, and oxidative stress, further exacerbating metabolic disturbances [<xref ref-type="bibr" rid="CR110">110</xref>]. Gut vascular barrier disruption is an early and common event in MASLD progression, promoting bacterial translocation to the liver [<xref ref-type="bibr" rid="CR111">111</xref>]. Patients with MASLD showed significantly increased gut permeability due to disrupted intercellular tight junctions, as evidenced by reduced zona occludens-1 (ZO-1) expression in duodenal biopsy specimens, which may play a crucial role in the pathogenesis of hepatic fat deposition [<xref ref-type="bibr" rid="CR107">107</xref>]. Children with MASLD demonstrated increased intestinal permeability, which correlates with the severity of hepatic involvement [<xref ref-type="bibr" rid="CR108">108</xref>]. IF increased the villus length and muscularis thickness in diabetic mice, while also preventing intestinal leakage and reducing plasma LPS levels [<xref ref-type="bibr" rid="CR78">78</xref>]. The expression of the tight junction protein claudin-1 in the intestinal barrier was elevated in the colon tissue of diabetic mice after IF treatment, which aligns with the improvement in intestinal permeability [<xref ref-type="bibr" rid="CR78">78</xref>]. ZO-1 expression in the ileum was elevated in IF mice due to modulation by the gut microbiota [<xref ref-type="bibr" rid="CR71">71</xref>]. IF also altered the composition of T cells in the gut lamina propria, resulting in a decrease in IL-17-producing T cells and an increase in regulatory T cells (Tregs) [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par36">Plasma peptidoglycan: Peptidoglycan is a component of Gram-positive bacteria, with Firmicutes being a phylum of Gram-positive bacteria. Plasma peptidoglycan serves as a biomarker for gut barrier function. Alterations in the gut microbiota of IF mice are considered beneficial for gut health and the integrity of the intestinal barrier [<xref ref-type="bibr" rid="CR48">48</xref>]. Diabetic mice exhibit elevated peptidoglycan levels, while IF diets reduce peptidoglycan levels during fasting [<xref ref-type="bibr" rid="CR48">48</xref>]. This suggests that gut barrier integrity is compromised in diabetes, whereas the IF regimen (fasting days) can improve it. Jin et al. demonstrated that the administration of peptidoglycan alone is sufficient to induce liver steatosis and inflammation in mice on a normal chow diet, with NOD2 activation by peptidoglycan motifs driving the progression of these hepatic conditions [<xref ref-type="bibr" rid="CR112">112</xref>]. Thus, the reduction of serum peptidoglycan induced by IF may represent a potential mechanism for alleviating MASLD.</p></sec><sec id="Sec7"><title>Gut bacterial diversity</title><p id="Par37">Gut bacteria diversity refers to the variety and abundance of bacterial species in the gastrointestinal tract, which is essential for digestive health, immune function, metabolic balance, and the gut-liver axis [<xref ref-type="bibr" rid="CR113">113</xref>]. IF significantly alleviated MASH and increased &#x003b1;-diversity in MASH mice induced by a high-fat and high-cholesterol diet [<xref ref-type="bibr" rid="CR21">21</xref>]. Animals or Individuals who practice long-term IF have a fecal microbiota that is significantly more diverse than that of those who consume ad libitum diet [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. An increase in gut microbiota diversity is regarded as a positive health indicator, as it enhances the ability to degrade and metabolize a variety of nutrients [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. A meta-analysis examining the association between gut microbiome composition and MASLD incorporated 54 studies with a total of 8,894 participants [<xref ref-type="bibr" rid="CR113">113</xref>]. The findings revealed a significant reduction in &#x003b1; diversity indices among MASLD patients, specifically in Shannon and Chao 1 indices [<xref ref-type="bibr" rid="CR113">113</xref>]. The majority of included studies in this review indicated a marked decrease in anti-inflammatory microbial taxa, such as <italic>Ruminococcaceae</italic>, alongside an elevation in pro-inflammatory taxa, including <italic>Fusobacterium</italic> and <italic>Escherichia coli</italic> [<xref ref-type="bibr" rid="CR113">113</xref>]. Matthew et al. conducted an analysis of 847 fecal samples from 262 patients with acute or chronic liver disease using shotgun metagenomic sequencing and targeted metabolomics [<xref ref-type="bibr" rid="CR114">114</xref>]. The study demonstrated that patients hospitalized due to liver disease exhibited reduced microbial diversity and a deficiency in bioactive metabolites, including SCFAs and bile acid derivatives, which can adversely affect immune defense and the integrity of the epithelial barrier [<xref ref-type="bibr" rid="CR114">114</xref>].</p></sec><sec id="Sec8"><title>Hepatoprotective and hepatotoxic microbiome</title><p id="Par38">Dysbiosis of the gut microbiome is associated with MASLD, typically characterized by a decrease in beneficial species (i.e., <italic>Ruminococcaceae</italic>) and an increase in pathogenic species (i.e., <italic>Fusobacterium</italic> and <italic>Escherichia</italic>) [<xref ref-type="bibr" rid="CR113">113</xref>]. Another meta-analysis quantitatively evaluated the relationship between specific gut microbial taxa and the risk of MASLD, incorporating data from 15 studies involving fecal microbiome analysis of 577 MASLD patients and 688 healthy controls [<xref ref-type="bibr" rid="CR115">115</xref>]. The results revealed that MASLD patients exhibited a significant increase in the abundance of <italic>Escherichia coli, Prevotella,</italic> and <italic>Streptococcus</italic>, while the levels of <italic>Faecalibacterium, Coprococcus,</italic> and <italic>Ruminococcus</italic> were markedly diminished compared to healthy controls [<xref ref-type="bibr" rid="CR115">115</xref>]. Additional approaches targeting hepatoprotective bacteria, including fecal microbiota transplantation and the administration of probiotics, prebiotics, synbiotics, and engineered bacteria, may enhance metabolic function and reduce the risk of developing MASLD [<xref ref-type="bibr" rid="CR16">16</xref>]. Based on Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>, both animal studies and human clinical trials demonstrate that various IF protocols promote the enrichment of anti-inflammatory, metabolic, and liver-beneficial microbiota, while concurrently reducing the abundance of pro-inflammatory bacterial populations.</p></sec><sec id="Sec9"><title>Hepatoprotective microbiome</title><p id="Par39">IF can enrich the gut microbiota with beneficial bacteria for liver metabolism, such as <italic>Lactobacillus, Bifidobacterium, Akkermansia muciniphila, Parabacteroides distasonis, Faecalibacterium prausnitzii,</italic> and <italic>Roseburia</italic>, while reducing harmful gut bacteria associated with MASLD, such as <italic>Escherichia coli</italic>.</p></sec><sec id="Sec10"><title>Lactobacillus</title><p id="Par40"><italic>Lactobacillus</italic> is frequently utilized as probiotics owing to their positive effects, which include the modulation of inflammatory immune responses and the enhancement of gut barrier function [<xref ref-type="bibr" rid="CR116">116</xref>]. Both mouse models and human clinical studies have demonstrated that IF can lead to an enrichment of <italic>Lactobacillus</italic> in the gut microbiota [<xref ref-type="bibr" rid="CR49">49</xref>]. The relationship between various <italic>Lactobacillus</italic> strains and obesity, as well as related metabolic disorders, has been extensively studied. Specifically, an increase in <italic>Lactobacillus</italic> levels may prevent obesity-related metabolic disturbances, potentially through alterations in bile acids within the gut lumen [<xref ref-type="bibr" rid="CR117">117</xref>]. In one clinical study, MASLD patients administered <italic>Lactobacillus acidophilus</italic> three times daily for one month exhibited significant reductions in transaminases (AST and ALT), indicating that <italic>lactobacilli</italic> may help improve liver inflammation [<xref ref-type="bibr" rid="CR118">118</xref>]. In another study, MASH patients who received <italic>Lactobacillus rhamnosus</italic> and inulin for 3&#x000a0;months experienced reductions in weight, waist circumference, and BMI, along with improved liver inflammation [<xref ref-type="bibr" rid="CR119">119</xref>]. <italic>Lactobacillus acidophilus</italic> supplementation inhibited MASLD-HCC development in mouse models through the protective effects of valeric acid, which enhances intestinal barrier integrity and disrupts the Rho-GTPase pathway via GPR41/43 receptor binding [<xref ref-type="bibr" rid="CR120">120</xref>].</p></sec><sec id="Sec11"><title>Bifidobacterium</title><p id="Par41"><italic>Bifidobacterium</italic> is a safe and effective probiotic that can be used to treat liver diseases and can be effectively enriched after IF regimen [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. It successfully restores the balance of the gut microbiota and improves biochemical and clinical parameters in MASLD and cirrhosis [<xref ref-type="bibr" rid="CR121">121</xref>]. The lack of <italic>Bifidobacterium</italic> is associated with an increased risk of metabolic-associated fatty liver disease in young patients with type 2 diabetes [<xref ref-type="bibr" rid="CR122">122</xref>]. One species of the <italic>Bifidobacterium</italic> genus, <italic>Bifidobacterium pseudolongum</italic>, was the most significantly depleted bacterium in mice with MASLD-associated HCC [<xref ref-type="bibr" rid="CR123">123</xref>]. This bacterium helped restore a healthy gut microbiome composition, improved gut barrier function, and provided protection against MASLD-HCC by secreting the anti-tumor metabolite acetate, which is transported to the liver through the portal vein [<xref ref-type="bibr" rid="CR123">123</xref>]. <italic>Bifidobacterium</italic> metabolizes lactulose to produce high concentrations of acetate, contributing to the acidification of the intestinal lumen in MASLD patients and mice, which collectively help reduce the growth of antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus faecium [<xref ref-type="bibr" rid="CR114">114</xref>].</p></sec><sec id="Sec12"><title>Akkermansia muciniphila</title><p id="Par42"><italic>Akkermansia muciniphila</italic>, a member of the phylum <italic>Verrucomicrobia</italic>, is a mucin-degrading bacterium that resides in the mucus layer [<xref ref-type="bibr" rid="CR124">124</xref>]. <italic>A. muciniphila</italic> may account for 3&#x02013;5% of a healthy gut microbiome, and its relative abundance is negatively correlated with body weight [<xref ref-type="bibr" rid="CR125">125</xref>]. It is an important gut symbiont for maintaining metabolic homeostasis and is currently recommended clinically as a novel probiotic for the treatment of obesity, diabetes, liver diseases, and other conditions [<xref ref-type="bibr" rid="CR126">126</xref>]. <italic>Akkermansia muciniphila</italic> exhibits an inverse correlation with inflammation onset, adipose tissue metabolic alterations, and obesity-related metabolic disorders [<xref ref-type="bibr" rid="CR127">127</xref>]. Oral supplementation of <italic>Akkermansia muciniphila</italic> can alleviate hyperinsulinemia and reduce plasma cholesterol levels, inflammatory biomarkers, and markers of liver dysfunction in overweight or obese adults with insulin resistance [<xref ref-type="bibr" rid="CR128">128</xref>]. <italic>A. muciniphila</italic> is associated with the expression of genes involved in bile acid synthesis, metabolism, and transport, contributing to the maintenance of normal bile formation. The synbiotic combination of <italic>A. muciniphila</italic> and quercetin has been shown to improve early obesity and MASLD by reshaping gut microbiota and modulating bile acid metabolism [<xref ref-type="bibr" rid="CR129">129</xref>]. Recent studies have found that treatment with <italic>A. muciniphila</italic> enhanced hepatic cholesterol absorption, BAs synthesis and transport, and improve the circulation and metabolism of BAs in the gut-liver axis [<xref ref-type="bibr" rid="CR130">130</xref>] Moreover, A. muciniphila increased the conversion of CDCA to tauro-CDCA in hepatocytes, thereby inhibiting the expression of pro-inflammatory factors through TGR5, which helped reduce systemic inflammation [<xref ref-type="bibr" rid="CR131">131</xref>]. In a murine model of liver cirrhosis, administration of <italic>A. muciniphila</italic> significantly attenuated hepatic fibrosis and hyperammonemia, and altered the bacterial composition in the small intestine [<xref ref-type="bibr" rid="CR132">132</xref>]. In an auxiliary study of a RCT, 34 overweight or obese adults underwent a FMD for 12&#x000a0;months, and it was found that their gut microbiota showed a significant increase in <italic>Akkermansia</italic> [<xref ref-type="bibr" rid="CR84">84</xref>]. A notable rise in the abundance of <italic>A. muciniphila</italic> was detected in nine healthy adults following a 29-day Islamic fasting, in comparison to baseline levels [<xref ref-type="bibr" rid="CR90">90</xref>]. Additionally, other methods of IF, including TRF, have also resulted in the enrichment of the hepatoprotective bacterium <italic>A. muciniphila</italic> [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR96">96</xref>].</p></sec><sec id="Sec13"><title>Parabacteroides distasonis</title><p id="Par43"><italic>Parabacteroides distasonis</italic> is an anti-inflammatory gut bacterium that contributes to dietary fiber metabolism and is associated with gut health and various health benefits [<xref ref-type="bibr" rid="CR133">133</xref>], which is also found significantly enriched after various IF rigemen [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. A three-week 5:2 IF program resulted in a significant enrichment of <italic>P. distasonis</italic> in the gut microbiota of 72 healthy adults [<xref ref-type="bibr" rid="CR98">98</xref>]. In a preliminary analysis of data from 736 American Gut Project (AGP) samples, the abundance of Parabacteroides was significantly negatively correlated with body mass index (BMI) [<xref ref-type="bibr" rid="CR134">134</xref>]. Among gut Parabacteroides, <italic>P. distasonis</italic> is defined as one of the 18 core members of the human gut microbiome and is believed to play an important physiological role in the host [<xref ref-type="bibr" rid="CR135">135</xref>]; additionally, <italic>P. distasonis</italic> is relatively less abundant in individuals with obesity and non-alcoholic fatty liver disease [<xref ref-type="bibr" rid="CR136">136</xref>]. According to previous reports, the enrichment of <italic>P. distasonis</italic> reduced weight gain, improve glycemic homeostasis, and correct obesity-related abnormalities, including hyperlipidemia and hepatic steatosis in ob/ob and high-fat diet (HFD)-fed mice through secondary bile acid-activated FXR signaling and succinate-activated intestinal gluconeogenesis [<xref ref-type="bibr" rid="CR134">134</xref>]. <italic>P. distasonis</italic> is reduced in patients with hepatic fibrosis and may inhibits MASH through its metabolite pentadecanoic acid, while also improving liver fibrosis by modulating bile acid metabolism and regulating hepatocyte pyroptosis [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. Hu et al. found that a 3-week IF intervention might lead to an enrichment of gut bacteria rich in CAZymes, including <italic>P. distasonis</italic>, which helps alleviate obesity and its complications by producing succinate [<xref ref-type="bibr" rid="CR98">98</xref>].</p></sec><sec id="Sec14"><title>Faecalibacterium prausnitzii</title><p id="Par44"><italic>Faecalibacterium prausnitzii</italic> is a protective factor against MASLD in early-onset T2D, independent of age, sex, diabetes duration, and other confounding factors [<xref ref-type="bibr" rid="CR122">122</xref>]. Clinical studies have shown that IF significantly increases the abundance of <italic>F. prausnitzii</italic> in the gut microbiota [<xref ref-type="bibr" rid="CR86">86</xref>]. The relative abundance of <italic>F. prausnitzii</italic> is significantly reduced in MASH patients compared to healthy cohort [<xref ref-type="bibr" rid="CR139">139</xref>]. Hu et al. administered 12 <italic>F. prausnitzii</italic> strains orally to HFD-fed C57BL/6&#x000a0;J mice for 12&#x000a0;weeks. Five strains&#x02014;A2-165, LB8, ZF21, PL45, and LC49&#x02014;significantly improved serum lipid profiles and mitigated glucose intolerance, adipose dysfunction, liver steatosis, inflammation, and oxidative stress in MASLD mice [<xref ref-type="bibr" rid="CR140">140</xref>]. Additionally, the strains LC49 and LB8 notably enhanced the production of SCFAs and regulated the gut microbiota [<xref ref-type="bibr" rid="CR140">140</xref>]. In MASH mouse models, supplementation with <italic>F. prausnitzii</italic> could improve glucose homeostasis, prevent hepatic lipid accumulation, inhibit liver injury and fibrosis, restore impaired gut barrier function, and alleviate liver steatosis and inflammation. Furthermore, <italic>F. prausnitzii</italic> treatment resulted in reduced hepatic lipid accumulation, decreased levels of AST and ALT, increased fatty acid oxidation in the liver, enhanced adiponectin signaling, improved insulin sensitivity in both subcutaneous and visceral adipose tissues, and a reduction in inflammatory responses in HFD mice [<xref ref-type="bibr" rid="CR141">141</xref>].</p></sec><sec id="Sec15"><title>Roseburia</title><p id="Par45"><italic>Roseburia</italic> is a genus of beneficial gut bacteria that ferments dietary fibers and produces SCFAs, promoting gut health and metabolic functions [<xref ref-type="bibr" rid="CR142">142</xref>]. Observational studies and RCT have found that various IF protocols, including TRF, Ramadan fasting, and the 5:2 diet, lead to an increase in <italic>Roseburia</italic> levels in the gut microbiota of both healthy and obese individuals [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR143">143</xref>]. Patients with HCC showed a diminished presence of SCFA-producing bacteria, including <italic>Roseburia</italic> [<xref ref-type="bibr" rid="CR144">144</xref>]. Furthermore, <italic>Roseburia</italic> is significantly reduced in individuals with obesity and T2D [<xref ref-type="bibr" rid="CR145">145</xref>]. In a mouse model of alcoholic liver disease (ALD), administration of <italic>Roseburia spp.</italic> significantly mitigated hepatic steatosis and inflammation [<xref ref-type="bibr" rid="CR146">146</xref>]. Notably, the flagellin protein of <italic>R. intestinalis</italic> activates Toll-like receptor 5 (TLR5), leading to increased expression of the tight junction protein occludin, which restores intestinal barrier integrity, and enhances IL-22 and REG3&#x003b3; expression, promoting gut microbiota restoration [<xref ref-type="bibr" rid="CR146">146</xref>].</p></sec><sec id="Sec16"><title>Enterobacteriaceae (Escherichia coli)</title><p id="Par46"><italic>Escherichia coli</italic> is one kind of flagellated commensal bacteria residing in the human intestine, serving as an opportunistic pathogen commonly associated with complications in liver cirrhosis patients including ascites [<xref ref-type="bibr" rid="CR147">147</xref>]. In a randomized-controlled bi-centric trial, a 3-month 5:2 IF regimen reduced <italic>E. coli</italic> levels in the gut of patients with metabolic syndrome, with a persistent depletion in <italic>Enterobacteriaceae</italic>, particularly <italic>E. coli</italic>, observed even at the end of a 3-month refeeding period [<xref ref-type="bibr" rid="CR85">85</xref>]. In cirrhotic mice, <italic>E. coli</italic> translocated to the liver via the portal circulation by disrupting the integrity of the gut vascular barrier through farnesoid X receptor (FXR) signaling [<xref ref-type="bibr" rid="CR148">148</xref>]. MASLD patients exhibited significantly higher serum immunoglobulin G titers against <italic>E. coli</italic> than healthy controls, indicating that <italic>E. coli</italic> may translocated to the bloodstream and subsequently actived systemic immune responses [<xref ref-type="bibr" rid="CR149">149</xref>]. MASLD or MASH patients harbor significantly higher levels of <italic>E. coli</italic> in their gut microbiota and intestinal mucosa [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]. Additionally, those with liver fibrosis exhibit even elevated <italic>E. coli</italic> levels compared to those without fibrosis [<xref ref-type="bibr" rid="CR152">152</xref>]. <italic>E. coli</italic> activates TWIST1 via its flagellin-induced Toll-like receptor 5 (TLR5) and nuclear factor &#x003ba;B (NF-&#x003ba;B) pathways, facilitating the endothelial-to-mesenchymal transition of hepatic sinusoidal endothelial cells and promoting MASLD development [<xref ref-type="bibr" rid="CR153">153</xref>]. The NF73-1 strain of Escherichia coli, isolated from the intestinal mucosa of MASH patients, translocated to the liver, activating the TLR2/NLRP3 pathway and leading to an increased population of M1 macrophages in the liver. These M1 macrophages, in turn, activated the mTOR-S6K1-SREBP-1/PPAR-&#x003b1; signaling pathway, thereby contributing to the progression of MASLD [<xref ref-type="bibr" rid="CR151">151</xref>].</p></sec><sec id="Sec17"><title>Microbial metabolites and molecules involved in bidirectional communication between gut and liver</title><p id="Par47">The IF-restructured gut microbiota also led to alterations in the microbial metabolites in plasma. Gut microbial metabolites, including BA, TMAO, and SCFA, are involved in the host's immune response and inflammation, and have a close association with liver health. IF may alter the circulating levels of microbial metabolites, which could help regulate the host's immune response and metabolic status.</p></sec><sec id="Sec18"><title>Bile acids</title><p id="Par48">Primary bile acids (BAs) are synthesized from cholesterol in the liver, serving as emulsifiers for dietary fats and endocrine hormones that regulate glucose and lipid metabolism. Conjugated and unconjugated primary BAs are stored in the gallbladder and released into the small intestine, where they undergo structural modifications to form various secondary BAs, which demonstrate reduced host toxicity and diverse hormonal regulatory functions [<xref ref-type="bibr" rid="CR154">154</xref>]. Microbial composition changes induced by IF can significantly modulate the enzymatic activity of these metabolic pathways including bile salt hydrolase and alter the bile acid pool composition [<xref ref-type="bibr" rid="CR48">48</xref>]. IF treatment could significantly increase the enrichment of bacteria expressing bile salt hydrolase activity, such as Lactobacillus and Bifidobacterium [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR80">80</xref>], which play crucial roles in deconjugating bile acids, modulating gut microbiota, influencing metabolic pathways, exhibiting antimicrobial properties, and contributing to overall host health [<xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. Certain Lactobacillus species produce bile acid hydrolase, which can conjugate bile acids that act as antagonists to the primary ileal bile acid receptor, FXR [<xref ref-type="bibr" rid="CR117">117</xref>]. FXR-mediated enterohepatic bile acid signaling directly influences the activity of cytochrome P450 7A1 (Cyp7a1), also known as cholesterol 7&#x003b1;-hydroxylase, which is the primary enzyme responsible for de novo bile acid synthesis from cholesterol [<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR158">158</xref>]. Compared to HFD mice with ad libitum feeding, this enzyme exhibits higher activity levels in HFD mice after TRF, which correlates with the reduced serum cholesterol observed in TRF-HFD mice [<xref ref-type="bibr" rid="CR159">159</xref>]. After IF treatment, there is an increase in primary, secondary, and tauroconjugated bile acids in the intestinal lumen of mice, indicating that IF enhances bile acid excretion [<xref ref-type="bibr" rid="CR21">21</xref>]. In MASLD accompanied by cholestasis, there is a notable increase in hepatocellular inflammation, necrosis, and apoptosis, as well as fibrosis and disturbances in carbohydrate and lipid metabolism, all contributing to the progressive development of MASLD. IF treatment also significantly increases beneficial metabolites of bile acids, such as ursodeoxycholic acid (UDCA), in the serum, which may enhance metabolic health [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR75">75</xref>] UDCA is a hydrophilic bile acid commonly used to treat cholestatic liver diseases and has shown efficacy in MASH and MASLD [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. UDCA may alleviate liver inflammation in NASH mice by altering gut microbiota composition or enhancing bile acid signaling [<xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]. Clinical studies indicate that UDCA can serve as a preventive measure against atherosclerosis, steatosis, and liver fibrosis in patients with non-alcoholic fatty liver disease [<xref ref-type="bibr" rid="CR160">160</xref>]. IF protocol can also increase TUDCA [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR78">78</xref>], which is formed from UDCA by combining with taurine in the liver [<xref ref-type="bibr" rid="CR164">164</xref>]. TUDCA has been shown to act as an endogenous chemical chaperone, protecting liver cells from endoplasmic reticulum stress, thereby treating MASLD [<xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR166">166</xref>]. Wang et al. found that TUDCA mitigated HFD-induced MASLD progression in mice by attenuating intestinal inflammation, enhancing gut barrier integrity, reducing intestinal fat transport, and modulating gut microbiota composition [<xref ref-type="bibr" rid="CR164">164</xref>].</p></sec><sec id="Sec19"><title>SCFAs</title><p id="Par49">Short-chain fatty acids (SCFAs), produced by the fermentation of indigestible fibers by gut bacteria, serve as the primary energy source for colonic cells and have been shown to enhance intestinal barrier function [<xref ref-type="bibr" rid="CR167">167</xref>]. SCFAs include acetate, propionate, and butyrate. Butyrate serves as an energy source for colonic epithelial cells, while acetate and propionate act as substrates for lipogenesis and gluconeogenesis [<xref ref-type="bibr" rid="CR168">168</xref>]. Butyrate is effective in preventing MASLD, MASH, inflammation, cancer, and liver damage, while also improving metabolic disorders such as insulin resistance and obesity [<xref ref-type="bibr" rid="CR169">169</xref>]. IF treatment significantly improved butyrate-producing <italic>Odoribacter</italic> [<xref ref-type="bibr" rid="CR78">78</xref>] and butyrate levels [<xref ref-type="bibr" rid="CR87">87</xref>]. The main bacteria that produce SCFAs are from the <italic>Ruminococcaceae</italic> family [<xref ref-type="bibr" rid="CR170">170</xref>], and some studies have shown that the abundance of <italic>Ruminococcaceae</italic> was significantly reduced in the feces of obese patients with MASLD and MASH [<xref ref-type="bibr" rid="CR171">171</xref>&#x02013;<xref ref-type="bibr" rid="CR173">173</xref>]. However, both animal experiments and clinical studies related to IF have demonstrated that IF could increase the intestinal abundance of <italic>Ruminococcaceae</italic> (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Supplementation with oral SCFAs or transplantation of SCFA-producing probiotics could enhance tight junction integrity in colonic cells [<xref ref-type="bibr" rid="CR174">174</xref>]. Therefore, interventions aimed at increasing intestinal SCFAs levels may mitigate liver disease progression by reducing immune-related damage from portal transmission of bacterial endotoxins. A systematic review indicates that increasing intestinal SCFAs concentration may reduce gut permeability and liver injury, suggesting that upregulating intestinal SCFAs could be a promising therapeutic strategy for various liver disease models [<xref ref-type="bibr" rid="CR175">175</xref>]. Reduced levels of SCFAs in the gut or bloodstream are also implicated in the progression of MASLD [<xref ref-type="bibr" rid="CR176">176</xref>&#x02013;<xref ref-type="bibr" rid="CR178">178</xref>]. G protein-coupled receptor 43 (GPR43) is a receptor for SCFAs that regulates intestinal inflammatory responses. The SCFAs/GPR43 signaling pathway is believed to enhance gut permeability and minimize liver injury induced by microbial components and products [<xref ref-type="bibr" rid="CR170">170</xref>]. Thus, the elevation of SCFAs concentrations induced by IF [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR89">89</xref>] may constitute a pivotal mechanism contributing to the hepatoprotective effects associated with IF.</p></sec><sec id="Sec20"><title>TMAO</title><p id="Par50">Trimethylamine N-oxide (TMAO) is one of the metabolites highly dependent on gut microbiota. Metabolize dietary precursors, such as L-carnitine, betaine and choline can be converted to trimethylamine (TMA) by gut microbiota in the intestine, which is subsequently transported to the liver via the portal circulation and metabolized to TMAO by flavin-containing monooxygenase 3 (FMO3) [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. TMA-producing bacteria, such as <italic>Klebsiella pneumoniae</italic> can produce TMA from choline via the CntC/D (choline-TMA lyase complex) and carnitine/butyrobetaine via the CntA/B (carnitine monooxygenase complex)&#x02014;while <italic>Proteus mirabilis</italic> only possesses the CntC/D complex and can produce TMA solely from choline [<xref ref-type="bibr" rid="CR181">181</xref>]. The increased abundance of TMA-producing bacteria may be one of the mechanisms leading to elevated plasma TMAO levels [<xref ref-type="bibr" rid="CR182">182</xref>], and the adverse effects of TMAO on glucose and lipid metabolism may be mediated by the gut microbial metabolite TMA [<xref ref-type="bibr" rid="CR183">183</xref>]. Additionally, it has been reported that healthy individuals with a high relative abundance of Firmicutes display increased circulating levels of TMAO [<xref ref-type="bibr" rid="CR184">184</xref>]. The average TMAO level in a fasting state is 14.3&#x000a0;ng, compared to a baseline average of 27.1&#x000a0;ng in a feeding state [<xref ref-type="bibr" rid="CR185">185</xref>].</p><p id="Par51">IF can significantly lower circulating TMAO levels [<xref ref-type="bibr" rid="CR186">186</xref>], potentially related to the duration of fasting: in overweight or obese adults, a one-day fast significantly reduces TMAO levels compared to a two-day continuous fast [<xref ref-type="bibr" rid="CR82">82</xref>]. A dose&#x02013;response meta-analysis indicates that for each 10&#x000a0;&#x000b5;mol/L increase in TMAO levels, the relative risk of all-cause mortality rises by 7.6% [<xref ref-type="bibr" rid="CR187">187</xref>]. TMAO are significantly associated with the histological characteristics of MASLD and the risk of MASH in patients with T2D [<xref ref-type="bibr" rid="CR188">188</xref>]. Prospective studies have shown that plasma TMAO concentrations are associated with all-cause mortality in MASLD patients [<xref ref-type="bibr" rid="CR189">189</xref>]. Furthermore, a meta-analysis involving 34,000 patients revealed that the risk of fatal or non-fatal cardiovascular events in MASLD patients is 64% higher than in non- MASLD patients [<xref ref-type="bibr" rid="CR190">190</xref>], potentially correlating with the severity of MASLD [<xref ref-type="bibr" rid="CR191">191</xref>]. Additionally, among adults in hospitals and communities in China, levels of TMAO in the blood are associated with the severity of MASLD [<xref ref-type="bibr" rid="CR192">192</xref>]. These findings suggest that TMAO may serve as an independent risk marker for MASLD. Indeed, TMAO promotes the development of MASLD by affecting bile acid metabolism, unfolded protein response and lipid metabolism. TMAO can reduce the size of the bile acid pool and inhibits the expression of key bile acid synthesis enzymes (Cyp7a1 and Cyp27a1) and bile acid transporters (Oatp1, Oatp4, Mrp2, and Ntcp) in the liver [<xref ref-type="bibr" rid="CR180">180</xref>]. Furthermore, suppressing TMAO formation can upregulate hepatic bile acid synthesis enzyme CYP7A1 and alter the expression of liver genes crucial for bile acid feedback regulation, thereby preventing diet-induced hepatic cholesterol accumulation [<xref ref-type="bibr" rid="CR193">193</xref>]. Another potential mechanism by which TMAO contributes to the development of MASLD may involve the unfolded protein response (UPR), a highly conserved pathway that monitors endoplasmic reticulum (ER) protein homeostasis, enabling cells to manage ER stress [<xref ref-type="bibr" rid="CR194">194</xref>]. TMAO can bind to R-like endoplasmic reticulum kinase (PERK), selectively activating the PERK branch of the unfolded protein response, which induces the transcription factor FoxO1, a key driver of metabolic diseases in a PERK-dependent manner, and consequently leads to metabolic disturbances such as elevated blood glucose and insulin resistance in mice, both of which are significant risk factors for MASLD [<xref ref-type="bibr" rid="CR195">195</xref>]. Additionally, studies have found that TMAO can promote lipid accumulation and fibrosis in vitro in hepatocytes by modulating the KRT17 gene [<xref ref-type="bibr" rid="CR196">196</xref>].</p></sec><sec id="Sec21"><title>Microbiota-derived hepatotoxins</title><p id="Par52">In individuals with liver disease, various gut microbiota and their cellular components frequently translocate into the portal circulation due to a disrupted intestinal barrier, subsequently reaching the liver [<xref ref-type="bibr" rid="CR197">197</xref>, <xref ref-type="bibr" rid="CR198">198</xref>]. Certain compounds produced by gut bacteria can adversely affect liver function, resulting in inflammation and hepatocellular damage [<xref ref-type="bibr" rid="CR198">198</xref>]. Among these, one of the most notable microbiota-derived hepatotoxins is lipopolysaccharides (LPS), which are the components of outer wall of Gram-negative bacteria and act as pathogen-associated molecular patterns (PAMPs) that activate Toll-like receptor 4 (TLR4), triggering pro-inflammatory signaling pathways [<xref ref-type="bibr" rid="CR198">198</xref>]. LPS has been recognized as a putative trigger for the systemic inflammatory response [<xref ref-type="bibr" rid="CR199">199</xref>]. Obese and diabetic mice exhibited increased intestinal permeability, decreased tight-junction integrity and elevated levels of LPS, which contributed to the development of insulin resistance [<xref ref-type="bibr" rid="CR200">200</xref>]. Lipopolysaccharide-binding protein (LBP)&#x000a0;is a liver-produced protein that binds bacterial endotoxin LPS, amplifies immune responses, and serves as a key biomarker for endotoxin activity. A prospective cohort study involving 920 adults found that LBP correlated with MASLD development and metabolic dysfunction in the general population [<xref ref-type="bibr" rid="CR201">201</xref>]. Another study of 237 MASLD patients revealed that LBP was associated with NASH severity and liver fibrosis, with higher LBP linked to inflammation, fibrosis, and the TM6SF2 rs58542926 T allele&#x02014;a genetic variant associated with impaired lipid metabolism and increased MASLD/NASH risk [<xref ref-type="bibr" rid="CR202">202</xref>]. Children with MASLD also exhibited significantly higher serum endotoxin concentrations compared to the control group [<xref ref-type="bibr" rid="CR203">203</xref>, <xref ref-type="bibr" rid="CR204">204</xref>]. Clinical study revealed that IF could significantly reduce the abundance of LPS-producing bacteria in obese human feces (Gram-negative species such as <italic>Bacteroides caccae</italic> and <italic>Bacteroides eggertii</italic>) and plasma LPS [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. This indicates that IF may be a potential therapeutic approach for improving endotoxemia in patients with MASLD, warranting further validation through future clinical trials.</p></sec><sec id="Sec22"><title>Dynamic fluctuation of the gut microbiome</title><p id="Par53">The circadian clock in mammals is an endogenous system with a stable and accurate periodicity, systematically orchestrating the temporal oscillations of biological processes throughout a 24-h cycle to maintain physiological homeostasis [<xref ref-type="bibr" rid="CR205">205</xref>]. Under the coordination of the host circadian clock and feeding behavior, the composition and function of the gut microbiota exhibit diurnal oscillations [<xref ref-type="bibr" rid="CR206">206</xref>]. Firmicutes are most abundant during feeding in the dark/active phase, reaching their lowest levels during fasting in the light/inactive phase. In contrast, Bacteroidetes and Verrucomicrobia increase during fasting and decrease during feeding [<xref ref-type="bibr" rid="CR63">63</xref>]. These periodic changes are associated with shifts in microbial community diversity, with alpha diversity rising during feeding and falling during fasting [<xref ref-type="bibr" rid="CR63">63</xref>]. Diurnal oscillations in microbial composition drive rhythmic fluctuations in microbial metabolites, including SCFAs and BAs, which subsequently coordinate host metabolic homeostasis in a temporally specific manner [<xref ref-type="bibr" rid="CR207">207</xref>]. These oscillations are essential for modulating peripheral circadian clocks and for the diurnal expression of metabolic regulators in the liver and gut that control glucose, cholesterol, and fatty acid homeostasis, as well as overall metabolic health [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR208">208</xref>, <xref ref-type="bibr" rid="CR209">209</xref>]. Antibiotic-induced microbiota depletion abolishes the expression of gut circadian rhythm genes and disrupts intestinal epithelial cell (IEC) homeostasis [<xref ref-type="bibr" rid="CR210">210</xref>]. Disruption of the gut microbiome's regular circadian rhythms can lead to dysregulation of the internal environment and metabolic disturbances, resulting in MASLD [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR207">207</xref>].</p><p id="Par54">Diet-induced obesity (DIO) markedly elevates the risk of MASLD by facilitating hepatic fat accumulation and disrupting metabolic pathways, leading to insulin resistance, inflammation, and lipid metabolism alterations that culminate in liver damage and associated complications [<xref ref-type="bibr" rid="CR211">211</xref>]. DIO can diminish or even eliminate the regular cyclical fluctuation of the gut microbiota community [<xref ref-type="bibr" rid="CR19">19</xref>]. Conventionally raised mice lose their diurnal feeding patterns after ad libitum consumption of a HFD, with caloric intake during the light phase doubling compared to their pre-diet feeding behavior [<xref ref-type="bibr" rid="CR212">212</xref>]. Disruption of this feeding pattern leads to dysregulated gut-liver axis circadian rhythms and dysregulation of metabolic regulators, resulting in increased adiposity, ectopic steatosis, and insulin resistance [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR205">205</xref>].</p><p id="Par55">Due to the peripheral circadian rhythm system's sensitivity to feeding patterns, dietary strategies such as IF are regarded as novel interventions for restoring oscillatory rhythms and alleviating metabolic syndrome. TRF is an emerging dietary intervention strategy that limits food consumption to a specific fixed time window of 8 to 12&#x000a0;h each day [<xref ref-type="bibr" rid="CR213">213</xref>]. By consistently implementing diurnal feeding-fasting cycles, TRF robustly reinforce the rhythmicity of circadian rhythms and reprogram metabolic homeostasis and nutrient turnover to align with anticipated food availability, all without reducing total caloric intake or physical activity [<xref ref-type="bibr" rid="CR214">214</xref>]. TRF prevents insulin resistance, reduces hepatic lipid accumulation, and maintains energy homeostasis in the progression of metabolic dysfunction, demonstrating efficacy even in core clock-deficient mice [<xref ref-type="bibr" rid="CR214">214</xref>]. Additionally, TRF can partially restore rhythmic microbial oscillations in MetS, suggesting that it may improve metabolic rhythms and prevent further deterioration of MASLD through a microbiota-dependent mechanism [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Mice subjected to a time-restricted high-fat diet exhibited less weight gain, milder liver steatosis, lower hepatic triglyceride levels, and distinct circadian rhythms in the hepatic expression of SIRT1, SREBP, and PPAR&#x003b1;, along with altered circadian rhythms in the abundance of Bacteroidetes and Firmicutes, compared to those fed a normal diet ad libitum [<xref ref-type="bibr" rid="CR20">20</xref>]. By restoring the rhythmicity of hepatoprotective genera, including Lactobacillus, Mucispirillum, Acetatifactor, and Lachnoclostridium, TRF mitigates HFD-induced weight gain, improves glucose tolerance, and reduces liver injury markers such as ALT, AST, alkaline phosphatase (ALP), and total cholesterol (TC) in MASH mice [<xref ref-type="bibr" rid="CR19">19</xref>]. Furthermore, TRF decreases lipid droplet accumulation, fibrosis formation, extensive hepatocellular ballooning, severe steatosis, and inflammation, significantly lowering the NAFLD activity score in these mice [<xref ref-type="bibr" rid="CR19">19</xref>]. This alleviation of MASH is contingent on the gut microbiota functioning at specific times of the day. Fecal microbiota transplantation (FMT) indicates that only the microbiota derived from the TRF feeding phase, not that from the TRF fasting phase, can protect mice from MASH and restore microbial rhythmicity [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par56">The feeding/fasting cycle not only induces diurnal rhythmic oscillations in the gut microbiota but also affects the rhythmic fluctuations of its regulated metabolites, such as SCFAs and BAs. This, in turn, alleviates metabolic disorders and MASLD through rhythmic signaling within the gut-liver axis and the oscillatory expression of hepatic genes [<xref ref-type="bibr" rid="CR215">215</xref>]. Dietary patterns such as IF can modulate the diurnal rhythms of SCFA-producing bacteria and SCFAs, resulting in significant alterations in metabolic states [<xref ref-type="bibr" rid="CR216">216</xref>]. GPR43 is a short-chain fatty acid receptor that is abundantly expressed in white adipose tissue [<xref ref-type="bibr" rid="CR217">217</xref>]. Upon activation by gut-derived SCFAs, it can regulate adipocyte sensitivity to insulin, thereby influencing lipid homeostasis [<xref ref-type="bibr" rid="CR217">217</xref>]. Additionally, microbial-derived SCFAs can activate GPR41, impacting host energy balance by stimulating leptin production in adipocytes [<xref ref-type="bibr" rid="CR218">218</xref>] and inducing enteroendocrine cell (EEC) secretion of glucagon-like peptide 1 (GLP-1) [<xref ref-type="bibr" rid="CR219">219</xref>]. A study involving fully conventional mice with engineered native bacteria that express bile salt hydrolase (BSH)&#x02014;an enzyme from the gut microbiome crucial for bile acid metabolism&#x02014;demonstrates that BSH-overexpressing engineered native bacteria can induce alterations in circulating bile acids of obesity model mice, resulting in persistent improvements in glucose tolerance [<xref ref-type="bibr" rid="CR220">220</xref>]. Regarding IF and bile acids, TRF partially restored the diurnal rhythms of the ileal microbiome and transcriptome, enhanced GLP-1 release, and modified the ileal bile acid pool and farnesoid X receptor (FXR)-FGF15 signaling pathway, thereby elucidating its metabolic and hepatoprotective benefits [<xref ref-type="bibr" rid="CR63">63</xref>]. TRF can alter the HFD-induced ratios of unconjugated to conjugated bile acids between light and dark phases, primarily driven by variations in unconjugated bile acids [<xref ref-type="bibr" rid="CR63">63</xref>]. SHP, encoded by Nr0b2 and a downstream target of FXR, is a key regulator in the bile acid signaling pathway [<xref ref-type="bibr" rid="CR221">221</xref>] and is significantly overexpressed in TRF mice [<xref ref-type="bibr" rid="CR63">63</xref>]. Additionally, circadian gene expression of bile acid transporters Fabp6 (IBABP), Slc51a (OST-&#x003b1;), and Slc51b (OST-&#x003b2;) was altered by HFD, but TRF could maintain gene expression levels for Fabp6 and preserved the circadian rhythmicity of Slc51a and Slc51b [<xref ref-type="bibr" rid="CR63">63</xref>]. Ultimately, ileal bile acid signaling regulates de novo bile acid synthesis from cholesterol via CYP7A1, with hepatic expression of Cyp7a1 suppressed in HFD mice exhibiting elevated serum cholesterol levels, while TRF preserved normal Cyp7a1 expression and cholesterol homeostasis in these HFD mice [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR222">222</xref>].</p></sec><sec id="Sec23"><title>White adipose tissue browning</title><p id="Par57">White adipose tissue (WAT) browning is a promising therapeutic strategy for treating obesity and related metabolic diseases, including MASLD [<xref ref-type="bibr" rid="CR223">223</xref>, <xref ref-type="bibr" rid="CR224">224</xref>]. Browning WAT, called beige adipose tissue can facilitate negative energy balance and release endocrine signals known as batokines to prevent and reverse MASLD [<xref ref-type="bibr" rid="CR224">224</xref>]. IF could promote browning of white adipose tissue by upregulating UCP-1 expression, improving insulin resistance in HFD-induced obesity [<xref ref-type="bibr" rid="CR75">75</xref>]. Li and colleagues found that ADF selectively induced the browning of white adipose tissue, dramatically ameliorating obesity, insulin resistance, and hepatic steatosis in high-fat-diet-induced obese mice, with the gut microbiota playing a coordinating role in this effect [<xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, alternate-day fasting inhibited intestinal lipid absorption, promoted white adipose tissue browning, and reduced obesity and metabolic disorder risks via the microbiota-metabolite-fat signaling axis in HFD mice [<xref ref-type="bibr" rid="CR67">67</xref>]. <italic>Akkermansia muciniphila</italic> reactivated browning of white adipose tissue, enhancing metabolic improvements to alleviate obesity [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par58"><bold>Conclusion</bold>IF emerges to be a compelling approach in the management of people with MASLD through facilitating beneficial alterations in the gut microbiota and promoting hepatic health. The intricate interactions within the gut-liver axis highlight its significance in mediating the therapeutic effects of IF&#x000a0;(see&#x000a0;Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Future research should prioritize the identification of specific microbial taxa and their metabolites that contribute to the observed clinical benefits, alongside randomized controlled trials assessing the efficacy of different IF protocols on metabolic and liver health. By incorporating IF into clinical practice, we may enhance therapeutic strategies for MASLD, ultimately improving patient outcomes and addressing the growing burden of this condition.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>IF influences the intestinal environment and acts on MASLD. Patients with MASLD exhibit distinct gut microbiota dysbiosis, characterized by increased pathogenic bacteria (e.g.,&#x000a0;<italic>Escherichia coli</italic>), reduced &#x003b1;-diversity, depletion of beneficial species (e.g.,&#x000a0;<italic>Lactobacillus</italic>&#x000a0;spp.), elevated hepatotoxic metabolites (e.g., TMAO), and impaired intestinal barrier function leading to endotoxemia. IF counteracts these pathological changes through multifaceted mechanisms: it restores microbial balance by enriching commensal taxa, enhances gut barrier integrity via tight junction protein upregulation, normalizes microbial metabolite profiles, and reestablishes circadian microbial rhythms. These coordinated modifications collectively attenuate MASLD progression by reducing hepatic inflammation, improving metabolic homeostasis, and decreasing endotoxin translocation, positioning IF as a promising gut microbiota-targeted therapeutic strategy for MASLD management</p></caption><graphic xlink:href="13578_2025_1406_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec24"><title>Challenges and future directions</title><p id="Par59">Despite the promising potential of IF in MASLD management, several challenges remain. First, adherence to IF regimens can be highly variable among individuals, influenced by cultural, socioeconomic, and lifestyle factors, which may limit its widespread applicability. Second, the gut microbiota exhibits considerable inter-individual diversity, making it difficult to pinpoint universally beneficial microbial shifts or generalize findings across populations. Additionally, the precise mechanisms linking IF-induced microbial changes to hepatic improvements&#x02014;such as whether effects are mediated by microbial metabolites, immune modulation, or barrier function&#x02014;require deeper investigation. Long-term safety and efficacy data, particularly in vulnerable groups (e.g., patients with advanced liver fibrosis or diabetes), are also lacking. Addressing these gaps through rigorous clinical trials, personalized approaches, and mechanistic studies will be critical to harnessing IF&#x02019;s full therapeutic potential.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>MASLD</term><def><p id="Par2">Metabolic dysfunction-associated steatotic liver disease</p></def></def-item><def-item><term>MASH</term><def><p id="Par3">Metabolic dysfunction-associated steatohepatitis</p></def></def-item><def-item><term>NAFLD</term><def><p id="Par4">Non-alcoholic fatty liver disease</p></def></def-item><def-item><term>NASH</term><def><p id="Par5">Non-alcoholic steatohepatitis</p></def></def-item><def-item><term>T2D</term><def><p id="Par6">Type 2 diabetes</p></def></def-item><def-item><term>IF</term><def><p id="Par7">Intermittent fasting</p></def></def-item><def-item><term>TRF</term><def><p id="Par8">Time-restricted feeding</p></def></def-item><def-item><term>ADF</term><def><p id="Par9">Alternate-day fasting</p></def></def-item><def-item><term>FMD</term><def><p id="Par10">Fasting-mimicking diet</p></def></def-item><def-item><term>SCFAs</term><def><p id="Par11">Short-chain fatty acids</p></def></def-item><def-item><term>TMAO</term><def><p id="Par12">Trimethylamine N-oxide</p></def></def-item><def-item><term>FXR</term><def><p id="Par13">Farnesoid X receptor</p></def></def-item><def-item><term>GPR</term><def><p id="Par14">G protein-coupled receptor</p></def></def-item><def-item><term>LPS</term><def><p id="Par15">Lipopolysaccharides</p></def></def-item><def-item><term>LBP</term><def><p id="Par16">Lipopolysaccharide-binding protein</p></def></def-item><def-item><term>IgG</term><def><p id="Par17">Immunoglobulin G</p></def></def-item><def-item><term>BMI</term><def><p id="Par18">Body mass index</p></def></def-item><def-item><term>ALT</term><def><p id="Par19">Alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p id="Par20">Aspartate aminotransferase</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Figures were created with BioRender.com.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed equally to the literature review, writing, and editing of this article.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Lo Kwee-Seong Biomedical Research Start-up Fund (7106480 and 7106481).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Data sharing is not applicable to this article as no new data were created or analyzed.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Geographical similarity and differences in the burden and genetic predisposition of NAFLD</article-title><source>Hepatology</source><year>2023</year><volume>77</volume><fpage>1404</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1002/hep.32774</pub-id><pub-id pub-id-type="pmid">36062393</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Yip TC, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology. 2023;77:1404&#x02013;27. 10.1002/hep.32774.<pub-id pub-id-type="pmid">36062393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>H&#x000e4;ring</surname><given-names>HU</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies</article-title><source>Lancet Diabet Endocrinol</source><year>2019</year><volume>7</volume><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/s2213-8587(18)30154-2</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Stefan N, H&#x000e4;ring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabet Endocrinol. 2019;7:313&#x02013;24. 10.1016/s2213-8587(18)30154-2.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Eslam</surname><given-names>M</given-names></name><etal/></person-group><article-title>A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.03.039</pub-id><pub-id pub-id-type="pmid">32278004</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202&#x02013;9. 10.1016/j.jhep.2020.03.039.<pub-id pub-id-type="pmid">32278004</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>AM</given-names></name><name><surname>Day</surname><given-names>C</given-names></name></person-group><article-title>Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>2063</fpage><lpage>2072</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1503519</pub-id><pub-id pub-id-type="pmid">29166236</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063&#x02013;72. 10.1056/NEJMra1503519.<pub-id pub-id-type="pmid">29166236</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Younossi</surname><given-names>ZM</given-names></name><etal/></person-group><article-title>The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review</article-title><source>Hepatology</source><year>2023</year><volume>77</volume><fpage>1335</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1097/hep.0000000000000004</pub-id><pub-id pub-id-type="pmid">36626630</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Younossi ZM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335&#x02013;47. 10.1097/hep.0000000000000004.<pub-id pub-id-type="pmid">36626630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Estes</surname><given-names>C</given-names></name><etal/></person-group><article-title>Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016&#x02013;2030</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>896</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.05.036</pub-id><pub-id pub-id-type="pmid">29886156</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Estes C, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016&#x02013;2030. J Hepatol. 2018;69:896&#x02013;904. 10.1016/j.jhep.2018.05.036.<pub-id pub-id-type="pmid">29886156</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Buzzetti</surname><given-names>E</given-names></name><name><surname>Pinzani</surname><given-names>M</given-names></name><name><surname>Tsochatzis</surname><given-names>EA</given-names></name></person-group><article-title>The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)</article-title><source>Metabolism</source><year>2016</year><volume>65</volume><fpage>1038</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2015.12.012</pub-id><pub-id pub-id-type="pmid">26823198</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038&#x02013;48. 10.1016/j.metabol.2015.12.012.<pub-id pub-id-type="pmid">26823198</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Dufour</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Current therapies and new developments in NASH</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>2123</fpage><lpage>2134</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-326874</pub-id><pub-id pub-id-type="pmid">35710299</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dufour JF, et al. Current therapies and new developments in NASH. Gut. 2022;71:2123&#x02013;34. 10.1136/gutjnl-2021-326874.<pub-id pub-id-type="pmid">35710299</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Marjot</surname><given-names>T</given-names></name><name><surname>Tomlinson</surname><given-names>JW</given-names></name><name><surname>Hodson</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>DW</given-names></name></person-group><article-title>Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD</article-title><source>Gut</source><year>2023</year><volume>72</volume><fpage>1607</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2023-329998</pub-id><pub-id pub-id-type="pmid">37286229</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Marjot T, Tomlinson JW, Hodson L, Ray DW. Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD. Gut. 2023;72:1607&#x02013;19. 10.1136/gutjnl-2023-329998.<pub-id pub-id-type="pmid">37286229</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome</article-title><source>Cell Metab</source><year>2020</year><volume>31</volume><fpage>92</fpage><lpage>104.e105</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.11.004</pub-id><pub-id pub-id-type="pmid">31813824</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wilkinson MJ, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab. 2020;31:92-104.e105. 10.1016/j.cmet.2019.11.004.<pub-id pub-id-type="pmid">31813824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Fanti</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Longo</surname><given-names>VD</given-names></name><name><surname>Brandhorst</surname><given-names>S</given-names></name></person-group><article-title>Time-restricted eating, intermittent fasting, and fasting-mimicking diets in weight loss</article-title><source>Curr Obes Rep</source><year>2021</year><volume>10</volume><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s13679-021-00424-2</pub-id><pub-id pub-id-type="pmid">33512641</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Fanti M, Mishra A, Longo VD, Brandhorst S. Time-restricted eating, intermittent fasting, and fasting-mimicking diets in weight loss. Curr Obes Rep. 2021;10:70&#x02013;80. 10.1007/s13679-021-00424-2.<pub-id pub-id-type="pmid">33512641</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Stockman</surname><given-names>MC</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Apovian</surname><given-names>CM</given-names></name></person-group><article-title>Intermittent fasting is the wait worth the weight?</article-title><source>Curr Obes Rep</source><year>2018</year><volume>7</volume><fpage>172</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1007/s13679-018-0308-9</pub-id><pub-id pub-id-type="pmid">29700718</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Stockman MC, Thomas D, Burke J, Apovian CM. Intermittent fasting is the wait worth the weight? Curr Obes Rep. 2018;7:172&#x02013;85. 10.1007/s13679-018-0308-9.<pub-id pub-id-type="pmid">29700718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Effect of 5:2 fasting diet on liver fat content in patients with type 2 diabetic with nonalcoholic fatty liver disease</article-title><source>Metab Syndr Relat Disord</source><year>2022</year><volume>20</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1089/met.2022.0014</pub-id><pub-id pub-id-type="pmid">35925752</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Xiao Y, Liu Y, Zhao L, Zhou Y. Effect of 5:2 fasting diet on liver fat content in patients with type 2 diabetic with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2022;20:459&#x02013;65. 10.1089/met.2022.0014.<pub-id pub-id-type="pmid">35925752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Kord Varkaneh</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: a randomized controlled trial</article-title><source>Front Nutr</source><year>2022</year><volume>9</volume><fpage>948655</fpage><pub-id pub-id-type="doi">10.3389/fnut.2022.948655</pub-id><pub-id pub-id-type="pmid">35958257</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kord Varkaneh H, et al. Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: a randomized controlled trial. Front Nutr. 2022;9: 948655. 10.3389/fnut.2022.948655.<pub-id pub-id-type="pmid">35958257</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Johari</surname><given-names>MI</given-names></name><etal/></person-group><article-title>A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>11232</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-47763-8</pub-id><pub-id pub-id-type="pmid">31375753</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Johari MI, et al. A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease. Sci Rep. 2019;9:11232. 10.1038/s41598-019-47763-8.<pub-id pub-id-type="pmid">31375753</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CL</given-names></name><name><surname>Schnabl</surname><given-names>B</given-names></name></person-group><article-title>The gut-liver axis and gut microbiota in health and liver disease</article-title><source>Nat Rev Microbiol</source><year>2023</year><volume>21</volume><fpage>719</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1038/s41579-023-00904-3</pub-id><pub-id pub-id-type="pmid">37316582</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023;21:719&#x02013;33. 10.1038/s41579-023-00904-3.<pub-id pub-id-type="pmid">37316582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>EF</given-names></name><etal/></person-group><article-title>Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes</article-title><source>Cell Metab</source><year>2018</year><volume>27</volume><fpage>1212</fpage><lpage>1221.e1213</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.04.010</pub-id><pub-id pub-id-type="pmid">29754952</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Sutton EF, et al. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 2018;27:1212-1221.e1213. 10.1016/j.cmet.2018.04.010.<pub-id pub-id-type="pmid">29754952</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Maughan</surname><given-names>RJ</given-names></name><name><surname>Fallah</surname><given-names>J</given-names></name><name><surname>Coyle</surname><given-names>EF</given-names></name></person-group><article-title>The effects of fasting on metabolism and performance</article-title><source>Br J Sports Med</source><year>2010</year><volume>44</volume><fpage>490</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1136/bjsm.2010.072181</pub-id><pub-id pub-id-type="pmid">20484315</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Maughan RJ, Fallah J, Coyle EF. The effects of fasting on metabolism and performance. Br J Sports Med. 2010;44:490&#x02013;4. 10.1136/bjsm.2010.072181.<pub-id pub-id-type="pmid">20484315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J</given-names></name><etal/></person-group><article-title>Resynchronized rhythmic oscillations of gut microbiota drive time-restricted feeding induced nonalcoholic steatohepatitis alleviation</article-title><source>Gut Microbes</source><year>2023</year><volume>15</volume><fpage>2221450</fpage><pub-id pub-id-type="doi">10.1080/19490976.2023.2221450</pub-id><pub-id pub-id-type="pmid">37309179</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Xia J, et al. Resynchronized rhythmic oscillations of gut microbiota drive time-restricted feeding induced nonalcoholic steatohepatitis alleviation. Gut Microbes. 2023;15:2221450. 10.1080/19490976.2023.2221450.<pub-id pub-id-type="pmid">37309179</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Time-restricted feeding reduces the detrimental effects of a high-fat diet, possibly by modulating the circadian rhythm of hepatic lipid metabolism and gut microbiota</article-title><source>Front Nutr</source><year>2020</year><volume>7</volume><fpage>596285</fpage><pub-id pub-id-type="doi">10.3389/fnut.2020.596285</pub-id><pub-id pub-id-type="pmid">33425971</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ye Y, et al. Time-restricted feeding reduces the detrimental effects of a high-fat diet, possibly by modulating the circadian rhythm of hepatic lipid metabolism and gut microbiota. Front Nutr. 2020;7:596285. 10.3389/fnut.2020.596285.<pub-id pub-id-type="pmid">33425971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><etal/></person-group><article-title>Intermittent fasting alleviates non-alcoholic steatohepatitis by regulating bile acid metabolism and promoting fecal bile acid excretion in high-fat and high-cholesterol diet fed mice</article-title><source>Mol Nutr Food Res</source><year>2023</year><pub-id pub-id-type="doi">10.1002/mnfr.202200595</pub-id><pub-id pub-id-type="pmid">38072647</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lin X, et al. Intermittent fasting alleviates non-alcoholic steatohepatitis by regulating bile acid metabolism and promoting fecal bile acid excretion in high-fat and high-cholesterol diet fed mice. Mol Nutr Food Res. 2023. 10.1002/mnfr.202200595.<pub-id pub-id-type="pmid">38072647</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults</article-title><source>Geroscience</source><year>2020</year><volume>42</volume><fpage>667</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1007/s11357-020-00156-6</pub-id><pub-id pub-id-type="pmid">31975053</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Martens CR, et al. Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults. Geroscience. 2020;42:667&#x02013;86. 10.1007/s11357-020-00156-6.<pub-id pub-id-type="pmid">31975053</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Randomized controlled trial for time-restricted eating in healthy volunteers without obesity</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>1003</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-28662-5</pub-id><pub-id pub-id-type="pmid">35194047</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Xie Z, et al. Randomized controlled trial for time-restricted eating in healthy volunteers without obesity. Nat Commun. 2022;13:1003. 10.1038/s41467-022-28662-5.<pub-id pub-id-type="pmid">35194047</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Varady</surname><given-names>KA</given-names></name><name><surname>Hellerstein</surname><given-names>MK</given-names></name></person-group><article-title>Alternate-day fasting and chronic disease prevention: a review of human and animal trials</article-title><source>Am J Clin Nutr</source><year>2007</year><volume>86</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/ajcn/86.1.7</pub-id><pub-id pub-id-type="pmid">17616757</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Varady KA, Hellerstein MK. Alternate-day fasting and chronic disease prevention: a review of human and animal trials. Am J Clin Nutr. 2007;86:7&#x02013;13. 10.1093/ajcn/86.1.7.<pub-id pub-id-type="pmid">17616757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Villareal</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults: a randomized clinical trial</article-title><source>J Bone Miner Res</source><year>2016</year><volume>31</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2701</pub-id><pub-id pub-id-type="pmid">26332798</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Villareal DT, et al. Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults: a randomized clinical trial. J Bone Miner Res. 2016;31:40&#x02013;51. 10.1002/jbmr.2701.<pub-id pub-id-type="pmid">26332798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoddy</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Safety of alternate day fasting and effect on disordered eating behaviors</article-title><source>Nutr J</source><year>2015</year><volume>14</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s12937-015-0029-9</pub-id><pub-id pub-id-type="pmid">25943396</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hoddy KK, et al. Safety of alternate day fasting and effect on disordered eating behaviors. Nutr J. 2015;14:44. 10.1186/s12937-015-0029-9.<pub-id pub-id-type="pmid">25943396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intermittent fasting improves cardiometabolic risk factors and alters gut microbiota in metabolic syndrome patients</article-title><source>J Clin Endocrinol Metab</source><year>2021</year><volume>106</volume><fpage>64</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgaa644</pub-id><pub-id pub-id-type="pmid">33017844</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Guo Y, et al. Intermittent fasting improves cardiometabolic risk factors and alters gut microbiota in metabolic syndrome patients. J Clin Endocrinol Metab. 2021;106:64&#x02013;79. 10.1210/clinem/dgaa644.<pub-id pub-id-type="pmid">33017844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Corley</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial</article-title><source>Diabet Med</source><year>2018</year><volume>35</volume><fpage>588</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1111/dme.13595</pub-id><pub-id pub-id-type="pmid">29405359</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Corley BT, et al. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med. 2018;35:588&#x02013;94. 10.1111/dme.13595.<pub-id pub-id-type="pmid">29405359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Antoni</surname><given-names>R</given-names></name><name><surname>Johnston</surname><given-names>KL</given-names></name><name><surname>Collins</surname><given-names>AL</given-names></name><name><surname>Robertson</surname><given-names>MD</given-names></name></person-group><article-title>Intermittent v continuous energy restriction differential effects on postprandial glucose and lipid metabolism following matched weight loss in overweight/obese participants</article-title><source>Br J Nutr</source><year>2018</year><pub-id pub-id-type="doi">10.1017/s0007114517003890</pub-id><pub-id pub-id-type="pmid">29508693</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Antoni R, Johnston KL, Collins AL, Robertson MD. Intermittent v continuous energy restriction differential effects on postprandial glucose and lipid metabolism following matched weight loss in overweight/obese participants. Br J Nutr. 2018. 10.1017/s0007114517003890.<pub-id pub-id-type="pmid">29508693</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Gallage</surname><given-names>S</given-names></name><etal/></person-group><article-title>A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR&#x003b1; and PCK1</article-title><source>Cell Metab</source><year>2024</year><volume>36</volume><fpage>1371</fpage><lpage>1393.e1377</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2024.04.015</pub-id><pub-id pub-id-type="pmid">38718791</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Gallage S, et al. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR&#x003b1; and PCK1. Cell Metab. 2024;36:1371-1393.e1377. 10.1016/j.cmet.2024.04.015.<pub-id pub-id-type="pmid">38718791</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Brandhorst</surname><given-names>S</given-names></name><etal/></person-group><article-title>A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan</article-title><source>Cell Metab</source><year>2015</year><volume>22</volume><fpage>86</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.05.012</pub-id><pub-id pub-id-type="pmid">26094889</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Brandhorst S, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015;22:86&#x02013;99. 10.1016/j.cmet.2015.05.012.<pub-id pub-id-type="pmid">26094889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota</article-title><source>Cell Metab</source><year>2017</year><volume>26</volume><fpage>801</fpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.10.007</pub-id><pub-id pub-id-type="pmid">29117546</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Li G, et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metab. 2017;26:801. 10.1016/j.cmet.2017.10.007.<pub-id pub-id-type="pmid">29117546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Improvement of non-alcoholic fatty liver disease in mice by intermittent use of a fasting-mimicking diet</article-title><source>Mol Nutr Food Res</source><year>2021</year><volume>65</volume><fpage>e2100381</fpage><pub-id pub-id-type="doi">10.1002/mnfr.202100381</pub-id><pub-id pub-id-type="pmid">34632700</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Zhao J, et al. Improvement of non-alcoholic fatty liver disease in mice by intermittent use of a fasting-mimicking diet. Mol Nutr Food Res. 2021;65:e2100381. 10.1002/mnfr.202100381.<pub-id pub-id-type="pmid">34632700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Hodge, A. et al. Non-alcoholic fatty liver disease intermittent fasting time intervention (NIFTI): fasting without calorie restriction improves hepatic transient elastography, visceral adiposity and insulin resistance compared to standard care. 2014; 29</mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Holmer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial</article-title><source>JHEP Rep</source><year>2021</year><volume>3</volume><fpage>100256</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2021.100256</pub-id><pub-id pub-id-type="pmid">33898960</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Holmer M, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. JHEP Rep. 2021;3:100256. 10.1016/j.jhepr.2021.100256.<pub-id pub-id-type="pmid">33898960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Popa</surname><given-names>AD</given-names></name><etal/></person-group><article-title>A scoping review of the relationship between intermittent fasting and the human gut microbiota: current knowledge and future directions</article-title><source>Nutrients</source><year>2023</year><pub-id pub-id-type="doi">10.3390/nu15092095</pub-id><pub-id pub-id-type="pmid">37836500</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Popa AD, et al. A scoping review of the relationship between intermittent fasting and the human gut microbiota: current knowledge and future directions. Nutrients. 2023. 10.3390/nu15092095.<pub-id pub-id-type="pmid">37836500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Frazier</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>EB</given-names></name></person-group><article-title>Intersection of the gut microbiome and circadian rhythms in metabolism</article-title><source>Trends Endocrinol Metab</source><year>2020</year><volume>31</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2019.08.013</pub-id><pub-id pub-id-type="pmid">31677970</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Frazier K, Chang EB. Intersection of the gut microbiome and circadian rhythms in metabolism. Trends Endocrinol Metab. 2020;31:25&#x02013;36. 10.1016/j.tem.2019.08.013.<pub-id pub-id-type="pmid">31677970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Zarrinpar</surname><given-names>A</given-names></name><name><surname>Chaix</surname><given-names>A</given-names></name><name><surname>Yooseph</surname><given-names>S</given-names></name><name><surname>Panda</surname><given-names>S</given-names></name></person-group><article-title>Diet and feeding pattern affect the diurnal dynamics of the gut microbiome</article-title><source>Cell Metab</source><year>2014</year><volume>20</volume><fpage>1006</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.11.008</pub-id><pub-id pub-id-type="pmid">25470548</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zarrinpar A, Chaix A, Yooseph S, Panda S. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. Cell Metab. 2014;20:1006&#x02013;17. 10.1016/j.cmet.2014.11.008.<pub-id pub-id-type="pmid">25470548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Catterson</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Short-term, intermittent fasting induces long-lasting gut health and TOR-independent lifespan extension</article-title><source>Curr Biol</source><year>2018</year><volume>28</volume><fpage>1714</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2018.04.015</pub-id><pub-id pub-id-type="pmid">29779873</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Catterson JH, et al. Short-term, intermittent fasting induces long-lasting gut health and TOR-independent lifespan extension. Curr Biol. 2018;28:1714&#x02013;24. 10.1016/j.cub.2018.04.015.<pub-id pub-id-type="pmid">29779873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczmarek</surname><given-names>JL</given-names></name><name><surname>Thompson</surname><given-names>SV</given-names></name><name><surname>Holscher</surname><given-names>HD</given-names></name></person-group><article-title>Complex interactions of circadian rhythms, eating behaviors, and the gastrointestinal microbiota and their potential impact on health</article-title><source>Nutr Rev</source><year>2017</year><volume>75</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1093/nutrit/nux036</pub-id><pub-id pub-id-type="pmid">28938796</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kaczmarek JL, Thompson SV, Holscher HD. Complex interactions of circadian rhythms, eating behaviors, and the gastrointestinal microbiota and their potential impact on health. Nutr Rev. 2017;75:673&#x02013;82. 10.1093/nutrit/nux036.<pub-id pub-id-type="pmid">28938796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><etal/></person-group><article-title>A catalog of the mouse gut metagenome</article-title><source>Nat Biotechnol</source><year>2015</year><volume>33</volume><fpage>1103</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/nbt.3353</pub-id><pub-id pub-id-type="pmid">26414350</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Xiao L, et al. A catalog of the mouse gut metagenome. Nat Biotechnol. 2015;33:1103&#x02013;8. 10.1038/nbt.3353.<pub-id pub-id-type="pmid">26414350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>H</given-names></name></person-group><article-title>Metagenome-wide association studies: fine-mining the microbiome</article-title><source>Nat Rev Microbiol</source><year>2016</year><volume>14</volume><fpage>508</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.83</pub-id><pub-id pub-id-type="pmid">27396567</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Wang J, Jia H. Metagenome-wide association studies: fine-mining the microbiome. Nat Rev Microbiol. 2016;14:508&#x02013;22. 10.1038/nrmicro.2016.83.<pub-id pub-id-type="pmid">27396567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Sowah</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Calorie restriction improves metabolic state independently of gut microbiome composition: a randomized dietary intervention trial</article-title><source>Genome Med</source><year>2022</year><pub-id pub-id-type="doi">10.1186/s13073-022-01030-0</pub-id><pub-id pub-id-type="pmid">35287713</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Sowah SA, et al. Calorie restriction improves metabolic state independently of gut microbiome composition: a randomized dietary intervention trial. Genome Med. 2022. 10.1186/s13073-022-01030-0.<pub-id pub-id-type="pmid">35287713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeb</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effect of time-restricted feeding on metabolic risk and circadian rhythm associated with gut microbiome in healthy males</article-title><source>Br J Nutr</source><year>2020</year><volume>123</volume><fpage>1216</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1017/s0007114519003428</pub-id><pub-id pub-id-type="pmid">31902372</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zeb F, et al. Effect of time-restricted feeding on metabolic risk and circadian rhythm associated with gut microbiome in healthy males. Br J Nutr. 2020;123:1216&#x02013;26. 10.1017/s0007114519003428.<pub-id pub-id-type="pmid">31902372</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Intermittent fasting positively modulates human gut microbial diversity and ameliorates blood lipid profile</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><fpage>922727</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.922727</pub-id><pub-id pub-id-type="pmid">36081793</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Khan MN, et al. Intermittent fasting positively modulates human gut microbial diversity and ameliorates blood lipid profile. Front Microbiol. 2022;13:922727. 10.3389/fmicb.2022.922727.<pub-id pub-id-type="pmid">36081793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>2060</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-29589-7</pub-id><pub-id pub-id-type="pmid">35440584</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Li M, et al. Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice. Nat Commun. 2022;13:2060. 10.1038/s41467-022-29589-7.<pub-id pub-id-type="pmid">35440584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>AR</given-names></name><name><surname>Kemp</surname><given-names>KM</given-names></name><name><surname>Burke</surname><given-names>SN</given-names></name><name><surname>Buford</surname><given-names>TW</given-names></name><name><surname>Carter</surname><given-names>CS</given-names></name></person-group><article-title>Influence of aging, macronutrient composition and time-restricted feeding on the fischer344 x brown norway rat gut microbiota</article-title><source>Nutrients</source><year>2022</year><pub-id pub-id-type="doi">10.3390/nu14091758</pub-id><pub-id pub-id-type="pmid">36615687</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hernandez AR, Kemp KM, Burke SN, Buford TW, Carter CS. Influence of aging, macronutrient composition and time-restricted feeding on the fischer344 x brown norway rat gut microbiota. Nutrients. 2022. 10.3390/nu14091758.<pub-id pub-id-type="pmid">36615687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Beli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice</article-title><source>Diabetes</source><year>2018</year><volume>67</volume><fpage>1867</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.2337/db18-0158</pub-id><pub-id pub-id-type="pmid">29712667</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Beli E, et al. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes. 2018;67:1867&#x02013;79. 10.2337/db18-0158.<pub-id pub-id-type="pmid">29712667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Cignarella</surname><given-names>F</given-names></name><etal/></person-group><article-title>Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota</article-title><source>Cell Metab</source><year>2018</year><volume>27</volume><fpage>1222</fpage><lpage>1235.e1226</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.05.006</pub-id><pub-id pub-id-type="pmid">29874567</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Cignarella F, et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab. 2018;27:1222-1235.e1226. 10.1016/j.cmet.2018.05.006.<pub-id pub-id-type="pmid">29874567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Fasting and refeeding triggers specific changes in bile acid profiles and gut microbiota</article-title><source>J Diabetes</source><year>2023</year><volume>15</volume><fpage>165</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.13356</pub-id><pub-id pub-id-type="pmid">36682739</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zhang Y, et al. Fasting and refeeding triggers specific changes in bile acid profiles and gut microbiota. J Diabetes. 2023;15:165&#x02013;80. 10.1111/1753-0407.13356.<pub-id pub-id-type="pmid">36682739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>Therapeutic effects of intermittent fasting combined with SLBZS and prebiotics on STZ-HFD-induced type 2 diabetic mice</article-title><source>Diabetes Metab Syndr Obes</source><year>2024</year><volume>17</volume><fpage>4013</fpage><lpage>4030</lpage><pub-id pub-id-type="doi">10.2147/dmso.S474196</pub-id><pub-id pub-id-type="pmid">39492963</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Liu X, Du P, Xu J, Wang W, Zhang C. Therapeutic effects of intermittent fasting combined with SLBZS and prebiotics on STZ-HFD-induced type 2 diabetic mice. Diabetes Metab Syndr Obes. 2024;17:4013&#x02013;30. 10.2147/dmso.S474196.<pub-id pub-id-type="pmid">39492963</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Keles</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Long-term intermittent caloric restriction remodels the gut microbiota in mice genetically prone to breast cancer</article-title><source>Nutrition</source><year>2024</year><volume>126</volume><fpage>112525</fpage><pub-id pub-id-type="doi">10.1016/j.nut.2024.112525</pub-id><pub-id pub-id-type="pmid">39168040</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Keles NA, et al. Long-term intermittent caloric restriction remodels the gut microbiota in mice genetically prone to breast cancer. Nutrition. 2024;126: 112525. 10.1016/j.nut.2024.112525.<pub-id pub-id-type="pmid">39168040</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intermittent fasting promotes repair of rotator cuff injury in the early postoperative period by regulating the gut microbiota</article-title><source>J Orthop Translat</source><year>2022</year><volume>36</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.jot.2022.09.006</pub-id><pub-id pub-id-type="pmid">36263387</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Xie S, et al. Intermittent fasting promotes repair of rotator cuff injury in the early postoperative period by regulating the gut microbiota. J Orthop Translat. 2022;36:216&#x02013;24. 10.1016/j.jot.2022.09.006.<pub-id pub-id-type="pmid">36263387</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intermittent administration of a fasting-mimicking diet intervenes in diabetes progression, restores &#x003b2; cells and reconstructs gut microbiota in mice</article-title><source>Nutr Metab</source><year>2018</year><volume>15</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.1186/s12986-018-0318-3</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Wei S, et al. Intermittent administration of a fasting-mimicking diet intervenes in diabetes progression, restores &#x003b2; cells and reconstructs gut microbiota in mice. Nutr Metab. 2018;15:80. 10.1186/s12986-018-0318-3.</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Isomalto-oligosaccharide potentiates alleviating effects of intermittent fasting on obesity-related cognitive impairment during weight loss and the rebound weight gain</article-title><source>J Agric Food Chem</source><year>2024</year><volume>72</volume><fpage>23875</fpage><lpage>23892</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.4c07351</pub-id><pub-id pub-id-type="pmid">39431286</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Liu T, et al. Isomalto-oligosaccharide potentiates alleviating effects of intermittent fasting on obesity-related cognitive impairment during weight loss and the rebound weight gain. J Agric Food Chem. 2024;72:23875&#x02013;92. 10.1021/acs.jafc.4c07351.<pub-id pub-id-type="pmid">39431286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>J</given-names></name><etal/></person-group><article-title>Investigating ramadan like fasting effects on the gut microbiome in BALB/c mice</article-title><source>Front Nutr</source><year>2022</year><pub-id pub-id-type="doi">10.3389/fnut.2022.832757</pub-id><pub-id pub-id-type="pmid">36712499</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Su J, et al. Investigating ramadan like fasting effects on the gut microbiome in BALB/c mice. Front Nutr. 2022. 10.3389/fnut.2022.832757.<pub-id pub-id-type="pmid">36712499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Palomba</surname><given-names>A</given-names></name><etal/></person-group><article-title>Time-restricted feeding induces Lactobacillus- and Akkermansia-specific functional changes in the rat fecal microbiota</article-title><source>NPJ Biofilms Microb</source><year>2021</year><volume>7</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1038/s41522-021-00256-x</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Palomba A, et al. Time-restricted feeding induces Lactobacillus- and Akkermansia-specific functional changes in the rat fecal microbiota. NPJ Biofilms Microb. 2021;7:85. 10.1038/s41522-021-00256-x.</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sex-specific effects of intermittent fasting on hippocampal neurogenesis via the gut-brain axis</article-title><source>Food Funct</source><year>2024</year><volume>15</volume><fpage>8432</fpage><lpage>8447</lpage><pub-id pub-id-type="doi">10.1039/d4fo00318g</pub-id><pub-id pub-id-type="pmid">39049753</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Luo Y, et al. Sex-specific effects of intermittent fasting on hippocampal neurogenesis via the gut-brain axis. Food Funct. 2024;15:8432&#x02013;47. 10.1039/d4fo00318g.<pub-id pub-id-type="pmid">39049753</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>RY</given-names></name><etal/></person-group><article-title>Intermittent fasting protects against Alzheimer&#x02019;s disease in mice by altering metabolism through remodeling of the gut microbiota</article-title><source>Nat Aging</source><year>2022</year><volume>2</volume><fpage>1024</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00311-y</pub-id><pub-id pub-id-type="pmid">37118092</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Pan RY, et al. Intermittent fasting protects against Alzheimer&#x02019;s disease in mice by altering metabolism through remodeling of the gut microbiota. Nat Aging. 2022;2:1024&#x02013;39. 10.1038/s43587-022-00311-y.<pub-id pub-id-type="pmid">37118092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>van der Merwe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Time of feeding alters obesity-associated parameters and gut bacterial communities, but not fungal populations, in C57BL/6 male mice</article-title><source>Curr Dev Nutr</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cdn/nzz145</pub-id><pub-id pub-id-type="pmid">32025616</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">van der Merwe M, et al. Time of feeding alters obesity-associated parameters and gut bacterial communities, but not fungal populations, in C57BL/6 male mice. Curr Dev Nutr. 2020. 10.1093/cdn/nzz145.<pub-id pub-id-type="pmid">32025616</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name></person-group><article-title>Time-restricted feeding during childhood has persistent effects on mice commensal microbiota</article-title><source>Ann Transl Med</source><year>2019</year><volume>7</volume><fpage>556</fpage><pub-id pub-id-type="doi">10.2103/atm.2019.09.64</pub-id><pub-id pub-id-type="pmid">31807537</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Hu D, Ye Y, Mao Y, Liao W, Xu W. Time-restricted feeding during childhood has persistent effects on mice commensal microbiota. Ann Transl Med. 2019;7:556. 10.2103/atm.2019.09.64.<pub-id pub-id-type="pmid">31807537</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>The effects of daily fasting hours on shaping gut microbiota in mice</article-title><source>BMC Microbiol</source><year>2020</year><volume>20</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s12866-020-01754-2</pub-id><pub-id pub-id-type="pmid">32209070</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Li L, et al. The effects of daily fasting hours on shaping gut microbiota in mice. BMC Microbiol. 2020;20:65. 10.1186/s12866-020-01754-2.<pub-id pub-id-type="pmid">32209070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Dantas Machado</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Diet and feeding pattern modulate diurnal dynamics of the ileal microbiome and transcriptome</article-title><source>Cell Rep</source><year>2022</year><volume>40</volume><fpage>111008</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111008</pub-id><pub-id pub-id-type="pmid">35793637</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Dantas Machado AC, et al. Diet and feeding pattern modulate diurnal dynamics of the ileal microbiome and transcriptome. Cell Rep. 2022;40: 111008. 10.1016/j.celrep.2022.111008.<pub-id pub-id-type="pmid">35793637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Graef</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Fasting increases microbiome-based colonization resistance and reduces host inflammatory responses during an enteric bacterial infection</article-title><source>PLoS Pathog</source><year>2021</year><volume>17</volume><fpage>e1009719</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1009719</pub-id><pub-id pub-id-type="pmid">34352037</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Graef FA, et al. Fasting increases microbiome-based colonization resistance and reduces host inflammatory responses during an enteric bacterial infection. PLoS Pathog. 2021;17: e1009719. 10.1371/journal.ppat.1009719.<pub-id pub-id-type="pmid">34352037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Does intermittent fasting associated with aerobic training influence parameters related to the gut-brain axis of Wistar rats?</article-title><source>J Affect Disord</source><year>2021</year><volume>293</volume><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2021.06.028</pub-id><pub-id pub-id-type="pmid">34214787</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Soares NL, et al. Does intermittent fasting associated with aerobic training influence parameters related to the gut-brain axis of Wistar rats? J Affect Disord. 2021;293:176&#x02013;85. 10.1016/j.jad.2021.06.028.<pub-id pub-id-type="pmid">34214787</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Prisco</surname><given-names>SZ</given-names></name><etal/></person-group><article-title>Intermittent fasting enhances right ventricular function in preclinical pulmonary arterial hypertension</article-title><source>J Am Heart Assoc</source><year>2021</year><volume>10</volume><fpage>e022722</fpage><pub-id pub-id-type="doi">10.1161/jaha.121.022722</pub-id><pub-id pub-id-type="pmid">34747187</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Prisco SZ, et al. Intermittent fasting enhances right ventricular function in preclinical pulmonary arterial hypertension. J Am Heart Assoc. 2021;10:e022722. 10.1161/jaha.121.022722.<pub-id pub-id-type="pmid">34747187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Gut microbiota mediates the anti-obesity effect of intermittent fasting by inhibiting intestinal lipid absorption</article-title><source>J Nutr Biochem</source><year>2023</year><volume>116</volume><fpage>109318</fpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2023.109318</pub-id><pub-id pub-id-type="pmid">36924854</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Yang H, et al. Gut microbiota mediates the anti-obesity effect of intermittent fasting by inhibiting intestinal lipid absorption. J Nutr Biochem. 2023;116:109318. 10.1016/j.jnutbio.2023.109318.<pub-id pub-id-type="pmid">36924854</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Teker</surname><given-names>HT</given-names></name><name><surname>Ceylani</surname><given-names>T</given-names></name></person-group><article-title>Intermittent fasting supports the balance of the gut microbiota composition</article-title><source>Int Microbiol</source><year>2023</year><volume>26</volume><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s10123-022-00272-7</pub-id><pub-id pub-id-type="pmid">35953616</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Teker HT, Ceylani T. Intermittent fasting supports the balance of the gut microbiota composition. Int Microbiol. 2023;26:51&#x02013;7. 10.1007/s10123-022-00272-7.<pub-id pub-id-type="pmid">35953616</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Preoperative fasting confers protection against intestinal ischaemia/reperfusion injury by modulating gut microbiota and their metabolites in a mouse model</article-title><source>Br J Anaesth</source><year>2022</year><volume>128</volume><fpage>501</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.bja.2021.11.025</pub-id><pub-id pub-id-type="pmid">34930601</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Huang W, et al. Preoperative fasting confers protection against intestinal ischaemia/reperfusion injury by modulating gut microbiota and their metabolites in a mouse model. Br J Anaesth. 2022;128:501&#x02013;12. 10.1016/j.bja.2021.11.025.<pub-id pub-id-type="pmid">34930601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Intermittent fasting alleviates risk markers in a murine model of ulcerative colitis by modulating the gut microbiome and metabolome</article-title><source>Nutrients</source><year>2022</year><pub-id pub-id-type="doi">10.3390/nu14245311</pub-id><pub-id pub-id-type="pmid">36615841</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Wu J, et al. Intermittent fasting alleviates risk markers in a murine model of ulcerative colitis by modulating the gut microbiome and metabolome. Nutrients. 2022. 10.3390/nu14245311.<pub-id pub-id-type="pmid">36615841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>RX</given-names></name><etal/></person-group><article-title>Intermittent fasting protects against food allergy in a murine model via regulating gut microbiota</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1167562</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1167562</pub-id><pub-id pub-id-type="pmid">37228621</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Ma RX, et al. Intermittent fasting protects against food allergy in a murine model via regulating gut microbiota. Front Immunol. 2023;14:1167562. 10.3389/fimmu.2023.1167562.<pub-id pub-id-type="pmid">37228621</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Loh</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>The effect of calorie intake, fasting, and dietary composition on metabolic health and gut microbiota in mice</article-title><source>BMC Biol</source><year>2021</year><volume>19</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s12915-021-00987-5</pub-id><pub-id pub-id-type="pmid">33740961</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Zhang Z, Chen X, Loh YJ, Yang X, Zhang C. The effect of calorie intake, fasting, and dietary composition on metabolic health and gut microbiota in mice. BMC Biol. 2021;19:51. 10.1186/s12915-021-00987-5.<pub-id pub-id-type="pmid">33740961</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Gregor</surname><given-names>A</given-names></name><etal/></person-group><article-title>A comparison of the impact of restrictive diets on the gastrointestinal tract of mice</article-title><source>Nutrients</source><year>2022</year><pub-id pub-id-type="doi">10.3390/nu14153120</pub-id><pub-id pub-id-type="pmid">35956298</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Gregor A, et al. A comparison of the impact of restrictive diets on the gastrointestinal tract of mice. Nutrients. 2022. 10.3390/nu14153120.<pub-id pub-id-type="pmid">35956298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Insoluble dietary fiber from okara combined with intermittent fasting treatment synergistically confers antiobesity effects by regulating gut microbiota and its metabolites</article-title><source>J Agric Food Chem</source><year>2023</year><volume>71</volume><fpage>13346</fpage><lpage>13362</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.3c03948</pub-id><pub-id pub-id-type="pmid">37651598</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Wang S, et al. Insoluble dietary fiber from okara combined with intermittent fasting treatment synergistically confers antiobesity effects by regulating gut microbiota and its metabolites. J Agric Food Chem. 2023;71:13346&#x02013;62. 10.1021/acs.jafc.3c03948.<pub-id pub-id-type="pmid">37651598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intermittent fasting improves insulin resistance by modulating the gut microbiota and bile acid metabolism in diet-induced obesity</article-title><source>Mol Nutr Food Res</source><year>2024</year><volume>68</volume><fpage>e2400451</fpage><pub-id pub-id-type="doi">10.1002/mnfr.202400451</pub-id><pub-id pub-id-type="pmid">39520336</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Lei S, et al. Intermittent fasting improves insulin resistance by modulating the gut microbiota and bile acid metabolism in diet-induced obesity. Mol Nutr Food Res. 2024;68: e2400451. 10.1002/mnfr.202400451.<pub-id pub-id-type="pmid">39520336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gut microbiota and transcriptome dynamics in every-other-day fasting are associated with neuroprotection in rats with spinal cord injury</article-title><source>Front Microbiol</source><year>2023</year><volume>14</volume><fpage>1206909</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1206909</pub-id><pub-id pub-id-type="pmid">37577426</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Wang J, et al. Gut microbiota and transcriptome dynamics in every-other-day fasting are associated with neuroprotection in rats with spinal cord injury. Front Microbiol. 2023;14:1206909. 10.3389/fmicb.2023.1206909.<pub-id pub-id-type="pmid">37577426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Intermittent fasting reshapes the gut microbiota and metabolome and reduces weight gain more effectively than melatonin in mice</article-title><source>Front Nutr</source><year>2021</year><volume>8</volume><fpage>784681</fpage><pub-id pub-id-type="doi">10.3389/fnut.2021.784681</pub-id><pub-id pub-id-type="pmid">34901130</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Liu J, et al. Intermittent fasting reshapes the gut microbiota and metabolome and reduces weight gain more effectively than melatonin in mice. Front Nutr. 2021;8:784681. 10.3389/fnut.2021.784681.<pub-id pub-id-type="pmid">34901130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>855</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14676-4</pub-id><pub-id pub-id-type="pmid">32071312</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Liu Z, et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun. 2020;11:855. 10.1038/s41467-020-14676-4.<pub-id pub-id-type="pmid">32071312</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota</article-title><source>Cell Metab</source><year>2017</year><volume>26</volume><fpage>672</fpage><lpage>685.e674</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.08.019</pub-id><pub-id pub-id-type="pmid">28918936</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Li G, et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metab. 2017;26:672-685.e674. 10.1016/j.cmet.2017.08.019.<pub-id pub-id-type="pmid">28918936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Rangan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology</article-title><source>Cell Rep</source><year>2019</year><volume>26</volume><fpage>2704</fpage><lpage>2719.e2706</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.019</pub-id><pub-id pub-id-type="pmid">30840892</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Rangan P, et al. Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology. Cell Rep. 2019;26:2704-2719.e2706. 10.1016/j.celrep.2019.02.019.<pub-id pub-id-type="pmid">30840892</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Restructuring the gut microbiota by intermittent fasting lowers blood pressure</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>1240</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1161/circresaha.120.318155</pub-id><pub-id pub-id-type="pmid">33596669</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Shi H, et al. Restructuring the gut microbiota by intermittent fasting lowers blood pressure. Circ Res. 2021;128:1240&#x02013;54. 10.1161/circresaha.120.318155.<pub-id pub-id-type="pmid">33596669</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Exploratory analysis of one versus two-day intermittent fasting protocols on the gut microbiome and plasma metabolome in adults with overweight/obesity</article-title><source>Front Nutr</source><year>2022</year><volume>9</volume><fpage>1036080</fpage><pub-id pub-id-type="doi">10.3389/fnut.2022.1036080</pub-id><pub-id pub-id-type="pmid">36386914</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Mohr AE, et al. Exploratory analysis of one versus two-day intermittent fasting protocols on the gut microbiome and plasma metabolome in adults with overweight/obesity. Front Nutr. 2022;9:1036080. 10.3389/fnut.2022.1036080.<pub-id pub-id-type="pmid">36386914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrocino</surname><given-names>I</given-names></name><etal/></person-group><article-title>The effects of time-restricted eating on metabolism and gut microbiota: a real-life study</article-title><source>Nutrients</source><year>2022</year><pub-id pub-id-type="doi">10.3390/nu14132569</pub-id><pub-id pub-id-type="pmid">35807750</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Ferrocino I, et al. The effects of time-restricted eating on metabolism and gut microbiota: a real-life study. Nutrients. 2022. 10.3390/nu14132569.<pub-id pub-id-type="pmid">35807750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Stanislawski</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The gut microbiota during a behavioral weight loss intervention</article-title><source>Nutrients</source><year>2021</year><pub-id pub-id-type="doi">10.3390/nu13093248</pub-id><pub-id pub-id-type="pmid">34579125</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Stanislawski MA, et al. The gut microbiota during a behavioral weight loss intervention. Nutrients. 2021. 10.3390/nu13093248.<pub-id pub-id-type="pmid">34579125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Maifeld</surname><given-names>A</given-names></name><etal/></person-group><article-title>Fasting alters the gut microbiome reducing blood pressure and body weight in metabolic syndrome patients</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>1970</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22097-0</pub-id><pub-id pub-id-type="pmid">33785752</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Maifeld A, et al. Fasting alters the gut microbiome reducing blood pressure and body weight in metabolic syndrome patients. Nat Commun. 2021;12:1970. 10.1038/s41467-021-22097-0.<pub-id pub-id-type="pmid">33785752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Remely</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased gut microbiota diversity and abundance of Faecalibacterium prausnitzii and Akkermansia after fasting: a pilot study</article-title><source>Wien Klin Wochenschr</source><year>2015</year><volume>127</volume><fpage>394</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1007/s00508-015-0755-1</pub-id><pub-id pub-id-type="pmid">25763563</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Remely M, et al. Increased gut microbiota diversity and abundance of Faecalibacterium prausnitzii and Akkermansia after fasting: a pilot study. Wien Klin Wochenschr. 2015;127:394&#x02013;8. 10.1007/s00508-015-0755-1.<pub-id pub-id-type="pmid">25763563</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadzadeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>The interplay between fasting, gut microbiota, and lipid profile</article-title><source>Int J Clin Pract</source><year>2021</year><volume>75</volume><fpage>e14591</fpage><pub-id pub-id-type="doi">10.1111/ijcp.14591</pub-id><pub-id pub-id-type="pmid">34227218</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Mohammadzadeh A, et al. The interplay between fasting, gut microbiota, and lipid profile. Int J Clin Pract. 2021;75: e14591. 10.1111/ijcp.14591.<pub-id pub-id-type="pmid">34227218</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Mesnage</surname><given-names>R</given-names></name><name><surname>Grundler</surname><given-names>F</given-names></name><name><surname>Schwiertz</surname><given-names>A</given-names></name><name><surname>Le Maho</surname><given-names>Y</given-names></name><name><surname>Wilhelmi de Toledo</surname><given-names>F</given-names></name></person-group><article-title>Changes in human gut microbiota composition are linked to the energy metabolic switch during 10d of Buchinger fasting</article-title><source>J Nutr Sci</source><year>2019</year><pub-id pub-id-type="doi">10.1017/jns.2019.33</pub-id><pub-id pub-id-type="pmid">31798864</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Mesnage R, Grundler F, Schwiertz A, Le Maho Y, Wilhelmi de Toledo F. Changes in human gut microbiota composition are linked to the energy metabolic switch during 10d of Buchinger fasting. J Nutr Sci. 2019. 10.1017/jns.2019.33.<pub-id pub-id-type="pmid">31798864</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Lilja</surname><given-names>S</given-names></name><etal/></person-group><article-title>Five days periodic fasting elevates levels of longevity related christensenella and sirtuin expression in humans</article-title><source>Int J Mol Sci</source><year>2021</year><pub-id pub-id-type="doi">10.3390/ijms22052331</pub-id><pub-id pub-id-type="pmid">33652686</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Lilja S, et al. Five days periodic fasting elevates levels of longevity related christensenella and sirtuin expression in humans. Int J Mol Sci. 2021. 10.3390/ijms22052331.<pub-id pub-id-type="pmid">33652686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zkul</surname><given-names>C</given-names></name><name><surname>Yal&#x00131;nay</surname><given-names>M</given-names></name><name><surname>Karakan</surname><given-names>T</given-names></name></person-group><article-title>Islamic fasting leads to an increased abundance of Akkermansia muciniphila and Bacteroides fragilis group: a preliminary study on intermittent fasting</article-title><source>Turk J Gastroenterol</source><year>2019</year><volume>30</volume><fpage>1030</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.5152/tjg.2019.19185</pub-id><pub-id pub-id-type="pmid">31854308</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">&#x000d6;zkul C, Yal&#x00131;nay M, Karakan T. Islamic fasting leads to an increased abundance of Akkermansia muciniphila and Bacteroides fragilis group: a preliminary study on intermittent fasting. Turk J Gastroenterol. 2019;30:1030&#x02013;5. 10.5152/tjg.2019.19185.<pub-id pub-id-type="pmid">31854308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>J</given-names></name><etal/></person-group><article-title>Remodeling of the gut microbiome during Ramadan-associated intermittent fasting</article-title><source>Am J Clin Nutr</source><year>2021</year><volume>113</volume><fpage>1332</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqaa388</pub-id><pub-id pub-id-type="pmid">33842951</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Su J, et al. Remodeling of the gut microbiome during Ramadan-associated intermittent fasting. Am J Clin Nutr. 2021;113:1332&#x02013;42. 10.1093/ajcn/nqaa388.<pub-id pub-id-type="pmid">33842951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeb</surname><given-names>F</given-names></name><etal/></person-group><article-title>Time-restricted feeding is associated with changes in human gut microbiota related to nutrient intake</article-title><source>Nutrition</source><year>2020</year><volume>78</volume><fpage>110797</fpage><pub-id pub-id-type="doi">10.1016/j.nut.2020.110797</pub-id><pub-id pub-id-type="pmid">32540674</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Zeb F, et al. Time-restricted feeding is associated with changes in human gut microbiota related to nutrient intake. Nutrition. 2020;78:110797. 10.1016/j.nut.2020.110797.<pub-id pub-id-type="pmid">32540674</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>I</given-names></name><etal/></person-group><article-title>Ramadan fasting leads to shifts in human gut microbiota structured by dietary composition</article-title><source>Front Microb</source><year>2021</year><volume>12</volume><fpage>642999</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.642999</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Ali I, et al. Ramadan fasting leads to shifts in human gut microbiota structured by dietary composition. Front Microb. 2021;12:642999. 10.3389/fmicb.2021.642999.</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The alteration of the gut microbiome during ramadan offers a novel perspective on ramadan fasting: a pilot study</article-title><source>Microorganisms</source><year>2023</year><pub-id pub-id-type="doi">10.3390/microorganisms11082106</pub-id><pub-id pub-id-type="pmid">37764155</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Jo Y, et al. The alteration of the gut microbiome during ramadan offers a novel perspective on ramadan fasting: a pilot study. Microorganisms. 2023. 10.3390/microorganisms11082106.<pub-id pub-id-type="pmid">37764155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Selen</surname><given-names>H</given-names></name><name><surname>K&#x000fc;&#x00219;&#x000fc;mler</surname><given-names>AS</given-names></name><name><surname>Karakan</surname><given-names>T</given-names></name><name><surname>Moral</surname><given-names>K</given-names></name></person-group><article-title>Effect of ramadan fasting on intestinal microbiota and fatty acid binding protein 4 in overweight and obese individuals</article-title><source>J Gastrointestin Liver Dis</source><year>2024</year><volume>33</volume><fpage>330</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1540/jgld-5559</pub-id><pub-id pub-id-type="pmid">39348582</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Selen H, K&#x000fc;&#x00219;&#x000fc;mler AS, Karakan T, Moral K. Effect of ramadan fasting on intestinal microbiota and fatty acid binding protein 4 in overweight and obese individuals. J Gastrointestin Liver Dis. 2024;33:330&#x02013;8. 10.1540/jgld-5559.<pub-id pub-id-type="pmid">39348582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Guevara-Cruz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intermittent fasting, calorie restriction, and a ketogenic diet improve mitochondrial function by reducing lipopolysaccharide signaling in monocytes during obesity: a randomized clinical trial</article-title><source>Clin Nutr</source><year>2024</year><volume>43</volume><fpage>1914</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2024.06.036</pub-id><pub-id pub-id-type="pmid">39003957</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Guevara-Cruz M, et al. Intermittent fasting, calorie restriction, and a ketogenic diet improve mitochondrial function by reducing lipopolysaccharide signaling in monocytes during obesity: a randomized clinical trial. Clin Nutr. 2024;43:1914&#x02013;28. 10.1016/j.clnu.2024.06.036.<pub-id pub-id-type="pmid">39003957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Saglam</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of ramadan intermittent fasting on gut microbiome: is the diet key?</article-title><source>Front Microbiol</source><year>2023</year><volume>14</volume><fpage>1203205</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1203205</pub-id><pub-id pub-id-type="pmid">37705730</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Saglam D, et al. Effects of ramadan intermittent fasting on gut microbiome: is the diet key? Front Microbiol. 2023;14:1203205. 10.3389/fmicb.2023.1203205.<pub-id pub-id-type="pmid">37705730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Intermittent fasting modulates the intestinal microbiota and improves obesity and host energy metabolism</article-title><source>NPJ Biofilms Microb</source><year>2023</year><pub-id pub-id-type="doi">10.1038/s41522-023-00386-4</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Hu X, et al. Intermittent fasting modulates the intestinal microbiota and improves obesity and host energy metabolism. NPJ Biofilms Microb. 2023. 10.1038/s41522-023-00386-4.</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Su&#x000e1;rez-Zamorano</surname><given-names>N</given-names></name><etal/></person-group><article-title>Microbiota depletion promotes browning of white adipose tissue and reduces obesity</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>1497</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1038/nm.3994</pub-id><pub-id pub-id-type="pmid">26569380</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Su&#x000e1;rez-Zamorano N, et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat Med. 2015;21:1497&#x02013;501. 10.1038/nm.3994.<pub-id pub-id-type="pmid">26569380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Castillo</surname><given-names>V</given-names></name><name><surname>Sanhueza</surname><given-names>E</given-names></name><name><surname>McNerney</surname><given-names>E</given-names></name><name><surname>Onate</surname><given-names>SA</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>A</given-names></name></person-group><article-title>Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle</article-title><source>J Med Microbiol</source><year>2016</year><volume>65</volume><fpage>1347</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.000371</pub-id><pub-id pub-id-type="pmid">27902422</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Garc&#x000ed;a-Castillo V, Sanhueza E, McNerney E, Onate SA, Garc&#x000ed;a A. Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle. J Med Microbiol. 2016;65:1347&#x02013;62. 10.1099/jmm.0.000371.<pub-id pub-id-type="pmid">27902422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Jasirwan</surname><given-names>COM</given-names></name><name><surname>Lesmana</surname><given-names>CRA</given-names></name><name><surname>Hasan</surname><given-names>I</given-names></name><name><surname>Sulaiman</surname><given-names>AS</given-names></name><name><surname>Gani</surname><given-names>RA</given-names></name></person-group><article-title>The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms</article-title><source>Biosci Microb Food Health</source><year>2019</year><volume>38</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1293/bmfh.18-032</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microb Food Health. 2019;38:81&#x02013;8. 10.1293/bmfh.18-032.</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Pabst</surname><given-names>O</given-names></name><etal/></person-group><article-title>Gut-liver axis: barriers and functional circuits</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2023</year><volume>20</volume><fpage>447</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1038/s41575-023-00771-6</pub-id><pub-id pub-id-type="pmid">37085614</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Pabst O, et al. Gut-liver axis: barriers and functional circuits. Nat Rev Gastroenterol Hepatol. 2023;20:447&#x02013;61. 10.1038/s41575-023-00771-6.<pub-id pub-id-type="pmid">37085614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Quesada-V&#x000e1;zquez</surname><given-names>S</given-names></name><name><surname>Aragon&#x000e8;s</surname><given-names>G</given-names></name><name><surname>Del Bas</surname><given-names>JM</given-names></name><name><surname>Escot&#x000e9;</surname><given-names>X</given-names></name></person-group><article-title>Diet, gut microbiota and non-alcoholic fatty liver disease three parts of the same axis</article-title><source>Cells</source><year>2020</year><pub-id pub-id-type="doi">10.3390/cells9010176</pub-id><pub-id pub-id-type="pmid">31936799</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Quesada-V&#x000e1;zquez S, Aragon&#x000e8;s G, Del Bas JM, Escot&#x000e9; X. Diet, gut microbiota and non-alcoholic fatty liver disease three parts of the same axis. Cells. 2020. 10.3390/cells9010176.<pub-id pub-id-type="pmid">31936799</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Lemke</surname><given-names>U</given-names></name><etal/></person-group><article-title>The glucocorticoid receptor controls hepatic dyslipidemia through Hes1</article-title><source>Cell Metab</source><year>2008</year><volume>8</volume><fpage>212</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.08.001</pub-id><pub-id pub-id-type="pmid">18762022</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Lemke U, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008;8:212&#x02013;23. 10.1016/j.cmet.2008.08.001.<pub-id pub-id-type="pmid">18762022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name><name><surname>Manchester</surname><given-names>JK</given-names></name><name><surname>Semenkovich</surname><given-names>CF</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Mechanisms underlying the resistance to diet-induced obesity in germ-free mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>979</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1073/pnas.0605374104</pub-id><pub-id pub-id-type="pmid">17210919</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">B&#x000e4;ckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979&#x02013;84. 10.1073/pnas.0605374104.<pub-id pub-id-type="pmid">17210919</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrow</surname><given-names>F</given-names></name><etal/></person-group><article-title>Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling</article-title><source>Hepatology</source><year>2021</year><volume>74</volume><fpage>704</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1002/hep.31755</pub-id><pub-id pub-id-type="pmid">33609303</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Barrow F, et al. Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling. Hepatology. 2021;74:704&#x02013;22. 10.1002/hep.31755.<pub-id pub-id-type="pmid">33609303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Miele</surname><given-names>L</given-names></name><etal/></person-group><article-title>Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>1877</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1002/hep.22848</pub-id><pub-id pub-id-type="pmid">19291785</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Miele L, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877&#x02013;87. 10.1002/hep.22848.<pub-id pub-id-type="pmid">19291785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgio</surname><given-names>V</given-names></name><etal/></person-group><article-title>Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity</article-title><source>Dig Liver Dis</source><year>2014</year><volume>46</volume><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2014.02.010</pub-id><pub-id pub-id-type="pmid">24631029</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Giorgio V, et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46:556&#x02013;60. 10.1016/j.dld.2014.02.010.<pub-id pub-id-type="pmid">24631029</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Brun</surname><given-names>P</given-names></name><etal/></person-group><article-title>Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2007</year><volume>292</volume><fpage>G518</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00024.2006</pub-id><pub-id pub-id-type="pmid">17023554</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Brun P, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G518-525. 10.1152/ajpgi.00024.2006.<pub-id pub-id-type="pmid">17023554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>1470</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.2337/db07-1403</pub-id><pub-id pub-id-type="pmid">18305141</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Cani PD, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470&#x02013;81. 10.2337/db07-1403.<pub-id pub-id-type="pmid">18305141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Mouries</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development</article-title><source>J Hepatol</source><year>2019</year><volume>71</volume><fpage>1216</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.08.005</pub-id><pub-id pub-id-type="pmid">31419514</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Mouries J, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216&#x02013;28. 10.1016/j.jhep.2019.08.005.<pub-id pub-id-type="pmid">31419514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of peptidoglycan on the development of steatohepatitis</article-title><source>Biochimica Biophys Acta (BBA) Mol Cell Biol Lipids</source><year>2020</year><volume>1865</volume><fpage>158595</fpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2019.158595</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Jin M, et al. Effects of peptidoglycan on the development of steatohepatitis. Biochimica Biophys Acta (BBA) Mol Cell Biol Lipids. 2020;1865:158595. 10.1016/j.bbalip.2019.158595.</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name><etal/></person-group><article-title>Composition of gut microbiota and non-alcoholic fatty liver disease: A SYSTEMATIC review and meta-analysis</article-title><source>Obes Rev</source><year>2024</year><volume>25</volume><fpage>e13646</fpage><pub-id pub-id-type="doi">10.1111/obr.13646</pub-id><pub-id pub-id-type="pmid">37813400</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Su X, et al. Composition of gut microbiota and non-alcoholic fatty liver disease: A SYSTEMATIC review and meta-analysis. Obes Rev. 2024;25: e13646. 10.1111/obr.13646.<pub-id pub-id-type="pmid">37813400</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Odenwald</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease</article-title><source>Nat Microbiol</source><year>2023</year><volume>8</volume><fpage>2033</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1038/s41564-023-01493-w</pub-id><pub-id pub-id-type="pmid">37845315</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Odenwald MA, et al. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023;8:2033&#x02013;49. 10.1038/s41564-023-01493-w.<pub-id pub-id-type="pmid">37845315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>B</given-names></name></person-group><article-title>Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis</article-title><source>Lipids Health Dis</source><year>2021</year><pub-id pub-id-type="doi">10.1186/s12944-021-01440-w</pub-id><pub-id pub-id-type="pmid">34895241</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis. Lipids Health Dis. 2021. 10.1186/s12944-021-01440-w.<pub-id pub-id-type="pmid">34895241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Umbrello</surname><given-names>G</given-names></name><name><surname>Esposito</surname><given-names>S</given-names></name></person-group><article-title>Microbiota and neurologic diseases: potential effects of probiotics</article-title><source>J Transl Med</source><year>2016</year><volume>14</volume><fpage>298</fpage><pub-id pub-id-type="doi">10.1186/s12967-016-1058-7</pub-id><pub-id pub-id-type="pmid">27756430</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Umbrello G, Esposito S. Microbiota and neurologic diseases: potential effects of probiotics. J Transl Med. 2016;14:298. 10.1186/s12967-016-1058-7.<pub-id pub-id-type="pmid">27756430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><etal/></person-group><article-title>Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>2384</fpage><pub-id pub-id-type="doi">10.1038/ncomms3384</pub-id><pub-id pub-id-type="pmid">24064762</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Li F, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4:2384. 10.1038/ncomms3384.<pub-id pub-id-type="pmid">24064762</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel Monem</surname><given-names>SM</given-names></name></person-group><article-title>Probiotic therapy in patients with nonalcoholic steatohepatitis in zagazig university hospitals</article-title><source>Euroa J Hepatogastroenterol</source><year>2017</year><volume>7</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.5005/jp-journals-10018-1226</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Abdel Monem SM. Probiotic therapy in patients with nonalcoholic steatohepatitis in zagazig university hospitals. Euroa J Hepatogastroenterol. 2017;7:101&#x02013;6. 10.5005/jp-journals-10018-1226.</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferolla</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis</article-title><source>Nutrients</source><year>2016</year><pub-id pub-id-type="doi">10.3390/nu8070397</pub-id><pub-id pub-id-type="pmid">27367724</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Ferolla SM, et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients. 2016. 10.3390/nu8070397.<pub-id pub-id-type="pmid">27367724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>HC-H</given-names></name><etal/></person-group><article-title>Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid</article-title><source>eBioMedicine</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104952</pub-id><pub-id pub-id-type="pmid">39232463</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Lau HC-H, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. eBioMedicine. 2024. 10.1016/j.ebiom.2023.104952.<pub-id pub-id-type="pmid">39232463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Hizo</surname><given-names>GH</given-names></name><name><surname>Rampelotto</surname><given-names>PH</given-names></name></person-group><article-title>The impact of probiotic bifidobacterium on liver diseases and the microbiota</article-title><source>Life (Basel)</source><year>2024</year><pub-id pub-id-type="doi">10.3390/life14020239</pub-id><pub-id pub-id-type="pmid">38398748</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Hizo GH, Rampelotto PH. The impact of probiotic bifidobacterium on liver diseases and the microbiota. Life (Basel). 2024. 10.3390/life14020239.<pub-id pub-id-type="pmid">38398748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lack of Faecalibacterium prausnitzii and Bifidobacterium is associated with a higher risk of metabolic associated fatty liver disease in young-onset type 2 diabetes</article-title><source>Int J Diabet Dev Countr</source><year>2024</year><volume>44</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/s13410-022-01161-5</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Chen S, et al. Lack of Faecalibacterium prausnitzii and Bifidobacterium is associated with a higher risk of metabolic associated fatty liver disease in young-onset type 2 diabetes. Int J Diabet Dev Countr. 2024;44:167&#x02013;74. 10.1007/s13410-022-01161-5.</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><fpage>1352</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.07.005</pub-id><pub-id pub-id-type="pmid">37459922</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Song Q, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023;79:1352&#x02013;65. 10.1016/j.jhep.2023.07.005.<pub-id pub-id-type="pmid">37459922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Derrien</surname><given-names>M</given-names></name><name><surname>Vaughan</surname><given-names>EE</given-names></name><name><surname>Plugge</surname><given-names>CM</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group><article-title>Akkermansia muciniphila gen nov, sp nov a human intestinal mucin-degrading bacterium</article-title><source>Int J Syst Evol Microbiol</source><year>2004</year><volume>54</volume><fpage>1469</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.02873-0</pub-id><pub-id pub-id-type="pmid">15388697</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen nov, sp nov a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54:1469&#x02013;76. 10.1099/ijs.0.02873-0.<pub-id pub-id-type="pmid">15388697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Everard</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>9066</fpage><lpage>9071</lpage><pub-id pub-id-type="doi">10.1073/pnas.1219451110</pub-id><pub-id pub-id-type="pmid">23671105</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Everard A, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110:9066&#x02013;71. 10.1073/pnas.1219451110.<pub-id pub-id-type="pmid">23671105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Plovier</surname><given-names>H</given-names></name><etal/></person-group><article-title>A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nm.4236</pub-id><pub-id pub-id-type="pmid">27892954</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Plovier H, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23:107&#x02013;13. 10.1038/nm.4236.<pub-id pub-id-type="pmid">27892954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Schneeberger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>16643</fpage><pub-id pub-id-type="doi">10.1038/srep16643</pub-id><pub-id pub-id-type="pmid">26563823</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Schneeberger M, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep. 2015;5:16643. 10.1038/srep16643.<pub-id pub-id-type="pmid">26563823</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Depommier</surname><given-names>C</given-names></name><etal/></person-group><article-title>Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><fpage>1096</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0495-2</pub-id><pub-id pub-id-type="pmid">31263284</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25:1096&#x02013;103. 10.1038/s41591-019-0495-2.<pub-id pub-id-type="pmid">31263284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Ju&#x000e1;rez-Fern&#x000e1;ndez</surname><given-names>M</given-names></name><etal/></person-group><article-title>The synbiotic combination of akkermansia muciniphila and quercetin ameliorates early obesity and NAFLD through gut microbiota reshaping and bile acid metabolism modulation</article-title><source>Antioxidants (Basel)</source><year>2021</year><pub-id pub-id-type="doi">10.3390/antiox10122001</pub-id><pub-id pub-id-type="pmid">34943104</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Ju&#x000e1;rez-Fern&#x000e1;ndez M, et al. The synbiotic combination of akkermansia muciniphila and quercetin ameliorates early obesity and NAFLD through gut microbiota reshaping and bile acid metabolism modulation. Antioxidants (Basel). 2021. 10.3390/antiox10122001.<pub-id pub-id-type="pmid">34943104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis</article-title><source>Gut Microbes</source><year>2021</year><volume>13</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1080/19490976.2021.1927633</pub-id><pub-id pub-id-type="pmid">34030573</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Rao Y, et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes. 2021;13:1&#x02013;19. 10.1080/19490976.2021.1927633.<pub-id pub-id-type="pmid">34030573</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><etal/></person-group><article-title>Akkermansia muciniphila protects mice against an emerging tick-borne viral pathogen</article-title><source>Nat Microbiol</source><year>2023</year><volume>8</volume><fpage>91</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01279-6</pub-id><pub-id pub-id-type="pmid">36604506</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Xie J, et al. Akkermansia muciniphila protects mice against an emerging tick-borne viral pathogen. Nat Microbiol. 2023;8:91&#x02013;106. 10.1038/s41564-022-01279-6.<pub-id pub-id-type="pmid">36604506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Oguri</surname><given-names>N</given-names></name><etal/></person-group><article-title>Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model</article-title><source>Npj Biofilms Microb</source><year>2024</year><volume>10</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1038/s41522-024-00564-y</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Oguri N, et al. Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model. Npj Biofilms Microb. 2024;10:81. 10.1038/s41522-024-00564-y.</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid</article-title><source>Nat Microbiol</source><year>2023</year><volume>8</volume><fpage>1534</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1038/s41564-023-01418-7</pub-id><pub-id pub-id-type="pmid">37386075</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Wei W, et al. Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid. Nat Microbiol. 2023;8:1534&#x02013;48. 10.1038/s41564-023-01418-7.<pub-id pub-id-type="pmid">37386075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids</article-title><source>Cell Rep</source><year>2019</year><volume>26</volume><fpage>222</fpage><lpage>235.e225</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.12.028</pub-id><pub-id pub-id-type="pmid">30605678</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Wang K, et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep. 2019;26:222-235.e225. 10.1016/j.celrep.2018.12.028.<pub-id pub-id-type="pmid">30605678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Falony</surname><given-names>G</given-names></name><etal/></person-group><article-title>Population-level analysis of gut microbiome variation</article-title><source>Science</source><year>2016</year><volume>352</volume><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1126/science.aad3503</pub-id><pub-id pub-id-type="pmid">27126039</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Falony G, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560&#x02013;4. 10.1126/science.aad3503.<pub-id pub-id-type="pmid">27126039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Del Chierico</surname><given-names>F</given-names></name><etal/></person-group><article-title>Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><fpage>451</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1002/hep.28572</pub-id><pub-id pub-id-type="pmid">27028797</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Del Chierico F, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451&#x02013;64. 10.1002/hep.28572.<pub-id pub-id-type="pmid">27028797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid</article-title><source>Nat Microbiol</source><year>2023</year><volume>8</volume><fpage>1534</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1038/s41564-023-01418-7</pub-id><pub-id pub-id-type="pmid">37386075</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Wei W, et al. Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid. Nat Microbiol. 2023;8:1534&#x02013;48. 10.1038/s41564-023-01418-7.<pub-id pub-id-type="pmid">37386075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>1829</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37459-z</pub-id><pub-id pub-id-type="pmid">37005411</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Zhao Q, et al. Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice. Nat Commun. 2023;14:1829. 10.1038/s41467-023-37459-z.<pub-id pub-id-type="pmid">37005411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet</article-title><source>Front Microbiol</source><year>2023</year><volume>14</volume><fpage>1123547</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1123547</pub-id><pub-id pub-id-type="pmid">37007480</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">Shin JH, et al. Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet. Front Microbiol. 2023;14:1123547. 10.3389/fmicb.2023.1123547.<pub-id pub-id-type="pmid">37007480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Specific strains of faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation</article-title><source>Nutrients</source><year>2022</year><pub-id pub-id-type="doi">10.3390/nu14142945</pub-id><pub-id pub-id-type="pmid">36615829</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Hu W, et al. Specific strains of faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation. Nutrients. 2022. 10.3390/nu14142945.<pub-id pub-id-type="pmid">36615829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Munukka</surname><given-names>E</given-names></name><etal/></person-group><article-title>Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice</article-title><source>ISME J</source><year>2017</year><volume>11</volume><fpage>1667</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1038/ismej.2017.24</pub-id><pub-id pub-id-type="pmid">28375212</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Munukka E, et al. Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice. ISME J. 2017;11:1667&#x02013;79. 10.1038/ismej.2017.24.<pub-id pub-id-type="pmid">28375212</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>K</given-names></name><etal/></person-group><article-title>Roseburia intestinalis: a beneficial gut organism from the discoveries in genus and species</article-title><source>Front Cell Infect Microbiol</source><year>2021</year><volume>11</volume><fpage>757718</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2021.757718</pub-id><pub-id pub-id-type="pmid">34881193</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Nie K, et al. Roseburia intestinalis: a beneficial gut organism from the discoveries in genus and species. Front Cell Infect Microbiol. 2021;11: 757718. 10.3389/fcimb.2021.757718.<pub-id pub-id-type="pmid">34881193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkul</surname><given-names>C</given-names></name><name><surname>Yalinay</surname><given-names>M</given-names></name><name><surname>Karakan</surname><given-names>T</given-names></name></person-group><article-title>Structural changes in gut microbiome after Ramadan fasting: a pilot study</article-title><source>Benef Microbes</source><year>2020</year><volume>11</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.3920/bm2019.0039</pub-id><pub-id pub-id-type="pmid">32073296</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Ozkul C, Yalinay M, Karakan T. Structural changes in gut microbiome after Ramadan fasting: a pilot study. Benef Microbes. 2020;11:227&#x02013;33. 10.3920/bm2019.0039.<pub-id pub-id-type="pmid">32073296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Nava</surname><given-names>GM</given-names></name><name><surname>Stappenbeck</surname><given-names>TS</given-names></name></person-group><article-title>Diversity of the autochthonous colonic microbiota</article-title><source>Gut Microbes</source><year>2011</year><volume>2</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.4161/gmic.2.2.15416</pub-id><pub-id pub-id-type="pmid">21694499</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Nava GM, Stappenbeck TS. Diversity of the autochthonous colonic microbiota. Gut Microbes. 2011;2:99&#x02013;104. 10.4161/gmic.2.2.15416.<pub-id pub-id-type="pmid">21694499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Valentin-Cortez</surname><given-names>FJ</given-names></name><name><surname>C&#x000f3;rdova-Gallardo</surname><given-names>J</given-names></name><name><surname>M&#x000e9;ndez-S&#x000e1;nchez</surname><given-names>N</given-names></name></person-group><article-title>Narrative review of gut microbiota and liver diseases: facts and fictions</article-title><source>Dig Med Res</source><year>2022</year><pub-id pub-id-type="doi">10.2103/dmr-21-85</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Valentin-Cortez FJ, C&#x000f3;rdova-Gallardo J, M&#x000e9;ndez-S&#x000e1;nchez N. Narrative review of gut microbiota and liver diseases: facts and fictions. Dig Med Res. 2022. 10.2103/dmr-21-85.</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>B</given-names></name><etal/></person-group><article-title>Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.11.001</pub-id><pub-id pub-id-type="pmid">31866426</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Seo B, et al. Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice. Cell Host Microbe. 2020;27:25&#x02013;40. 10.1016/j.chom.2019.11.001.<pub-id pub-id-type="pmid">31866426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Wiest</surname><given-names>R</given-names></name><name><surname>Lawson</surname><given-names>M</given-names></name><name><surname>Geuking</surname><given-names>M</given-names></name></person-group><article-title>Pathological bacterial translocation in liver cirrhosis</article-title><source>J Hepatol</source><year>2014</year><volume>60</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2013.07.044</pub-id><pub-id pub-id-type="pmid">23993913</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60:197&#x02013;209. 10.1016/j.jhep.2013.07.044.<pub-id pub-id-type="pmid">23993913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Sorribas</surname><given-names>M</given-names></name><etal/></person-group><article-title>FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis</article-title><source>J Hepatol</source><year>2019</year><volume>71</volume><fpage>1126</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.06.017</pub-id><pub-id pub-id-type="pmid">31295531</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">Sorribas M, et al. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol. 2019;71:1126&#x02013;40. 10.1016/j.jhep.2019.06.017.<pub-id pub-id-type="pmid">31295531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Balmer</surname><given-names>ML</given-names></name><etal/></person-group><article-title>The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota</article-title><source>Sci Transl Med</source><year>2014</year><pub-id pub-id-type="doi">10.1126/scitranslmed.3008618</pub-id><pub-id pub-id-type="pmid">24848256</pub-id>
</element-citation><mixed-citation id="mc-CR149" publication-type="journal">Balmer ML, et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med. 2014. 10.1126/scitranslmed.3008618.<pub-id pub-id-type="pmid">24848256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1002/hep.26093</pub-id><pub-id pub-id-type="pmid">22767219</pub-id>
</element-citation><mixed-citation id="mc-CR150" publication-type="journal">Zhu L, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:1.<pub-id pub-id-type="pmid">22767219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>E coli NF73&#x02013;1 isolated from NASH patients aggravates NAFLD in mice by translocating into the liver and stimulating M1 polarization</article-title><source>Front Cell Infect Microbiol</source><year>2020</year><volume>10</volume><fpage>535940</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.535940</pub-id><pub-id pub-id-type="pmid">33363046</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Zhang Y, et al. E coli NF73&#x02013;1 isolated from NASH patients aggravates NAFLD in mice by translocating into the liver and stimulating M1 polarization. Front Cell Infect Microbiol. 2020;10: 535940. 10.3389/fcimb.2020.535940.<pub-id pub-id-type="pmid">33363046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name><surname>Loomba</surname><given-names>R</given-names></name><etal/></person-group><article-title>Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease</article-title><source>Cell Metabolism</source><year>2017</year><volume>25</volume><fpage>1054</fpage><lpage>1062.e1055</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.04.001</pub-id><pub-id pub-id-type="pmid">28467925</pub-id>
</element-citation><mixed-citation id="mc-CR152" publication-type="journal">Loomba R, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metabolism. 2017;25:1054-1062.e1055. 10.1016/j.cmet.2017.04.001.<pub-id pub-id-type="pmid">28467925</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Escherichia coli promotes endothelial to mesenchymal transformation of liver sinusoidal endothelial cells and exacerbates nonalcoholic fatty liver disease via its flagellin</article-title><source>Cell Mol Gastroenterol Hepatol</source><year>2023</year><volume>16</volume><fpage>857</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2023.08.001</pub-id><pub-id pub-id-type="pmid">37572735</pub-id>
</element-citation><mixed-citation id="mc-CR153" publication-type="journal">Shen B, et al. Escherichia coli promotes endothelial to mesenchymal transformation of liver sinusoidal endothelial cells and exacerbates nonalcoholic fatty liver disease via its flagellin. Cell Mol Gastroenterol Hepatol. 2023;16:857&#x02013;79. 10.1016/j.jcmgh.2023.08.001.<pub-id pub-id-type="pmid">37572735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>SL</given-names></name><name><surname>Stine</surname><given-names>JG</given-names></name><name><surname>Bisanz</surname><given-names>JE</given-names></name><name><surname>Okafor</surname><given-names>CD</given-names></name><name><surname>Patterson</surname><given-names>AD</given-names></name></person-group><article-title>Bile acids and the gut microbiota: metabolic interactions and impacts on disease</article-title><source>Nat Rev Microbiol</source><year>2023</year><volume>21</volume><fpage>236</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00805-x</pub-id><pub-id pub-id-type="pmid">36253479</pub-id>
</element-citation><mixed-citation id="mc-CR154" publication-type="journal">Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21:236&#x02013;47. 10.1038/s41579-022-00805-x.<pub-id pub-id-type="pmid">36253479</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>The complex structure of bile salt hydrolase from Lactobacillus salivarius reveals the structural basis of substrate specificity</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>12438</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-48850-6</pub-id><pub-id pub-id-type="pmid">31455813</pub-id>
</element-citation><mixed-citation id="mc-CR155" publication-type="journal">Xu F, et al. The complex structure of bile salt hydrolase from Lactobacillus salivarius reveals the structural basis of substrate specificity. Sci Rep. 2019;9:12438. 10.1038/s41598-019-48850-6.<pub-id pub-id-type="pmid">31455813</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bile salt hydrolases: at the crossroads of microbiota and human health</article-title><source>Microorganisms</source><year>2021</year><pub-id pub-id-type="doi">10.3390/microorganisms9061122</pub-id><pub-id pub-id-type="pmid">34067328</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Bourgin M, et al. Bile salt hydrolases: at the crossroads of microbiota and human health. Microorganisms. 2021. 10.3390/microorganisms9061122.<pub-id pub-id-type="pmid">34067328</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Calkin</surname><given-names>AC</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name></person-group><article-title>Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR</article-title><source>Nat Rev Mol Cell Biol</source><year>2012</year><volume>13</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/nrm3312</pub-id><pub-id pub-id-type="pmid">22414897</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012;13:213&#x02013;24. 10.1038/nrm3312.<pub-id pub-id-type="pmid">22414897</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>FXR signaling in the enterohepatic system</article-title><source>Mol Cell Endocrinol</source><year>2013</year><volume>368</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2012.05.004</pub-id><pub-id pub-id-type="pmid">22609541</pub-id>
</element-citation><mixed-citation id="mc-CR158" publication-type="journal">Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368:17&#x02013;29. 10.1016/j.mce.2012.05.004.<pub-id pub-id-type="pmid">22609541</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name><surname>Hatori</surname><given-names>M</given-names></name><etal/></person-group><article-title>Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet</article-title><source>Cell Metab</source><year>2012</year><volume>15</volume><fpage>848</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.04.019</pub-id><pub-id pub-id-type="pmid">22608008</pub-id>
</element-citation><mixed-citation id="mc-CR159" publication-type="journal">Hatori M, et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab. 2012;15:848&#x02013;60. 10.1016/j.cmet.2012.04.019.<pub-id pub-id-type="pmid">22608008</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name><surname>Nadinskaia</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease</article-title><source>World J Gastroenterol</source><year>2021</year><volume>27</volume><fpage>959</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.3748/wjg.v27.i10.959</pub-id><pub-id pub-id-type="pmid">33776366</pub-id>
</element-citation><mixed-citation id="mc-CR160" publication-type="journal">Nadinskaia M, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27:959&#x02013;75. 10.3748/wjg.v27.i10.959.<pub-id pub-id-type="pmid">33776366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review</article-title><source>BMC Gastroenterol</source><year>2013</year><volume>13</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/1471-230X-13-140</pub-id><pub-id pub-id-type="pmid">24053454</pub-id>
</element-citation><mixed-citation id="mc-CR161" publication-type="journal">Xiang Z, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. 10.1186/1471-230X-13-140.<pub-id pub-id-type="pmid">24053454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis</article-title><source>Biomed Pharmacother</source><year>2024</year><volume>174</volume><fpage>116617</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2024.116617</pub-id><pub-id pub-id-type="pmid">38643542</pub-id>
</element-citation><mixed-citation id="mc-CR162" publication-type="journal">Li H, Wang M, Chen P, Zhu M, Chen L. A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis. Biomed Pharmacother. 2024;174: 116617. 10.1016/j.biopha.2024.116617.<pub-id pub-id-type="pmid">38643542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name><surname>Marchian&#x000f2;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><fpage>1602</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-28647-4</pub-id><pub-id pub-id-type="pmid">36709356</pub-id>
</element-citation><mixed-citation id="mc-CR163" publication-type="journal">Marchian&#x000f2; S, et al. Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH. Sci Rep. 2023;13:1602. 10.1038/s41598-023-28647-4.<pub-id pub-id-type="pmid">36709356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease</article-title><source>Br J Pharmacol</source><year>2018</year><volume>175</volume><fpage>469</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1111/bph.14095</pub-id><pub-id pub-id-type="pmid">29139555</pub-id>
</element-citation><mixed-citation id="mc-CR164" publication-type="journal">Wang W, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018;175:469&#x02013;84. 10.1111/bph.14095.<pub-id pub-id-type="pmid">29139555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Muramatsu-Kato</surname><given-names>K</given-names></name><name><surname>Ferdous</surname><given-names>UJ</given-names></name><name><surname>Kohmura-Kobayashi</surname><given-names>Y</given-names></name><name><surname>Kanayama</surname><given-names>N</given-names></name></person-group><article-title>Undernourishment in utero and hepatic steatosis in later life: A potential issue in Japanese people</article-title><source>Congenit Anom (Kyoto)</source><year>2017</year><volume>57</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1111/cga.12200</pub-id><pub-id pub-id-type="pmid">27859643</pub-id>
</element-citation><mixed-citation id="mc-CR165" publication-type="journal">Itoh H, Muramatsu-Kato K, Ferdous UJ, Kohmura-Kobayashi Y, Kanayama N. Undernourishment in utero and hepatic steatosis in later life: A potential issue in Japanese people. Congenit Anom (Kyoto). 2017;57:178&#x02013;83. 10.1111/cga.12200.<pub-id pub-id-type="pmid">27859643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y-J</given-names></name><etal/></person-group><article-title>Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes</article-title><source>Lab Investig</source><year>2014</year><volume>94</volume><fpage>1114</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2014.98</pub-id><pub-id pub-id-type="pmid">25111690</pub-id>
</element-citation><mixed-citation id="mc-CR166" publication-type="journal">Choi Y-J, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Investig. 2014;94:1114&#x02013;25. 10.1038/labinvest.2014.98.<pub-id pub-id-type="pmid">25111690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name><surname>Parada Venegas</surname><given-names>D</given-names></name><etal/></person-group><article-title>Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>277</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00277</pub-id><pub-id pub-id-type="pmid">30915065</pub-id>
</element-citation><mixed-citation id="mc-CR167" publication-type="journal">Parada Venegas D, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. 10.3389/fimmu.2019.00277.<pub-id pub-id-type="pmid">30915065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>C</given-names></name><name><surname>Rivera</surname><given-names>L</given-names></name><name><surname>Furness</surname><given-names>JB</given-names></name><name><surname>Angus</surname><given-names>PW</given-names></name></person-group><article-title>The role of the gut microbiota in NAFLD</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2016</year><volume>13</volume><fpage>412</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2016.85</pub-id><pub-id pub-id-type="pmid">27273168</pub-id>
</element-citation><mixed-citation id="mc-CR168" publication-type="journal">Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412&#x02013;25. 10.1038/nrgastro.2016.85.<pub-id pub-id-type="pmid">27273168</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name><surname>Pant</surname><given-names>K</given-names></name><name><surname>Venugopal</surname><given-names>SK</given-names></name><name><surname>Lorenzo Pisarello</surname><given-names>MJ</given-names></name><name><surname>Gradilone</surname><given-names>SA</given-names></name></person-group><article-title>The role of gut microbiome-derived short-chain fatty acid butyrate in hepatobiliary diseases</article-title><source>Am J Pathol</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.ajpath.2023.06.007</pub-id><pub-id pub-id-type="pmid">37422149</pub-id>
</element-citation><mixed-citation id="mc-CR169" publication-type="journal">Pant K, Venugopal SK, Lorenzo Pisarello MJ, Gradilone SA. The role of gut microbiome-derived short-chain fatty acid butyrate in hepatobiliary diseases. Am J Pathol. 2023. 10.1016/j.ajpath.2023.06.007.<pub-id pub-id-type="pmid">37422149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukui</surname><given-names>H</given-names></name></person-group><article-title>Role of gut dysbiosis in liver diseases: what have we learned so far?</article-title><source>Diseases</source><year>2019</year><pub-id pub-id-type="doi">10.3390/diseases7040058</pub-id><pub-id pub-id-type="pmid">31726747</pub-id>
</element-citation><mixed-citation id="mc-CR170" publication-type="journal">Fukui H. Role of gut dysbiosis in liver diseases: what have we learned so far? Diseases. 2019. 10.3390/diseases7040058.<pub-id pub-id-type="pmid">31726747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1002/hep.26093</pub-id><pub-id pub-id-type="pmid">23055155</pub-id>
</element-citation><mixed-citation id="mc-CR171" publication-type="journal">Zhu L, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601&#x02013;9. 10.1002/hep.26093.<pub-id pub-id-type="pmid">23055155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name><surname>Raman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease</article-title><source>Clin Gastroenterol Hepatol</source><year>2013</year><volume>11</volume><issue>868&#x02013;875</issue><fpage>e861</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2013.02.015</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Raman M, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(868&#x02013;875):e861-863. 10.1016/j.cgh.2013.02.015.</mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>8096</fpage><pub-id pub-id-type="doi">10.1038/srep08096</pub-id><pub-id pub-id-type="pmid">25644696</pub-id>
</element-citation><mixed-citation id="mc-CR173" publication-type="journal">Jiang W, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096. 10.1038/srep08096.<pub-id pub-id-type="pmid">25644696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis</article-title><source>Pharmacol Res</source><year>2021</year><volume>165</volume><fpage>105420</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105420</pub-id><pub-id pub-id-type="pmid">33434620</pub-id>
</element-citation><mixed-citation id="mc-CR174" publication-type="journal">Liu P, et al. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. Pharmacol Res. 2021;165: 105420. 10.1016/j.phrs.2021.105420.<pub-id pub-id-type="pmid">33434620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name><surname>Pohl</surname><given-names>K</given-names></name><name><surname>Moodley</surname><given-names>P</given-names></name><name><surname>Dhanda</surname><given-names>A</given-names></name></person-group><article-title>The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: a systematic review</article-title><source>J Gastroenterol Hepatol</source><year>2022</year><volume>37</volume><fpage>1498</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1111/jgh.15899</pub-id><pub-id pub-id-type="pmid">35612373</pub-id>
</element-citation><mixed-citation id="mc-CR175" publication-type="journal">Pohl K, Moodley P, Dhanda A. The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: a systematic review. J Gastroenterol Hepatol. 2022;37:1498&#x02013;506. 10.1111/jgh.15899.<pub-id pub-id-type="pmid">35612373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name><surname>Duscha</surname><given-names>A</given-names></name><etal/></person-group><article-title>Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>1067</fpage><lpage>1080.e1016</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.035</pub-id><pub-id pub-id-type="pmid">32160527</pub-id>
</element-citation><mixed-citation id="mc-CR176" publication-type="journal">Duscha A, et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell. 2020;180:1067-1080.e1016. 10.1016/j.cell.2020.02.035.<pub-id pub-id-type="pmid">32160527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name><surname>Mollica</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Butyrate regulates liver mitochondrial function, efficiency, and dynamics in insulin-resistant obese mice</article-title><source>Diabetes</source><year>2017</year><volume>66</volume><fpage>1405</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.2337/db16-0924</pub-id><pub-id pub-id-type="pmid">28223285</pub-id>
</element-citation><mixed-citation id="mc-CR177" publication-type="journal">Mollica MP, et al. Butyrate regulates liver mitochondrial function, efficiency, and dynamics in insulin-resistant obese mice. Diabetes. 2017;66:1405&#x02013;18. 10.2337/db16-0924.<pub-id pub-id-type="pmid">28223285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group><article-title>Altered gut microbiome profile in patients with pulmonary arterial hypertension</article-title><source>Hypertension</source><year>2020</year><volume>75</volume><fpage>1063</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1161/hypertensionaha.119.14294</pub-id><pub-id pub-id-type="pmid">32088998</pub-id>
</element-citation><mixed-citation id="mc-CR178" publication-type="journal">Kim S, et al. Altered gut microbiome profile in patients with pulmonary arterial hypertension. Hypertension. 2020;75:1063&#x02013;71. 10.1161/hypertensionaha.119.14294.<pub-id pub-id-type="pmid">32088998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease</article-title><source>Nature</source><year>2011</year><volume>472</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nature09922</pub-id><pub-id pub-id-type="pmid">21475195</pub-id>
</element-citation><mixed-citation id="mc-CR179" publication-type="journal">Wang Z, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57&#x02013;63. 10.1038/nature09922.<pub-id pub-id-type="pmid">21475195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name><surname>Koeth</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>576</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1038/nm.3145</pub-id><pub-id pub-id-type="pmid">23563705</pub-id>
</element-citation><mixed-citation id="mc-CR180" publication-type="journal">Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576&#x02013;85. 10.1038/nm.3145.<pub-id pub-id-type="pmid">23563705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuka</surname><given-names>J</given-names></name><etal/></person-group><article-title>Metformin decreases bacterial trimethylamine production and trimethylamine N-oxide levels in db/db mice</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>14555</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-71470-4</pub-id><pub-id pub-id-type="pmid">32884086</pub-id>
</element-citation><mixed-citation id="mc-CR181" publication-type="journal">Kuka J, et al. Metformin decreases bacterial trimethylamine production and trimethylamine N-oxide levels in db/db mice. Sci Rep. 2020;10:14555. 10.1038/s41598-020-71470-4.<pub-id pub-id-type="pmid">32884086</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Obaide</surname><given-names>MAI</given-names></name><etal/></person-group><article-title>Gut microbiota-dependent trimethylamine-n-oxide and serum biomarkers in patients with T2DM and advanced CKD</article-title><source>J Clin Med</source><year>2017</year><pub-id pub-id-type="doi">10.3390/jcm6090086</pub-id><pub-id pub-id-type="pmid">28925931</pub-id>
</element-citation><mixed-citation id="mc-CR182" publication-type="journal">Al-Obaide MAI, et al. Gut microbiota-dependent trimethylamine-n-oxide and serum biomarkers in patients with T2DM and advanced CKD. J Clin Med. 2017. 10.3390/jcm6090086.<pub-id pub-id-type="pmid">28925931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Gut microbiota metabolite TMA may mediate the effects of TMAO on glucose and lipid metabolism in C57BL/6J mice</article-title><source>Mol Nutr Food Res</source><year>2024</year><volume>68</volume><fpage>e2300443</fpage><pub-id pub-id-type="doi">10.1002/mnfr.202300443</pub-id><pub-id pub-id-type="pmid">38456781</pub-id>
</element-citation><mixed-citation id="mc-CR183" publication-type="journal">Li XY, et al. Gut microbiota metabolite TMA may mediate the effects of TMAO on glucose and lipid metabolism in C57BL/6J mice. Mol Nutr Food Res. 2024;68: e2300443. 10.1002/mnfr.202300443.<pub-id pub-id-type="pmid">38456781</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial</article-title><source>Mol Nutr Food Res</source><year>2017</year><pub-id pub-id-type="doi">10.1002/mnfr.201600324</pub-id><pub-id pub-id-type="pmid">28722302</pub-id>
</element-citation><mixed-citation id="mc-CR184" publication-type="journal">Cho CE, et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. Mol Nutr Food Res. 2017. 10.1002/mnfr.201600324.<pub-id pub-id-type="pmid">28722302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name><surname>Washburn</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Pilot study of novel intermittent fasting effects on metabolomic and trimethylamine N-oxide changes during 24-hour water-only fasting in the FEELGOOD trial</article-title><source>Nutrients</source><year>2019</year><pub-id pub-id-type="doi">10.3390/nu11020246</pub-id><pub-id pub-id-type="pmid">30678028</pub-id>
</element-citation><mixed-citation id="mc-CR185" publication-type="journal">Washburn RL, et al. Pilot study of novel intermittent fasting effects on metabolomic and trimethylamine N-oxide changes during 24-hour water-only fasting in the FEELGOOD trial. Nutrients. 2019. 10.3390/nu11020246.<pub-id pub-id-type="pmid">30678028</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name><surname>Videja</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fasting-mimicking diet reduces trimethylamine N-oxide levels and improves serum biochemical parameters in healthy volunteers</article-title><source>Nutrients</source><year>2022</year><pub-id pub-id-type="doi">10.3390/nu14051093</pub-id><pub-id pub-id-type="pmid">35268068</pub-id>
</element-citation><mixed-citation id="mc-CR186" publication-type="journal">Videja M, et al. Fasting-mimicking diet reduces trimethylamine N-oxide levels and improves serum biochemical parameters in healthy volunteers. Nutrients. 2022. 10.3390/nu14051093.<pub-id pub-id-type="pmid">35268068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name><surname>Schiattarella</surname><given-names>GG</given-names></name><etal/></person-group><article-title>Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>2948</fpage><lpage>2956</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx342</pub-id><pub-id pub-id-type="pmid">29020409</pub-id>
</element-citation><mixed-citation id="mc-CR187" publication-type="journal">Schiattarella GG, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J. 2017;38:2948&#x02013;56. 10.1093/eurheartj/ehx342.<pub-id pub-id-type="pmid">29020409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name><surname>Le&#x000f3;n-Mimila</surname><given-names>P</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes</article-title><source>Diabetes Metab</source><year>2021</year><volume>47</volume><fpage>101183</fpage><pub-id pub-id-type="doi">10.1016/j.diabet.2020.07.010</pub-id><pub-id pub-id-type="pmid">32791310</pub-id>
</element-citation><mixed-citation id="mc-CR188" publication-type="journal">Le&#x000f3;n-Mimila P, et al. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab. 2021;47:101183. 10.1016/j.diabet.2020.07.010.<pub-id pub-id-type="pmid">32791310</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Guerrero</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease</article-title><source>Liver Int</source><year>2021</year><volume>41</volume><fpage>2371</fpage><lpage>2382</lpage><pub-id pub-id-type="doi">10.1111/liv.14963</pub-id><pub-id pub-id-type="pmid">33993608</pub-id>
</element-citation><mixed-citation id="mc-CR189" publication-type="journal">Flores-Guerrero JL, et al. Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease. Liver Int. 2021;41:2371&#x02013;82. 10.1111/liv.14963.<pub-id pub-id-type="pmid">33993608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Lonardo</surname><given-names>A</given-names></name><name><surname>Zoppini</surname><given-names>G</given-names></name><name><surname>Barbui</surname><given-names>C</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis</article-title><source>J Hepatol</source><year>2016</year><volume>65</volume><fpage>589</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.05.013</pub-id><pub-id pub-id-type="pmid">27212244</pub-id>
</element-citation><mixed-citation id="mc-CR190" publication-type="journal">Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589&#x02013;600. 10.1016/j.jhep.2016.05.013.<pub-id pub-id-type="pmid">27212244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Tilg</surname><given-names>H</given-names></name></person-group><article-title>NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>1691</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320622</pub-id><pub-id pub-id-type="pmid">32321858</pub-id>
</element-citation><mixed-citation id="mc-CR191" publication-type="journal">Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691&#x02013;705. 10.1136/gutjnl-2020-320622.<pub-id pub-id-type="pmid">32321858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>19076</fpage><pub-id pub-id-type="doi">10.1038/srep19076</pub-id><pub-id pub-id-type="pmid">26743949</pub-id>
</element-citation><mixed-citation id="mc-CR192" publication-type="journal">Chen YM, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076. 10.1038/srep19076.<pub-id pub-id-type="pmid">26743949</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name><surname>Pathak</surname><given-names>P</given-names></name><etal/></person-group><article-title>Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2020</year><pub-id pub-id-type="doi">10.1152/ajpheart.00584.2019</pub-id><pub-id pub-id-type="pmid">32330092</pub-id>
</element-citation><mixed-citation id="mc-CR193" publication-type="journal">Pathak P, et al. Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism. Am J Physiol Heart Circ Physiol. 2020. 10.1152/ajpheart.00584.2019.<pub-id pub-id-type="pmid">32330092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name><surname>Hetz</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Kaufman</surname><given-names>RJ</given-names></name></person-group><article-title>Mechanisms, regulation and functions of the unfolded protein response</article-title><source>Nat Rev Mol Cell Biol</source><year>2020</year><volume>21</volume><fpage>421</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0250-z</pub-id><pub-id pub-id-type="pmid">32457508</pub-id>
</element-citation><mixed-citation id="mc-CR194" publication-type="journal">Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421&#x02013;38. 10.1038/s41580-020-0250-z.<pub-id pub-id-type="pmid">32457508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction</article-title><source>Cell Metab</source><year>2019</year><volume>30</volume><fpage>1141</fpage><lpage>1151.e1145</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.08.021</pub-id><pub-id pub-id-type="pmid">31543404</pub-id>
</element-citation><mixed-citation id="mc-CR195" publication-type="journal">Chen S, et al. Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab. 2019;30:1141-1151.e1145. 10.1016/j.cmet.2019.08.021.<pub-id pub-id-type="pmid">31543404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name><surname>Nian</surname><given-names>F</given-names></name><etal/></person-group><article-title>Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro</article-title><source>Biochem Biophys Res Commun</source><year>2023</year><volume>669</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2023.05.041</pub-id><pub-id pub-id-type="pmid">37271025</pub-id>
</element-citation><mixed-citation id="mc-CR196" publication-type="journal">Nian F, et al. Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro. Biochem Biophys Res Commun. 2023;669:134&#x02013;42. 10.1016/j.bbrc.2023.05.041.<pub-id pub-id-type="pmid">37271025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>YS</given-names></name><name><surname>Shah</surname><given-names>VH</given-names></name></person-group><article-title>The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension</article-title><source>Clin Mol Hepatol</source><year>2012</year><volume>18</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.3350/cmh.2012.18.4.337</pub-id><pub-id pub-id-type="pmid">23323248</pub-id>
</element-citation><mixed-citation id="mc-CR197" publication-type="journal">Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol. 2012;18:337&#x02013;46. 10.3350/cmh.2012.18.4.337.<pub-id pub-id-type="pmid">23323248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukui</surname><given-names>H</given-names></name></person-group><article-title>Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia</article-title><source>World J Hepatol</source><year>2015</year><volume>7</volume><fpage>425</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i3.425</pub-id><pub-id pub-id-type="pmid">25848468</pub-id>
</element-citation><mixed-citation id="mc-CR198" publication-type="journal">Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol. 2015;7:425&#x02013;42. 10.4254/wjh.v7.i3.425.<pub-id pub-id-type="pmid">25848468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name><surname>Vatanen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans</article-title><source>Cell</source><year>2016</year><volume>165</volume><fpage>842</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.007</pub-id><pub-id pub-id-type="pmid">27133167</pub-id>
</element-citation><mixed-citation id="mc-CR199" publication-type="journal">Vatanen T, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165:842&#x02013;53. 10.1016/j.cell.2016.04.007.<pub-id pub-id-type="pmid">27133167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability</article-title><source>Gut</source><year>2009</year><volume>58</volume><fpage>1091</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1136/gut.2008.165886</pub-id><pub-id pub-id-type="pmid">19240062</pub-id>
</element-citation><mixed-citation id="mc-CR200" publication-type="journal">Cani PD, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091&#x02013;103. 10.1136/gut.2008.165886.<pub-id pub-id-type="pmid">19240062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VW</given-names></name><etal/></person-group><article-title>Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study</article-title><source>Aliment Pharmacol Ther</source><year>2015</year><volume>42</volume><fpage>731</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1111/apt.13327</pub-id><pub-id pub-id-type="pmid">26202818</pub-id>
</element-citation><mixed-citation id="mc-CR201" publication-type="journal">Wong VW, et al. Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. Aliment Pharmacol Ther. 2015;42:731&#x02013;40. 10.1111/apt.13327.<pub-id pub-id-type="pmid">26202818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease</article-title><source>Aliment Pharmacol Ther</source><year>2017</year><volume>46</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1111/apt.14119</pub-id><pub-id pub-id-type="pmid">28464257</pub-id>
</element-citation><mixed-citation id="mc-CR202" publication-type="journal">Pang J, et al. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;46:175&#x02013;82. 10.1111/apt.14119.<pub-id pub-id-type="pmid">28464257</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name><surname>Farhadi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis</article-title><source>Liver Int</source><year>2008</year><volume>28</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2008.01723.x</pub-id><pub-id pub-id-type="pmid">18397235</pub-id>
</element-citation><mixed-citation id="mc-CR203" publication-type="journal">Farhadi A, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 2008;28:1026&#x02013;33. 10.1111/j.1478-3231.2008.01723.x.<pub-id pub-id-type="pmid">18397235</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name><surname>Alisi</surname><given-names>A</given-names></name><name><surname>Manco</surname><given-names>M</given-names></name><name><surname>Devito</surname><given-names>R</given-names></name><name><surname>Piemonte</surname><given-names>F</given-names></name><name><surname>Nobili</surname><given-names>V</given-names></name></person-group><article-title>Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2010</year><volume>50</volume><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3181c7bdf1</pub-id><pub-id pub-id-type="pmid">20400911</pub-id>
</element-citation><mixed-citation id="mc-CR204" publication-type="journal">Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50:645&#x02013;9. 10.1097/MPG.0b013e3181c7bdf1.<pub-id pub-id-type="pmid">20400911</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Mota</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>Circadian clock regulation on lipid metabolism and metabolic diseases</article-title><source>Adv Exp Med Biol</source><year>2020</year><volume>1276</volume><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/978-981-15-6082-8_5</pub-id><pub-id pub-id-type="pmid">32705594</pub-id>
</element-citation><mixed-citation id="mc-CR205" publication-type="journal">Pan X, Mota S, Zhang B. Circadian clock regulation on lipid metabolism and metabolic diseases. Adv Exp Med Biol. 2020;1276:53&#x02013;66. 10.1007/978-981-15-6082-8_5.<pub-id pub-id-type="pmid">32705594</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>MC</given-names></name><name><surname>Chang</surname><given-names>EB</given-names></name></person-group><article-title>Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2021</year><volume>18</volume><fpage>679</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/s41575-021-00452-2</pub-id><pub-id pub-id-type="pmid">34002082</pub-id>
</element-citation><mixed-citation id="mc-CR206" publication-type="journal">Choi H, Rao MC, Chang EB. Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism. Nat Rev Gastroenterol Hepatol. 2021;18:679&#x02013;89. 10.1038/s41575-021-00452-2.<pub-id pub-id-type="pmid">34002082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name><surname>Saran</surname><given-names>AR</given-names></name><name><surname>Dave</surname><given-names>S</given-names></name><name><surname>Zarrinpar</surname><given-names>A</given-names></name></person-group><article-title>Circadian rhythms in the pathogenesis and treatment of fatty liver disease</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><fpage>1948</fpage><lpage>1966.e1941</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.01.050</pub-id><pub-id pub-id-type="pmid">32061597</pub-id>
</element-citation><mixed-citation id="mc-CR207" publication-type="journal">Saran AR, Dave S, Zarrinpar A. Circadian rhythms in the pathogenesis and treatment of fatty liver disease. Gastroenterology. 2020;158:1948-1966.e1941. 10.1053/j.gastro.2020.01.050.<pub-id pub-id-type="pmid">32061597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name><surname>Bishehsari</surname><given-names>F</given-names></name><name><surname>Voigt</surname><given-names>RM</given-names></name><name><surname>Keshavarzian</surname><given-names>A</given-names></name></person-group><article-title>Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer</article-title><source>Nat Rev Endocrinol</source><year>2020</year><volume>16</volume><fpage>731</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/s41574-020-00427-4</pub-id><pub-id pub-id-type="pmid">33106657</pub-id>
</element-citation><mixed-citation id="mc-CR208" publication-type="journal">Bishehsari F, Voigt RM, Keshavarzian A. Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer. Nat Rev Endocrinol. 2020;16:731&#x02013;9. 10.1038/s41574-020-00427-4.<pub-id pub-id-type="pmid">33106657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez Lopez</surname><given-names>DE</given-names></name><name><surname>Lashinger</surname><given-names>LM</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name><name><surname>Bray</surname><given-names>MS</given-names></name></person-group><article-title>Circadian rhythms and the gut microbiome synchronize the host's metabolic response to diet</article-title><source>Cell Metab</source><year>2021</year><volume>33</volume><fpage>873</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.03.015</pub-id><pub-id pub-id-type="pmid">33789092</pub-id>
</element-citation><mixed-citation id="mc-CR209" publication-type="journal">Gutierrez Lopez DE, Lashinger LM, Weinstock GM, Bray MS. Circadian rhythms and the gut microbiome synchronize the host&#x02019;s metabolic response to diet. Cell Metab. 2021;33:873&#x02013;87. 10.1016/j.cmet.2021.03.015.<pub-id pub-id-type="pmid">33789092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherji</surname><given-names>A</given-names></name><name><surname>Kobiita</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>T</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><article-title>Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>812</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.020</pub-id><pub-id pub-id-type="pmid">23663780</pub-id>
</element-citation><mixed-citation id="mc-CR210" publication-type="journal">Mukherji A, Kobiita A, Ye T, Chambon P. Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs. Cell. 2013;153:812&#x02013;27. 10.1016/j.cell.2013.04.020.<pub-id pub-id-type="pmid">23663780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name><surname>Hagstr&#x000f6;m</surname><given-names>H</given-names></name><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Hegmar</surname><given-names>H</given-names></name><name><surname>Nasr</surname><given-names>P</given-names></name></person-group><article-title>Natural history and progression of metabolic dysfunction-associated steatotic liver disease</article-title><source>Lancet Gastroenterol Hepatol</source><year>2024</year><volume>9</volume><fpage>944</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/s2468-1253(24)00193-6</pub-id><pub-id pub-id-type="pmid">39243773</pub-id>
</element-citation><mixed-citation id="mc-CR211" publication-type="journal">Hagstr&#x000f6;m H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9:944&#x02013;56. 10.1016/s2468-1253(24)00193-6.<pub-id pub-id-type="pmid">39243773</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name><surname>Kohsaka</surname><given-names>A</given-names></name><etal/></person-group><article-title>High-fat diet disrupts behavioral and molecular circadian rhythms in mice</article-title><source>Cell Metab</source><year>2007</year><volume>6</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.09.006</pub-id><pub-id pub-id-type="pmid">17983587</pub-id>
</element-citation><mixed-citation id="mc-CR212" publication-type="journal">Kohsaka A, et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab. 2007;6:414&#x02013;21. 10.1016/j.cmet.2007.09.006.<pub-id pub-id-type="pmid">17983587</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname><given-names>VD</given-names></name><name><surname>Panda</surname><given-names>S</given-names></name></person-group><article-title>Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan</article-title><source>Cell Metab</source><year>2016</year><volume>23</volume><fpage>1048</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.06.001</pub-id><pub-id pub-id-type="pmid">27304506</pub-id>
</element-citation><mixed-citation id="mc-CR213" publication-type="journal">Longo VD, Panda S. Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan. Cell Metab. 2016;23:1048&#x02013;59. 10.1016/j.cmet.2016.06.001.<pub-id pub-id-type="pmid">27304506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name><surname>Chaix</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Le</surname><given-names>HD</given-names></name><name><surname>Chang</surname><given-names>MW</given-names></name><name><surname>Panda</surname><given-names>S</given-names></name></person-group><article-title>Time-restricted feeding prevents obesity and metabolic syndrome in mice lacking a circadian clock</article-title><source>Cell Metab</source><year>2019</year><volume>29</volume><fpage>303</fpage><lpage>319.e304</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.08.004</pub-id><pub-id pub-id-type="pmid">30174302</pub-id>
</element-citation><mixed-citation id="mc-CR214" publication-type="journal">Chaix A, Lin T, Le HD, Chang MW, Panda S. Time-restricted feeding prevents obesity and metabolic syndrome in mice lacking a circadian clock. Cell Metab. 2019;29:303-319.e304. 10.1016/j.cmet.2018.08.004.<pub-id pub-id-type="pmid">30174302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name><surname>Zarrinpar</surname><given-names>A</given-names></name><name><surname>Chaix</surname><given-names>A</given-names></name><name><surname>Panda</surname><given-names>S</given-names></name></person-group><article-title>Daily eating patterns and their impact on health and disease</article-title><source>Trends Endocrinol Metab</source><year>2016</year><volume>27</volume><fpage>69</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.11.007</pub-id><pub-id pub-id-type="pmid">26706567</pub-id>
</element-citation><mixed-citation id="mc-CR215" publication-type="journal">Zarrinpar A, Chaix A, Panda S. Daily eating patterns and their impact on health and disease. Trends Endocrinol Metab. 2016;27:69&#x02013;83. 10.1016/j.tem.2015.11.007.<pub-id pub-id-type="pmid">26706567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name></person-group><article-title>Dynamic balancing of intestinal short-chain fatty acids: the crucial role of bacterial metabolism</article-title><source>Trends Food Sci Technol</source><year>2020</year><volume>100</volume><fpage>118</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.tifs.2020.02.026</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Xu Y, Zhu Y, Li X, Sun B. Dynamic balancing of intestinal short-chain fatty acids: the crucial role of bacterial metabolism. Trends Food Sci Technol. 2020;100:118&#x02013;30. 10.1016/j.tifs.2020.02.026.</mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>I</given-names></name><etal/></person-group><article-title>The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>1829</fpage><pub-id pub-id-type="doi">10.1038/ncomms2852</pub-id><pub-id pub-id-type="pmid">23652017</pub-id>
</element-citation><mixed-citation id="mc-CR217" publication-type="journal">Kimura I, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829. 10.1038/ncomms2852.<pub-id pub-id-type="pmid">23652017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>16767</fpage><lpage>16772</lpage><pub-id pub-id-type="doi">10.1073/pnas.0808567105</pub-id><pub-id pub-id-type="pmid">18931303</pub-id>
</element-citation><mixed-citation id="mc-CR218" publication-type="journal">Samuel BS, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A. 2008;105:16767&#x02013;72. 10.1073/pnas.0808567105.<pub-id pub-id-type="pmid">18931303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000f8;hr</surname><given-names>MK</given-names></name><etal/></person-group><article-title>GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes</article-title><source>Endocrinology</source><year>2013</year><volume>154</volume><fpage>3552</fpage><lpage>3564</lpage><pub-id pub-id-type="doi">10.1210/en.2013-1142</pub-id><pub-id pub-id-type="pmid">23885020</pub-id>
</element-citation><mixed-citation id="mc-CR219" publication-type="journal">N&#x000f8;hr MK, et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology. 2013;154:3552&#x02013;64. 10.1210/en.2013-1142.<pub-id pub-id-type="pmid">23885020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Intestinal transgene delivery with native E.&#x000a0;coli chassis allows persistent physiological changes</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>3263</fpage><lpage>3277</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.06.050</pub-id><pub-id pub-id-type="pmid">35931082</pub-id>
</element-citation><mixed-citation id="mc-CR220" publication-type="journal">Russell BJ, et al. Intestinal transgene delivery with native E.&#x000a0;coli chassis allows persistent physiological changes. Cell. 2022;185:3263&#x02013;77. 10.1016/j.cell.2022.06.050.<pub-id pub-id-type="pmid">35931082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><mixed-citation publication-type="other">Miao, J. <italic>et al.</italic> Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. <italic>Genes Dev</italic><bold>23</bold>, 986&#x02013;996 (2009). <underline>https://doi.org:</underline>10.1101/gad.1773909</mixed-citation></ref><ref id="CR222"><label>222.</label><mixed-citation publication-type="other">Chiang, J. Y. Bile acids: regulation of synthesis. <italic>J Lipid Res</italic><bold>50</bold>, 1955&#x02013;1966 (2009). <underline>https://doi.org:</underline>10.1194/jlr.R900010-JLR200</mixed-citation></ref><ref id="CR223"><label>223.</label><mixed-citation publication-type="other">Cui, X. B. &#x00026; Chen, S. Y. White adipose tissue browning and obesity. <italic>J Biomed Res</italic><bold>31</bold>, 1&#x02013;2 (2016). <underline>https://doi.org:</underline>10.7555/jbr.31.20160101</mixed-citation></ref><ref id="CR224"><label>224.</label><mixed-citation publication-type="other">Wang, W. &#x00026; Seale, P. Control of brown and beige fat development. <italic>Nat Rev Mol Cell Biol</italic><bold>17</bold>, 691&#x02013;702 (2016). 10.1038/nrm.2016.96</mixed-citation></ref></ref-list></back></article>